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Prostate cancer (PCa) is currently one of the most common types of cancer in men and 
the incidence is rising. In 2018, 376,000 European men were diagnosed with and 107,000 
died of PCa.1 Consequently one of the major challenges in PCa is defining the best 
strategy for the individual patient within a vast and heterogeneous patient population. In 
localized disease, the chance of dying from PCa within 10 years without direct treatment 
ranges between 8.3 and 25.6%.2 For these patients, the initial consideration is whether 
the potential survival benefit from treatment outweighs the impact on the quality of life. 
Risk stratification in PCa aims to identify those patients with a low risk of dying from their 
malignancy using tumor grade, stage and serum prostate specific antigen (PSA) levels.3 For 
histological grading, prostate (tumor) biopsies are obtained, the tissue is fixed, sectioned, 
stained and assessed using the Gleason grading system. Initially developed by Donald 
Gleason in 1966, the Gleason grading system characterizes the PCa tissue based on 
histological growth patterns and loss of normal glandular structures.4 The Gleason score 
is the sum of the two most frequent growth patterns, graded from 1-5 with increasing 
invasiveness and loss of normal tissue architecture. While a Gleason score ≤6 is defined 
as clinically irrelevant and ≥8 as aggressive, Gleason 7 encompasses a heterogeneous 
patient population with variable clinical outcome. Patients with a Gleason 7 PCa can 
be further stratified by scoring for the presence of cribriform and/or intraductal tumor 
growth patterns, which correlates with worse disease specific survival.5 TNM staging is 
generally applied to solid cancers and describes to which extent Tumors have invaded 
the healthy tissue, disregarded natural organ boundaries, spread to (nearby) lymph 
Nodes and Metastasized to distant sites.6 PSA serves as a biomarker for PCa despite its 
lack of cancer specificity. In the healthy prostate, luminal epithelial cells express kallikrein 
3 (KLK3) which encodes for PSA.7 PSA is a serine protease that is excreted by prostate cells 
and collected in the urethra, where it cleaves several matrix proteins and contributes to 
semen motility.8 In healthy individuals, only very low levels of PSA are detected in the 
bloodstream compared to the seminal fluid. Several conditions affecting the prostate, 
both benign and malignant, can give rise to serum PSA levels. It is commonly thought 
that PCa growth patterns, including loss of the basal cell layer and disruption of the 
basement membrane, leads to increased PSA levels in the bloodstream.9 If the Gleason 
grade, TNM stage and serum PSA levels together indicate (very) low-risk PCa, an active 
surveillance program is usually recommended.3 Active surveillance includes regular 
prostate examinations,  PSA monitoring and repeated tumor sampling to initiate active 
treatment only when signs of disease progression arise.6 For patients with intermediate or 
high risk localized PCa there are two major treatment options that aim to cure; surgery and 
radiotherapy. Surgical removal of the prostate aims to eradicate the PCa while retaining 
continence, potency and can be performed using modern laparoscopic or robot-assisted 
10 Chapter I
techniques. This decreases hospital stay and blood loss compared to more invasive 
open surgery procedures.3 Radiotherapy is particularly effective when combined with 
neoadjuvant androgen deprivation therapy. In vitro studies have shown that hormonal 
manipulation act as a radiosensitizer, by interfering with radiation induced DNA damage 
repair.10,11 Overall local treatment with curative intent is highly effective, as the onset of 
metastatic disease is about 2.4-3 per 1000 person-years.12 However in subsets of patients, 
such as those with a cribriform and/or intraductal carcinoma positive tumor, the disease 
specific survival can drop from 97-99% to 65-69% during 15 years of follow-up.5 
The role of androgens in prostate cancer
The work of Charles Huggins in the 1940s established PCa as an endocrine related 
disease. First Huggins showed that androgens were vital for normal prostate physiology, 
as surgical castration decreased prostate size and function in dogs, which could be 
reversed by testosterone.13 Huggins together with Hodges, then aimed to define serum 
phosphatases as biomarkers for PCa and studied the impact of androgens on alkaline and 
acid phosphatase levels.14 They observed that acid phosphatase levels were increased in 
patients with metastatic PCa (mPCa), decreased by bilateral orchiectomy and increased 
again after testosterone injections.15 Huggins was awarded the Nobel prize in 1966 
and his work transformed the field of PCa. Since then, testosterone has been validated 
as a vital component in prostate organogenesis, tissue homeostasis and neoplastic 
development.16 Cycles of gonadotropin-releasing hormone (GnRH) production in the 
hypothalamus, stimulates luteinizing hormone (LH) release from the pituitary, which in 
turn activates testosterone production by the Leydig cells in the testes. The secondary 
source of testosterone production are the adrenal glands, which account for 5% of the 
total production.17 Removing the testes by bilateral orchiectomy thus depletes patients 
of the vast majority of their circulating testosterone. Nowadays, androgen deprivation 
therapy (ADT) is the most commonly used method to infer testosterone depletion and 
is the first line of defense in mPCa.18 Continuous stimulation with GnRH agonists or 
antagonists block the release of LH, resulting in testosterone levels to drop with acceptable 
testosterone levels being below ≤50ng/dl.19,20 Testosterone, and its more potent 
derivative dihydrotestosterone (DHT), stimulate neoplastic behavior in PCa through the 
transcriptional activity of the androgen receptor (AR). The AR is part of the nuclear receptor 
family, and bears strong resemblance to family members such as the progesterone 
and glucocorticoid receptor.21 These paralogs share a common protein structure of an 
amino(N)-terminal domain (NTD) harboring the transactivation units, a central DNA 
binding domain (DBD), a flexible hinge region and the carboxyl(C)-terminal ligand 
binding domain (LBD) which interacts with hormones.22 Upon binding of testosterone or 
DHT, the AR dislocates from its chaperones, a complex of heat shock proteins including 
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HSP90 and initiates a conformational change (Figure 1). This N/C interaction is unique for 
the AR and locks the ligand in its place to prevent receptor degradation.23,24 The AR then 
translocates to the nucleus, although the mechanism underlying AR transport has not yet 
been fully elucidated. The current hypothesis is that the AR is tethered to tubulins until 
ligand binding initiates transport across the microtubule structures by the motor-protein 
dynein.25 Contrastingly, nuclear import of the AR has been well established and relies on 
the interaction of the nuclear localization signal (NLS) with nuclear importin proteins.26 In 
the nucleus, the AR interacts as a homodimer with palindromic DNA sequences, known as 
androgen response elements (AREs), which are located in the promotor/enhancer region 
of AR regulated genes. The AR relies on co-factors to initiate chromatin relaxation, recruit 
the preinitiation complex and initiate transcription. 
ARE 
Testosterone DHT 








 prostate cancer 
Figure 1: The role of the androgen receptor in the different stages of prostate cancer. During 
the hormone sensitive stage, testosterone and dihydrotestosterone (DHT) bind and activate the 
androgen receptor (AR) which then translocates to the nucleus (left). Here it dimerizes and binds 
androgen response elements (ARE) to initiate gene transcription. Androgen deprivation therapy 
blocks the vast majority of testosterone productions and results in inativation of the AR pathway 
(middle). Alterations to the AR gene, including mutations and amplifications, can reactivate the AR 
pathway and promote castrate resistance (right).
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Recently, the crystal structure of a ligand activated AR homodimer interacting with DNA 
was revealed. This showed that two AR-LBDs and DBDs lie at the center bound to DNA, 
while two NTDs wrap around and interact with co-factors.27 Furthermore, AR activation 
can lead to transcriptional activation and indirect suppression of several hundred genes.28 
ChIP-Seq studies have identified that the AR cistrome diverges between healthy and PCa, 
showing its differential role in cancer versus normal.29 Two examples of oncogenes which 
are differentially expressed in PCa versus normal are MYC and ERG. In normal prostate 
epithelial cells, AR activation triggers growth arrest and differentiation, which is in part 
due to suppression of the transcription factor MYC.30 Contrastingly, MYC is commonly 
expressed, and amplification of the gene locus on chromosome 8q frequently occurs in 
advanced PCa.31,32 The expression of ERG is the product of a fusion with the AR regulated 
TMPRSS2 gene. The 5’ region of TMPRSS2 is fused to ERG caused by a interstitial deletion 
between the two genes, that allows the TMPRSS2 promotor to activate ERG expression 
via the AR.33 The AR has also been shown to interact with different cofactors in PCa, such 
as FOXA1 and HOXB13. This enables genomic redistribution of the AR and results in 
differential activation/repression of genes with a FOXA1 and ARE DNA motifs in promotor 
or enhancer regions.34 ADT blocks the transcriptional activity of the AR in PCa, thereby 
stalling proliferation and malignant behavior. Although ADT is initially effective in the 
vast majority of patients with mPCa, disease progression is inevitable and typically occurs 
between 6 months and 2 years after initiation of ADT.35
Castration resistant prostate cancer
In the early 1990s, several in vitro studies aimed to dissect the underlying mechanism(s) 
of disease progression in PCa patient exposed to ADT. The mechanisms described in 
vitro included bypass of the AR receptor pathway, AR mutations and hypersensitivity 
for androgens, however clinical validation was lacking. In 1995 Visakorpi et al. showed 
that AR gene amplifications were frequent in recurrent tumor samples but absent in 
primary disease.36 Additionally, AR mutations were found to be associated with a short 
time to progression in mPCa patients treated with ADT.37 These studies implied that 
the AR pathway plays an essential role in disease progression despite castrate levels of 
serum testosterone. Until then, disease progression under ADT was defined as hormone 
refractory PCa, but given these developments was redefined as castration resistant PCa 
(CRPC). Recent whole genome sequencing studies underscore the role of AR in CRPC, 
as AR amplifications, mutations and promotor site alterations occur in ~80% of CRPC 
patients but are rare in castration naïve patients.38 These AR aberrations induce castration 
resistance by androgen hypersensitivity, due to AR overexpression or amplification and 
ligand promiscuity caused by AR mutations.39,40 Additionally, tumor samples from CRPC 
patients have been shown to harbor testosterone levels similar to benign prostate.40,41 This 
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has been linked to overexpression of the steroid enzyme 17β-HSD in CRPC which enables 
adrenal androgen precursors to be converted to testosterone and DHT.20
Targeting androgen receptor signaling in CRPC
The discovery that the AR pathway plays an important role in the development of 
castration resistant disease sparked the development of several AR (pathway) inhibitors. 
In the late 1960s, testosterone was already known as a ligand for cytoplasmic receptors, 
which promoted transcriptional activity and proliferation in prostate cells. Although the 
exact structure of these “androgen receptors “ were then unknown, cyproterone acetate 
was found to interfere with the receptor-testosterone interaction.41 Unfortunately, the 
steroidal cyproterone acetate had limited clinical efficacy and was characterized by several 
(adverse) effects. The non-steroidal flutamide and bicalutamide were approved for clinical 
use in 1982 and 1995 resp. due to their increased AR affinity, selectivity and potency to 
suppress testosterone mediated proliferation.42 These targeted anti-androgens can be 
used in conjunction with GnRH analogues to infer complete androgen blockade. This 
has the added benefit of compensating for the initial surge in testosterone levels after 
initiating GnRH analogue treatment. Interestingly, in some patients that progressed to 
the CRPC stage while receiving complete androgen blockade treatment, discontinuation 
of bicalutamide or flutamide resulted in a PSA drop. The short-term disease regression 
observed in these patients was termed the  “anti-androgen withdrawal phenomenon”. 
It was later identified that AR mutations within the LBD were able to not only confer 
anti-androgen resistance but could confer ligand promiscuity. Anti-androgens target 
the hormone binding pocket in the LBD of the AR, alterations within this region such 
as the T877A and W741C/L mutations impact the AR-LBD interaction with flutamide 
and bicalutamide respectively, resulting in an agonist-like activation.43 In 2009 the 
third-generation anti-androgen enzalutamide was selected from a compound screen 
as it showed superior antagonistic properties compared to bicalutamide. Moreover, 
enzalutamide interfered with AR pathway activity in LNCaP cells, which harbors the AR 
T877A mutation conferring bicalutamide resistance.44,45
 
Enzalutamide was approved for clinical use after the pivotal PREVAIL and AFFIRM trials 
showed increased survival in chemotherapy-naïve and chemotherapy-resistant CRPC 
patients respectively.46,47 Abiraterone was introduced following the COU-AA-302 trial 
and functions upstream in the AR pathway.48 Abiraterone interferes with CYP17A1, a 
crucial enzyme in the production of adrenal androgens. Therefore, abiraterone blocks 
the remaining source of testosterone production from adrenal precursors in patients 
receiving ADT. Although enzalutamide and abiraterone show substantial efficacy, overall 
response is hampered by intrinsic, acquired and cross-resistance between the two 
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androgen-directed therapies.49-51 In 2012, Li and colleagues showed that cells expressing 
AR splice variants were inherently resistant to enzalutamide. These AR splice variants lack 
the AR-LBD, which allows for ligand independent activation and circumvents antagonist 
binding.52 Expression of the AR variant 7 (AR-V7) in PCa patients treated with enzalutamide 
or abiraterone has been associated with impaired PSA response and inferior treatment 
outcome.53 Therefore, detection of AR splice variants can help to stratify patients towards 
chemotherapy, rather than androgen directed treatment.54,55
Taxane chemotherapy in mCRPC
Until 2004, the use of chemotherapy in CRPC was limited to mitoxantrone, which 
provided palliative support but no survival benefit.56 The TAX327 trial led to the 
introduction of docetaxel for metastatic CRPC. This taxane chemotherapeutic, induced a 
3-month overall survival benefit compared to mitoxantrone.57 The first-generation taxane 
paclitaxel, was discovered in the 1960s as part of a screening program for antitumor 
agents in the plant kingdom and is derived from the Pacific Yew tree (Taxus brevifolia).58 
Because extraction was a time consuming and ineffective process, extensive efforts were 
initiated to determine the chemical structure of paclitaxel. This eventually led to semi-
synthetization and production of analogues including docetaxel. Cabazitaxel is the most 
recent addition to the taxane chemotherapeutics and has been approved for treatment 
in docetaxel refractory patients.59 Taxanes function by targeting the β-tubulin subunit of 
the tubulin polymer that make up the cytoskeleton structure called microtubules and 
induce microtubule stabilization.60 Microtubules are dependent on a cycle of tubulin 
polymerization and depolymerization to shorten and lengthen filaments and function 
in key cellular processes such as cell mobility, transport and chromatid separation in 
mitosis. Taxanes block tubulin depolymerization leading to microtubule stabilization. This 
disrupts the mitotic spindle formation, that subsequently activates the spindle assembly 
checkpoint and leads to cell cycle stalling in the G2/M phase.61 Arrest in mitosis can 
directly lead to cell death induction, called mitotic catastrophe, or cells can exit mitosis 
without proper chromosome segregation leading to aneuploidy.62 Whether cells slip out 
of cell cycle arrest or die depends on competing signals. Slow degradation of the cell cycle 
regulator cyclin B1 promotes slippage, while build-up of apoptotic activators promotes 
cell death.63 Recent data shows that the STING/cGAS apoptosis pathway may also play a 
role in determining cell fate after taxane treatment. The STING/cGAS pathway is a natural 
defense mechanism for foreign extra-nuclear DNA, and triggers immunogenic cell death. 
Paclitaxel treatment in breast cancer cells has been shown to activate intrinsic apoptosis 
during mitotic arrest cells via cGAS, but had limited therapeutic efficacy in cells lacking 
cGAS due to mitotic slippage.64 However, taxane efficacy is most likely not limited to 
mitogenic cell death, as illustrated by the lack of clinical efficacy of targeted therapeutics 
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that block target mitotic spindle formation which mimic the effect of taxanes on mitosis.61 
In vitro studies have suggested that part of the taxane efficacy in PCa is due to the block in 
AR transport which is mediated by microtubule dynamics.25,65
Intrinsic and acquired resistance towards taxane treatment often occurs in mPCa, 
however there is little knowledge about the underlying mechanisms, at least in a 
clinical setting. Overexpression of ABCB1 has been frequently described as a multi drug-
resistance mechanism in various cancer models. ABCB1 encodes for the transporter 
P-glycoprotein 1 (Pgp), which has broad substrate affinity and is able to export a wide 
range of chemotherapeutics, including taxanes. Cabazitaxel has decreased affinity for 
Pgp compared to docetaxel, potentiating its activity in docetaxel resistant cells with Pgp 
overexpression.66 However, ABCB1 gene expression is frequently reduced due to hyper-
methylation in PCa compared to normal prostate tissue.67 Overall, genomic alterations or 
overexpression of ABCB1 occurs in small subset of cancer patients, implicating a minor role 
in chemoresistance.68 Our group has previously described the loss of SLCO1B3 expression 
in a docetaxel resistant in vivo model of PCa, which could lead to reduced docetaxel 
uptake, tumor accumulation and target engagement.69,70 Diminished target engagement 
can also be a direct consequence of altered expression of tubulin isoforms. Tubulin-βIII 
overexpression has been shown to impair taxane efficacy and is associated with tumor 
aggressiveness.71,72  Several other cancer associated pathways have been implicated in 
taxane resistance including epithelial to mesenchymal transition, which contributes to 
metastatic potential, and mutations in the DNA repair protein BRCA2.73-75 
The interaction between androgens and taxane treatment efficacy in 
mPCa
While taxanes and AR pathway inhibitors were initially approved for the use in CRPC 
patients, the CHAARTED and STAMPEDE trials have caused a paradigm shift in the field. 
These clinical studies showed that adding docetaxel to ADT, induced a tremendous overall 
survival benefit of 10-13 months in metastatic castrate naïve PCa (mCNPC) patients.76,77 
Contrastingly, adjuvant docetaxel monotherapy was found to be ineffective in delaying 
biochemical recurrence in patients with high risk PCa undergoing radical prostatectomy. 
These clinical studies show that ADT improves docetaxel treatment efficacy, suggesting 
an interaction between the AR pathway and taxane induced cell death. The underlying 
mechanism of increased taxane treatment efficacy in androgen deprived patient is likely 
multifaceted. It has been shown that docetaxel pharmacokinetics are affected by ADT, 
with CRPC patients showing a 100% increase in docetaxel clearance and a two-fold 
decrease in exposure.78 This is in line with the observations that docetaxel treatment in 
the castrate naïve setting is associated with an increase in neutropenic fever, most likely 
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due to increased exposure.79  Moreover, increased testosterone levels in CRPC patients 
have been correlated with significantly shorter progression free survival after taxane 
treatment in two retrospective studies.80,81 There have also been several preclinical studies 
that showed an interaction between AR signalling and taxane efficacy. AR activation by 
DHT was  shown to increase cell viability of LAPC4 cells treated with docetaxel.82 Moreover, 
combining enzalutamide with cabazitaxel treatment decreased cell viability in VCaP cells 
as well as inducing a small increase in TUNEL (apoptotic) positive cells in the 22RV1 in 
vivo model.74 Overall these studies support an interaction between the AR pathway and 
taxane activity and suggest that suppressing androgen signalling could improve taxane 
treatment efficacy, leading the way for new combination modalities.
With these recent shifts and several new therapeutics under clinical evaluation, the 
treatment landscape of metastatic PCa has become increasingly complex. Furthermore, 
several interactions have been observed, impacting treatment efficacy and sequencing. 
Impaired response to enzalutamide treatment has been reported for CRPC patients who 
have progressed on abiraterone and vice versa, implicating cross-resistance.83,84 Moreover, 
cabazitaxel was found to be superior as a third-line treatment in patients pretreated with 
docetaxel and AR pathway inhibitors, compared to the alternative AR pathway inhibitor.85 
A retrospective analysis of the GETUG-AFU trial also implicated that docetaxel rechallenge 
in mCRPC patients previously treated with ADT and docetaxel has limited efficacy.86 
Overall, with the expanding landscape and treatment interactions observed, there is an 
unmet need for biomarkers to support treatment selection.
Circulating tumor cells 
Circulating tumor cells (CTCs) are neoplastic cells that originate from solid tumors and have 
entered the peripheral bloodstream or lymphatic system. CTCs can originate from primary 
or metastatic tumors, but are identified in greater numbers in patients with disseminated 
disease.87 CTCs are part of the metastatic cascade in cancer, and hold strong clinical 
implications, as the majority patients with solid cancers die from metastatic disease.88 This 
is in part illustrated by the predictive value of high CTC numbers (≥5 per 7.5 ml peripheral 
blood) in relation to disease progression and response to therapeutic interventions.89,90 
In order to successfully invade foreign tissue, tumor cells have to overcome several rate 
limiting steps including extravasation from the primary tumor, survival and escape from 
the circulation, successfully invading foreign tissue and initiating tumor formation. The 
metastatic process thus invokes a major bottleneck for cell survival, and the amount 
of CTCs identified in the circulation far exceeds the successfully disseminated tumor 
cells.91 Moreover, the metastatic process is seemingly far from random, as distinct tissue 
preferences have been identified for metastatic spread of different solid cancers, including 
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PCa which frequently metastasizes to the bone.92 Although the metastasizing capacity of a 
single CTC is low, insights into the underlying mechanisms promoting dissemination have 
been gained from studying CTCs. Both CTC clusters and CTCs adhering to neutrophils, 
harbor increased metastatic potential.93 Interestingly, large scale whole genome analysis 
of metastatic cancers did not reveal unique genomic alterations compared localized 
disease, implicating that the metastatic potential could be inherent to cancer.94
Sampling CTCs as a liquid biopsy harbors the potential to study disease progression in 
individual patients as an alternative to using static sources such as tumor biopsy samples. 
For example, the expression of AR-V7 in CTCs of mCRPC patients has recently been validated 
as a prognostic marker for response to AR pathway inhibitors in a prospective clinical trial.95 
Advances into CTC enrichment, detection and single cell omics techniques also enable 
more in-depth studies into genetic and transcriptomic heterogeneity of cancer.96 mPCa 
has been shown to harbor extensive intra-patient genomic heterogeneity and complex 
seeding relationships between primary and metastatic tumor sites.97 A single-cell RNA 
sequencing study in mPCa unveiled extensive intra- and inter-patient heterogeneity 
from CTCs, which shows the potential of CTCs to capture intra-patient heterogeneity.98 
However, the authors noted that the study was hampered by the limited number of CTCs 
analyzed. In-depth omics studies are thus limited by the number of CTCs obtained by 
standard sampling as the median CTC count in mPCa patients is 2-20 per 7.5 ml peripheral 
blood.89 Leukapheresis is a standardized procedure to enrich for mononuclear cells by 
continuously centrifugation of blood, including CTCs.99 Leukapheresis thus harbors the 
potential to maximize the CTC yield thereby providing a platform for in-depth studies into 
intra-patient heterogeneity. Using leukapheresis, Lambros et al. performed single cell copy 
number analysis on 185 CTCs from 14 mPCa patients.100 The CTCs displayed substantial 
copy number heterogeneity, with divergent clones that were previously unidentified in 
matching biopsy samples. Besides omics studies, viable CTCs could be expanded ex vivo 
to provide new preclinical models and may be used in drug screening. Overall, sampling 
CTCs could offer a real-time insights into the genetic, transcriptomic and phenotypic 
make-up of cancer.  
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Models of prostate cancer
In vitro and in vivo models play a vital role in pre-clinical oncology research and enabled 
the implementation of numerous new treatment modalities. However, obtaining new 
models of (metastatic) PCa has shown to be particularly challenging. As PCa is a relatively 
slow growing neoplasm, in vitro expansion of tumor cells has been hampered by the 
overgrowth of benign basal and stromal cells.101 The initial repertoire of commonly used 
PCa cell lines consisted of PC3, DU145 and LNCaP, of which only the latter expresses AR 
and PSA.102 The development of patient derived xenograft (PDX) substantially increased 
the catalogue of PCa models, as the success rate for in vivo expansion of PCa cells is 
considerably higher than in vitro. Examples include the Rotterdam panel of 12 unique PDX 
models developed in the department of Urology at the Erasmus MC, the LuCaP panel from 
the University of Washington and the large sets from MD-Anderson and the University 
of Vancouver (characterized  by Navone et al.).103-105 Unfortunately, establishing a PDX is 
a lengthy procedure and serial transplantation requires numerous laboratory animals to 
maintain a stable model. In vitro expansion of established PDX models harbors several 
advantages and has been successfully achieved for some models, including the AR and 
PSA expressing cell lines PC346C, VCaP and 22RV1. Still the clinical disease course of PCa 
with its inherent heterogeneity is underrepresented. This is in part highlighted by the 
underrepresentation of TMPRSS2-ERG fusions in PDX models which enables AR regulated 
ERG expression. While expression of ERG was identified in 28% of the Movember GAP1 
PDX panel, while the TMPRSS2-ERG fusion was previously detected 38% of the PCa patients 
with localized non-indolent disease and in 43% of the mCRPC population.32,38,106 To expand 
the current set of available models and to mimic the impact of therapeutic interventions, 
established in vitro or in vivo models can be subjected to ADT or other commonly applied 
treatments. The established sublines are used to study resistance mechanisms, such as the 
previously identified cross-resistance between androgen directed therapies.65,107 A recent 
addition to in vitro models used are organoids, a three dimensional, self-organizing model 
that more accurately represents the original tissue organization and composition than 
standard 2D in vitro models. Organoids were first described by Sato and colleagues in 
2009, who recreated the crypt-villus structure in colorectal tissue in vitro, with inherent 
cell phenotypes.108  To obtain colorectal organoids, the cell culture media was composed 
of epithelial/stem cell factors and cells were mixed with a gel that mimics the tissue 
extracellular matrix composition. This culture technique has now been adapted and 
applied to several different healthy tissues and tumor types.109 In 2016 the first patient 
derived PCa organoids were established, Gao et al. obtained seven organoid cell lines 
with an overall success rate of 19%.110,111 This is a substantial improvement compared 
to standard culture techniques, although contamination of normal cells still presents 
as a major limitation. Interestingly, one of the obtained organoid models was derived 
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from CTCs, thereby circumventing the outgrowth of normal epithelial and stromal cells. 
However, obtaining sufficient amounts of cells for ex vivo culture most likely limits this 
approach to patients from which we can obtain several hundreds of CTCs. This hurdle 
could potentially be resolved by obtaining high number of CTCs by leukapheresis as 
previously mentioned. Overall the organoid models obtained by Gao et al. are a valuable 
addition to the current set of PCa models, as they maintained common genomic alterations 
such as a TMPRSS2-ERG fusion, PTEN loss and TP53 mutations. The PCa organoids were 
also used in drug screening, which shows potential for high throughput drug testing in 
models that better represent tumor tissue organization, bridging the gap between 2D 
cell lines and PDX models. For example, gastrointestinal cancer organoid models have 
already been shown to reflect the clinical response of the individual patient, highlighting 
the potential for personalized cancer therapy.112 High-throughput drug screening using 
patient-derived neuroendocrine PCa organoids, for which effective treatment options 





Scope of this thesis
This thesis consists of two parts. In Part I we aimed to demonstrate that androgen 
signaling impacts taxane activity and define the mechanisms underlying optimal taxane 
treatment efficacy in CRPC. 
In Chapter II and III we set out to demonstrate that AR pathway stimulation by 
testosterone impacts taxane treatment activity, using in vivo and in vitro models of AR 
positive CRPC. We aimed to define mechanisms underlying taxane activity by investigating 
tumor accumulation, target engagement, cell viability and death. In Chapter IV we set 
out to validate cellular thermal shift assays (CETSA) as a method to infer taxane target 
engagement and its correlation to taxane tumor accumulation. 
Based on the results described in Chapter II and III we hypothesized that targeting AR 
signaling improves taxane treatment efficacy. We therefore intended to define the 
combination of cabazitaxel with enzalutamide as a viable treatment strategy for CRPC in 
Chapter V. 
In Part II we aimed to provide a platform for personalized cancer therapy in mPCa. In 
Chapter VI we enriched CTCs from mPCa patients using diagnostic leukapheresis (DLA) 
to enable ex vivo expansion of PCa organoids. Subsequently, we aimed to show that 
these CTC derived organoids can reflect treatment response of the individual patient and 
function as reliable disease models. Lastly, we aimed to show that enriched CTCs capture 
the inherent intratumor heterogeneity of mPCa. 
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Inactivation of the androgen receptor (AR) pathway by androgen deprivation therapy 
(ADT) is the mainstay of (metastatic) prostate cancer therapy. Ultimately, the AR pathway 
will be re-activated despite castrate levels of circulating androgens. Thereby, maintaining 
its role even in castration resistant prostate cancer (CRPC). The recent STAMPEDE and 
CHAARTED trials showed that docetaxel in combination with ADT increased survival in 
hormone sensitive prostate cancer patients, suggesting cross-talk between AR signaling 
and chemotherapy efficacy. We hypothesized that a similar interaction may also apply for 
CRPC that is treated with cabazitaxel. We studied the impact of androgen status on the 
efficacy, pharmacodynamics and -kinetics of cabazitaxel in a unique and clinically relevant 
patient derived xenograft model of castration resistant disease. We found that cabazitaxel 
is highly effective in a castrate setting with strongly reduced AR activation, while tumor 
growth inhibition by cabazitaxel was completely abolished in the presence of high AR 
pathway activity. Moreover, additional experiments showed that intratumoral cabazitaxel 
levels were 3.5 times higher in tumors from castrated mice as compared to tumors from 
androgen-supplemented animals. We confirmed that cabazitaxel pharmacokinetics were 
not affected by testosterone, suggesting that androgen status might influence cabazitaxel 
tumor uptake directly. This study reveals the impact of androgen status on cabazitaxel 
efficacy and supports the potential of combination of taxane chemotherapeutics with AR 
axis targeting agents.
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Introduction
The treatment landscape of metastatic castration resistant prostate cancer (mCRPC) 
has expanded with the introduction of taxanes (docetaxel and cabazitaxel), second 
generation androgen receptor (AR) antagonists and the CYP17A inhibitor abiraterone. 
Despite substantial clinical impact, the absolute survival benefit in mCRPC remains 
limited, additionally cross-resistance between drugs may affect treatment efficacy.1 As 
a result, attention has been directed towards defining the optimal treatment sequence. 
Recent clinical trial results have shown that combining therapies rather than treatment 
sequence, may provide the most optimal approach for metastatic prostate cancer 
patients. The CHAARTED and STAMPEDE trials have shown robust overall survival benefits 
by combining androgen deprivation therapy (ADT) with docetaxel.2,3 Of note, preliminary 
results have shown that docetaxel without ADT is ineffective in castrate-naive patients 
(SPCG12, trial NCT00376792)4. This might suggest that reducing circulating androgen 
levels and androgen receptor activity affects taxane efficacy. Cabazitaxel is the second-line 
taxane, which is effective in patients with disease progression during or after docetaxel.5 
We hypothesized that, similarly to docetaxel, cabazitaxel efficacy could be affected by 
androgen-induced AR activation. To test our hypothesis, we evaluated the efficacy of 
cabazitaxel in a preclinical model of CRPC in the presence or absence of androgens. Since 
previous work from our group has shown that reduced intratumoral taxane concentrations 
affect treatment activity,⁶ we also studied the effect of hormone manipulation on 




The human prostate CRPC cell line PC346C-DCC-K was established from the PC346C cell 
line by long-term culturing in the absence of androgens 7,8. The AR expressing PC346C-
DCC-K cell line can grow in the absence of androgens, but the AR pathway remains active, 
as indicated by prostate specific antigen (PSA) expression (supplementary figure 1a). 
Cell line authenticity was confirmed by short tandem repeat analysis with the Promega 
PowerPlex 16 kit. Cells were regularly tested for mycoplasma infection, and kept into 
culture for a maximum of 25 passages after initiating the castrate resistance phenotype.
Animal welfare 
All animal experiments were approved by the Animal experiment committee under the 
Dutch experiments on Animal Act. The current study is in compliance with the Arrive 
guidelines.
Effect of testosterone on cabazitaxel efficacy
Twenty-four athymic male NMRI nude mice (NMRI-Foxn1nu; Taconic, Ry, Denmark) were 
subcutaneously inoculated with 5 million PC346C-DCC-K cells, while being anesthetized 
with isoflurane/O2. Tumor volume (TV) was monitored twice weekly by digital calipers, 
animals were randomized based on TV at start to ensure homogeneous groups. Mice 
were surgical castrated once tumors surpassed a volume of 150 mm3, during the surgical 
castration mice were anesthetized with Ketamine/Medetomidine (75 mg/kg and 1 mg/kg) 
and analgesia was provided by Carprofen (5 mg/kg). Six to ten days after castration, mice 
were randomized to receive either a silastic implant (Freudenberg Medical) containing 
testosterone (40 mg), or an empty implant as a control. During implantation of the silastic 
pellets mice were anesthetized with isoflurane/O2. The next day, mice were randomized 
to receive either one intraperitoneal injection of cabazitaxel (33mg/kg, Sanofi) or placebo 
(saline). Blood for PSA analysis was sampled (submandibular vein) at tumor formation 
and biweekly during the experiment until sacrifice. Plasma was isolated from whole 
blood samples by centrifugation at 8000 rpm for 10 minutes, and PSA was analyzed by an 
electrochemiluminescence immunoassay. Mice were kept on a 12h dark/light cycle, food 
and water were provided ad libitum. Mice were sacrificed once the tumors surpassed a 
volume of 1500 mm3, or at 90 days after cabazitaxel. Statistical analysis was performed 
using either SPSS (IBM, version 21) or Graphpad prism (Graphpad software, version 5.01), 
sample size was calculated using G*power (Kiel University, version 3.1.9.2) and based on 
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an in vivo pilot study (power of 90%, α = 0.01 and effect size of 0.85). Statistical analyses of 
tumor growth was performed using SPSS and Graphpad prism. 
Tumor tissues were formalin fixed and paraffin embedded for immunohistochemistry (IHC) 
analysis of the AR and cell cycle marker Ki67. In short, 4 µm tissue sections were incubated 
with primary anti-AR (1:300, SP107 Cell Marque) or anti-Ki67 (1:100, MIB-1 Dako) and 
visualized with DAB/H2O2 (Dako EnVision kit). IHC staining’s were blinded for treatment 
and scored by two readers, AR staining was scored by multiplying the percentage positive 
tumor cells with the staining intensity score (0-3). Ki67 staining was scored for percentage 
positive in the tumor cells. 
Cabazitaxel uptake
The experimental set-up and group size was similar to the cabazitaxel efficacy experiment, 
with the following exception; tumors were isolated 7 days after cabazitaxel injection. 
Tumors were snap frozen and stored in -80°C. Intratumoral cabazitaxel concentration was 
determined by a five times dilution of tissue in blank human lithium heparinized plasma 
(w/v), and homogenized by using a tissue homogenizer. Cabazitaxel concentrations were 
determined by a validated UPLC-MS/MS method and based on the method as described 
previously6,9, and corrected for tumor weight. The lower limit of quantitation (LLOQ) was 
established at 1.00 ng/mL for cabazitaxel in human lithium heparinized plasma. Peak area 
ratios of cabazitaxel versus the Internal Standard in human lithium heparinized plasma 
was a linear function of the concentration from 1.00 to 500 ng/mL.  The within- and 
between-run precision at four tested concentrations, including the LLQ, were ≤10.1 and 
≤10.9%, respectively, while the average accuracy ranged from 97.5 to 110%.
Cabazitaxel PK
Fourteen non-tumor baring athymic male nude mice were castrated, and seven days later, 
randomized to receive either a silastic implant containing testosterone or an empty pellet 
as a control. Two days later mice received one bolus injection of cabazitaxel (33 mg/kg), 
and blood was sampled from the submandibular vein at the following time points: 30, 60, 
120 and 180 minutes. Plasma was isolated from whole blood samples by centrifugation 
at 6800 g for 10 minutes. Cabazitaxel concentrations were determined by UPLC-MS/MS.6,9 
Sample size was calculated using Gpower and based on a previous study (power of 80%, 
α = 0.05 and effect size of 0.4).6
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Results
We subcutaneously implanted male immune-deficient mice with the AR wt and PSA 
secreting CRPC cell line PC346C-DCC-K (Figure 1a). 7 The PC346C-DCC-K model does not 
express AR variants (supplementary figure 1a) and shows reduced in vitro response to the 
anti-androgen enzalutamide compared to the parental model (supplementary figure 1b).10 
We confirmed the CRPC phenotype of this model in vivo, as tumors continued to grow 
after surgical castration of the mice (Figure 1b, c). Subsequent treatment with cabazitaxel 
induced a near-complete tumor response with none of the castrate mice reaching the 
end-point (TV 1500 mm3) (Figure 2a). In contrast, tumors in castrate mice that received 
testosterone supplementation failed to show a response to cabazitaxel treatment, with 
time till TV 1500 mm3 not significantly different from placebo-treated mice (log-rank 
P=0.199). Testosterone supplemented mice had, even after correcting for tumor volume, 
increased levels of PSA compared to castrate mice, indicating an active AR pathway in 
these tumors (Figure 2b).11 IHC analysis of cabazitaxel-treated tumors in testosterone-
supplemented mice showed high levels of AR positive cells with strong nuclear staining 
(Figure 2c). Moreover, in tumors from cabazitaxel-treated castrate mice, fewer AR positive 
cells with less intense nuclear staining were observed, as well as reduced Ki67 staining 
(Figure 2d). To determine a potential mechanism of interaction we measured intratumoral 
cabazitaxel levels; drug concentrations were 3.5 times higher in tumors from castrate mice 
compared to testosterone supplemented mice (Figure 3a; 1.36 ng cabazitaxel/mg tumor 
tissue vs. 0.39 ng cabazitaxel/mg tumor tissue, respectively). Pharmacokinetic analysis 
of cabazitaxel serum levels showed that the systemic exposure to cabazitaxel was not 
affected by testosterone supplementation (Figure 3b). 
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Figure 1: Tumor growth dynamics of the PC346-DCC-K tumor model, confirms CRPC phenotype. 
(a) Schematic overview of the experimental set-up; mice were inoculated with PC346-DCC-K cells 
and castrated at TV>150 mm3. The next week, mice were randomized to receive either a testosterone 
pellet or treatment control, and either cabazitaxel or placebo. (b, c) Average tumor growth of the 
cabazitaxel (b) and placebo (c) treated tumors (± SEM). The PC346-DCC-K tumors (n=5-6) continued 
to grow after surgical castration of the mice (day 0), underlining the CRPC phenotype of this model. 











Time (days from castration)











201612840-20 -16 -12 -8 -4




















Tumor volume ≥1500 mm3





~ 7 days4-6 weeks
Add pellet +/- testosterone
at TV ≥ 250 mm3
c
38 Chapter II
Figure 2. The efficacy of cabazitaxel is abolished by testosterone supplementation while 
remaining high in castrate mice. (a) Kaplan Meier survival curve showing the time till TV 1500 mm3 
for the four treatment groups (n=5-6), survival was compared by a log-rank test. One mice in the 
cabazitaxel group was excluded due to weight loss. (b) Normalized PSA (µg/L) levels ± SD. PSA was 
measured in plasma collected at the end of the experiment and normalized for TV. One cabazitaxel 
treated castrate mice had undetectable PSA levels (<0.1 µg/L). PSA values were compared by a one-
way Anova with a Bonferroni post-test, *** indicates a p-value <0.001. (c) Representative images of 
the IHC staining of the AR and Ki67 in PC346C-DCC-K tumors from cabazitaxel treated castrate or 
testosterone supplemented mice. (d) Scoring of IHC staining; the percentage positive Ki67 cells ± 
SEM and the AR nuclear staining score ± SEM. The percentage Ki67 positive cells was compared by 
a one-way Anova with a Bonferroni post-test, * indicates a P-value <0.05. The AR nuclear staining 
score was compared by a Kruskal-Wallis test with a Dunn’s post-test, ** indicates a P-value of <0.01 
and *** indicate a P value of <0.001.
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Figure 3: Testosterone supplementation decreases the intratumoral cabazitaxel concentration, 
but does not alter the cabazitaxel pharmacokinetics. (a) Intratumoral cabazitaxel concentrations 
were measured in PC346-DCC-K tumors from castrate and testosterone supplemented mice, tumors 
were excised seven days after cabazitaxel treatment (33 mg/kg). Mean intratumoral cabazitaxel 
concentrations (ng/mg tumor) ± SD are plotted, t-test was used to compare the concentrations, ** 
indicates a P-value of 0.0031. (b) Castrate or testosterone supplemented mice received one bolus 
injection of cabazitaxel, blood samples were drawn at four time-points (30, 60, 120 and 180 minutes). 
Cabazitaxel concentrations were measured in plasma fraction, mean cabazitaxel concentrations ± 
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Discussion
In conclusion, this preclinical study supports recent clinical data of improved taxane 
efficacy when combined with ADT. Additionally it provides a potential mechanism of 
action by greater intratumoral accumulation of taxanes during ADT. This preclinical 
study emphasizes the permanent role of the AR pathway in CRPC and demonstrate its 
impact on the antitumor activity of cabazitaxel. We show that response to cabazitaxel 
in an AR-positive CRPC model can be successfully prolonged and resistance delayed by 
concomitant androgen depletion, thereby reducing AR-activation. As reduced cabazitaxel 
accumulation seems not to be a consequence of a testosterone-induced change in 
cabazitaxel exposure, alternatively, testosterone may have an impact on cabazitaxel 
accumulation. We have previously shown that docetaxel and cabazitaxel uptake is reduced 
by knockdown of SLCO1B3.12 Interestingly, OATP drug transporters (encoded by the SLCO 
family) are also known to function as steroid transporters.13 Further studies are underway 
to unravel the molecular mechanisms that link the testosterone to the cellular cytotoxic 
effect of cabazitaxel. The current study was performed in a unique CRPC tumor models 
that retained its AR expression upon castration (or testosterone-free culture conditions), 
which allows us to study the role of the AR in cabazitaxel efficacy. Most hormone sensitive 
prostate cancer cell lines cultured in the absence of androgens lose their AR expression, 
and are therefore unfit to examine the interplay between the AR and taxane efficacy. 
Our data provides a rationale for the combined treatment of cabazitaxel with novel 
antiandrogen treatments in CRPC patients with an active AR pathway, in order to maximize 
efficacy of the taxane treatment.14 Additional studies are warranted to test whether novel 
antiandrogen treatment, such as abiraterone and enzalutamide, indeed increase taxane 
efficacy. Such studies may provide guidance to define the optimal window of opportunity 
for clinical use of combined treatment of taxanes and antiandrogen agents not only in 
castrate-naïve, but also in metastatic CRPC patients. 
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Supplementary figure 1: Androgen receptor characterization of the PC346C-DCC-K model. 
(a) Normalized gene expression of the AR, AR-V7 and PSA in PC346C-DCC-K and a panel of well-
established prostate cancer cell lines. Gene expression was normalized using three housekeeping 
genes (HPRT1, PBGD and GAPDH). Data is expressed as mean ±SEM (n=2-4). (b) Western blot showing 
the expression of the full length AR (AR-FL, SP107 Cell Marque) and PSA (ER-PR8 Dako Agilent, left 
panel) in PC346C-DCC-K and AR-V7 (Abcam, ab198394) in comparison to well established prostate 
cancer cell lines. (c) Cell survival assay (MTT) showing the response of the PC346C-DCC-K to the 
anti-androgen enzalutamide. Data shown is average of three experiments, mean ± SD is plotted on 
logarithmic scale. IC50 value was calculated using Graphpad.
Supplementary Table 1 – Primers and probes for AR-V7 and HPRT1
Gene Primer/probe/assay ID Assay Supplier
AR-V7
Forward: 5’-CTG TGC GCC AGC AGA AAT-3’






5’-TTC CTT GGT CAG GCA GTA TAA TCC-3’
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Supplementary methods
mRNA expression of the AR pathway using real-time PCR
Total RNA of the cell lines was isolated using RNA-Bee (Amsbio). For characterization of 
the AR and AR-V7 in the PC346C-DCC-K model we included the following cell lines: the 
parental AR/PSA positive PC346C, an AR negative PC346C derived CRPC clone (PC346C-
DCC)1, the AR-V7 positive VCaP and the AR-V7 negative cell line LnCaP.2 Real-time 
polymerase chain reaction (RT-PCR) was performed in a 7500 Fast Real-Time PCR System 
(Applied Biosystems, Thermo Fisher Scientific Inc.), as described previously.3 In short, AR, 
AR-V7, PSA, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were measured 
by TaqMan assay (ABsolute QPCR ROX Mix, Thermo Scientific) while Porphobilinogen 
Deaminase (PBGD) and hypoxanthineguanine phosphoribosyltransferase 1 (HPRT1) were 
measured by SYBER Green assay (Absolute SYBER Green ROX Mix; Thermo Fisher Scientific). 
Primers and probes for AR, PSA, GAPDH and PBGD have previously been described.4 The 
primer probe sequences for AR-V7 and HPRT1 are shown in supplementary table 1. Gene 
expression was normalized, using the standard curve method, against the geometric 
mean of three housekeeping genes HPRT, PBGD and GAPDH.
Western Blot 
Western blotting was performed as described previously.5 In short cell were lysed 
used RIPA buffer (10 mM TRIS-HCl (pH 7.4), 50 mM NaCl, 5 mM EDTA, 1% Triton X-100, 
1% desoxycholate, 0.1% SDS) with a protease inhibitor cocktail (Sigma). Fifteen µg 
total protein lysates were loaded on a 10% polyacrylamide gel and were blotted on a 
nitrocellulose membrane. Blots were incubated with AR (1:2000, Sp107 Cell Marque), AR-
V7 (1:1000, Abcam EPR15656) or PSA (1:2000, Dako Agilent ER-PR8) and either beta-actin 
or GAPDH as a loading control (1:10.000 Sigma A1978 and 1:5000 Santa Cruz SC47724, 
resp.) and imaged using chemiluminescence.  
Cell viability assay PC346C-DCC-K 
The cell viability assay based on the enzymatic reduction of MTT (3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide, Sigma) was performed as 
described previously,5 with the following modifications. Cells were seeded at a density 
of 5.000 cells per well in a 96-wells plate. The following day cells were exposed to 
enzalutamide (ranging from 0.1 to 10 uM, Axon Medchem) in the presence of 0.1 nM 
R1881, and cells were incubated for 10 days. Three replicates per condition were use, data 
presented is the average of three individual experiments (mean ±SD). IC50 values were 
calculated with Graphpad prism (Graphpad software, version 6.07).
46 Chapter II
II
47Testosterone Diminishes Cabazitaxel Efficacy
References
1. Marques RB, van Weerden WM, Erkens-Schulze S, et al. The human PC346 xenograft and cell 
line panel: a model system for prostate cancer progression. Eur Urol. 2006;49(2):245-257.
2. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice var-
iants expressed in castration-resistant prostate cancer require full-length androgen re-
ceptor. Proceedings of the National Academy of Sciences of the United States of America. 
2010;107(39):16759-16765.
3. Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G. Modulation 
of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS 
One. 2011;6(8):e23144.
4. Marques RB, Aghai A, de Ridder CMA, et al. High Efficacy of Combination Therapy Using PI3K/
AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Eur Urol. 
2015;67(6):1177-1185.
5. Marques RB, Erkens-Schulze S, de Ridder CM, et al. Androgen receptor modifications in pros-




Androgen Receptor Signaling 
Impairs Docetaxel Efficacy in 
Castration Resistant Prostate 
Cancer
Lisanne Mout, Matthijs Moll, Mingqing Chen, Eleonora S. de Morrée, 
Corrina M.A. de Ridder, Alice Gibson, Debra Stuurman, Ashraf Aghai, 
Sigrun Erkens-Schulze, Ron H.J. Mathijssen, Alex Sparreboom, 
Ronald de Wit, Martijn P. Lolkema and Wytske M. van Weerden
Br J Cancer. 2020 Dec;123(12):1715-1719
50 Chapter III
Abstract
Androgen receptor (AR) signaling drives neoplastic growth and therapy resistance in 
prostate cancer. Recent clinical data show that docetaxel combined with androgen 
deprivation therapy improves outcome in hormone sensitive disease. We studied whether 
testosterone and AR signaling interferes with docetaxel treatment efficacy in castration 
resistant prostate cancer (CRPC). We found that testosterone supplementation significantly 
impaired docetaxel tumor accumulation in a CRPC model, resulting in decreased tubulin 
stabilization and anti-tumor activity. Furthermore, testosterone competed with docetaxel 
for uptake by the drug transporter OATP1B3. Irrespective of docetaxel-induced tubulin 
stabilization, AR signaling by testosterone counteracted docetaxel efficacy. AR pathway 
activation could also reverse long-term tumor regression by docetaxel treatment in vivo. 
These results indicate that to optimize docetaxel efficacy, androgen levels and AR signaling 
need to be suppressed. This study lends evidence for continued maximum suppression 
of AR signaling by combining targeted therapeutics with docetaxel in castrate-resistant 
prostate cancer. 
III
51Androgens impair docetaxel efficacy in PCa
Background 
The treatment of advanced or metastatic prostate cancer is focused around androgen 
deprivation therapy (ADT), as testosterone and dihydrotestosterone (DHT) promote 
neoplastic behavior of prostate cancer cells through androgen receptor (AR) signaling. 
While ADT almost invariably induces disease regression, the majority of prostate tumors 
will at some point become resistant due to AR pathway aberrations.1-3 For patients who 
progress while receiving ADT, also referred to castration resistant prostate cancer (CRPC), 
docetaxel is the standard first-line chemotherapy. Recently, the combination of ADT 
with docetaxel, has been introduced also in the metastatic castrate-naïve setting as this 
combination significantly increased overall survival.4,5 Conversely, docetaxel without ADT 
after radical prostatectomy did not delay disease recurrence.6 These clinical trials suggest 
that the anti-tumor efficacy of docetaxel in castrate-naïve prostate cancer is improved 
by inhibition of AR pathway signaling. In this study we explore the impact of sustained 
(adrenal) androgen levels and/or AR pathway signaling on docetaxel efficacy in CRPC. 
Moreover, we studied the underlying mechanisms of AR-pathway activation on docetaxel 
treatment efficacy by examining docetaxel tumor accumulation, target engagement and 
cell death induction. 
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Methods
The AR-positive CRPC patient-derived cell line models, PC346C-DCC-K and VCaP-DCC-E, 
were derived from the hormone sensitive prostate cancer cell lines, PC346C and VCaP 
resp. through long-term propagation in castrate conditions.7 Both PC346C-DCC-K and 
the parental cell line PC346C do not express AR variants (supplementary figure 1)8, while 
VCaP-DCC-E shows increased expression of AR-V7 compared to VCaP. Furthermore, these 
cell lines do not express ABCB1 (P-glycoprotein) which has been shown to induce multi-
drug resistance.9 For in vivo experiments, NMRI nu/nu male mice were subcutaneously 
inoculated with PC346C-DCC-K cells and surgically castrated once tumors established 
(supplementary methods). After one week, mice received a testosterone pellet or treatment 
control. One injection of docetaxel (33 mg/kg) or NaCl was given the following day. Tumor 
volume was monitored weekly by calipers and mice were euthanized before the humane 
endpoint was reached by cervical dislocation (details in supplementary methods).10 
For in vivo accumulation studies, tumors were obtained three days after docetaxel 
treatment. Tumor samples were used to determine docetaxel accumulation by LC-MS/
MS11,12, α-tubulin acetylation by western blot and cell-death by TUNEL staining. Uptake 
of docetaxel by OATP1B3 was studied in Hek293T cells transiently expressing SLCO1B3, 
uptake of C14-docetaxel was measured in the presence or absence of testosterone. To 
assess the impact of AR pathway stimulation on docetaxel sensitivity, cell viability assays 
were conducted. We exposed PC346C-DCC-K and VCaP-DCC-E cells in vitro to a dose range 
of docetaxel with or without androgens.  
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Results
We first investigated the effect of androgen signaling on the anti-tumor efficacy of 
docetaxel in the AR positive CRPC model PC346C-DCC-K (Supplementary figure 1). 
In all castrate mice, docetaxel treatment resulted in long-term and complete tumor 
regression (Figure 1A). While in testosterone supplemented mice, docetaxel treatment 
only induced a short-term tumor response, after which all tumors rapidly progressed. 
The partial response to docetaxel in these mice, shows that testosterone interfered with 
docetaxel treatment efficacy. We therefore examined docetaxel tumor accumulation 
in the presence of testosterone, as we previously identified that impaired uptake of 
taxane chemotherapeutics correlates with treatment resistance.11 Indeed, testosterone 
supplemented mice displayed a 40% reduction of docetaxel tumor levels: median of 
2.8 ng/mg tumor from testosterone supplemented mice versus 4.4 ng/mg in androgen 
deprived animals (P-value <0.001, Figure 1B). Moreover, testosterone supplementation 
resulted in strong AR pathway activation in PC346C-DCC-K tumors as exemplified by 
increased PSA production, AR nuclear localization, AR target gene expression and tumor 
cell proliferation (Supplementary figure 2). 
To study the underlying mechanism of impaired docetaxel tumor accumulation, we 
examined the impact of testosterone on docetaxel uptake by the influx drug transporter 
OATP1B3 (encoded by SLCO1B3). SLCO1B3 is frequently overexpressed in prostate 
cancer, and docetaxel and testosterone are both OATP1B3 substrates (Supplementary 
figure 3).13-16 We found that in Hek293T cells expressing SLCO1B3, pre/co-incubation 
with testosterone, decreased docetaxel uptake by 17% (P-value =0.004, Figure 1C). This 
implicates that testosterone competes with docetaxel for OATP1B3 mediated uptake, 
resulting in reduced docetaxel tumor accumulation. As testosterone supplementation 
interferes with docetaxel accumulation, this will likely affect tubulin target engagement 
and subsequent stabilization. 
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Figure 1: Testosterone supplementation strongly impairs docetaxel efficacy and accumulation. 
A) Impact of testosterone supplementation on docetaxel treatment in tumor bearing mice 
(PC346C-DCC-K). Kaplan-Meier curve depicting the cumulative survival in the four treatment 
groups; Docetaxel (once 33 mg/kg i.v.) or placebo in castrate (DocCx n=13 and PlacCx n=13 resp.) 
or testosterone supplemented mice (PlacTest n=6 and DocTest n=6 resp.). Time till progression was 
calculated from the day of docetaxel treatment until tumors exceeded a volume of 1500 mm3. Mice 
were censored when tumors did not reach 1500 mm3 in size during the maximum follow-up of 60 
days. One mouse in the DocCx treatment group was euthanized due to continued weight loss after 
treatment. Results from the pair-wise comparison using the log-rank test are shown in the table. B) 
Docetaxel accumulation in PC346C-DCC-K tumors obtained three days after treatment in castrate 
or testosterone supplemented mice (DocCx n=6 and DocTest n=6 resp.). *** indicates P < 0.0001. 
C) Normalized uptake of 3H-estradiol-17β-D-glucuronide (EbG) and C14-docetaxel in Hek293T cells 
transiently expressing SLCO1B3, pre/co-incubated with 200 µM testosterone or vehicle control. 
Uptake of EbG and docetaxel was normalized to uptake in SLCO1B3 expressing cells in the absence 
of testosterone, EbG was used as a positive control for OATP1B3 mediated uptake. Shown are the 
individual normalized uptake values (n=9) obtained from three experiments. ** indicate P<0.01 and 



















































































 We therefore investigated acetylation of a-tubulin, which is a result of taxane-mediated 
tubulin stabilization.17 Indeed, α-tubulin acetylation was significantly correlated with 
docetaxel tumor accumulation levels (supplementary figure 4A and B). Moreover, we 
observed a trend towards decreased tubulin stabilization in PC346C-DCC-K tumors 
from short-term docetaxel-treated mice supplemented with testosterone (19% 
decrease, P=0.17, Figure 2A and Supplementary figure 4C). Overall, these data confirm 
that testosterone reduces docetaxel target engagement as a result of impaired tumor 
accumulation. To further assess docetaxel activity, we quantified docetaxel-induced cell-
death by TUNEL. Testosterone interfered with docetaxel induced cell-death, as shown 
by the strong reduction in TUNEL staining compared to docetaxel treated castrate mice 
(P=<0.001, Figure 2B and Supplementary figure 5). Moreover, TUNEL staining in tumors 
from docetaxel-treated mice supplemented with testosterone was not significantly 
different to untreated controls (P-value=0.36). Therefore, tubulin stabilization by docetaxel 
treatment in testosterone supplemented mice, albeit reduced, did not translate into cell-
death induction. 
We thus hypothesized that AR pathway activation by testosterone further abrogates 
docetaxel efficacy. Indeed, a small but consistent survival advantage was achieved by 
R1881 under effective docetaxel concentrations in AR positive CRPC cell lines (Figure 2C, 
>0.3 nM docetaxel with P=0.032 and P=0.073 for PC346C-DCC-K and VCaP-DCC-E resp). 
R1881 did not impact docetaxel response in AR negative PCa cells (Supplementary figure 
6). This indicates that androgen stimulation can protect AR positive CRPC cells from 
docetaxel-induced cell death. The increased cell viability under docetaxel treatment led 
us to investigate whether AR-pathway stimulation alone could re-induce proliferation in 
vivo. We therefore repeated the docetaxel treatment in castrate mice as depicted in Figure 
1A and investigated the impact of AR-pathway activation. Testosterone-induced strong 
AR pathway stimulation, as shown by AR nuclear localization and target gene expression, 
which led to rapid outgrowth in five out of seven PC346C-DCC-K tumors (Figure 2D, 
supplementary figure 7). Overall, AR pathway activation was able to overcome long-term 
tumor regression induced by docetaxel treatment. 
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Figure 2: Testosterone and AR pathway activity interfere with docetaxel induced target 
engagement and cell death. A) Acetylated-α-tubulin as a measurement for tubulin stabilization 
in PC346C-DCC-K tumors obtained 3 days after docetaxel treatment, in castrate and testosterone 
supplemented mice (DocCx n=6 and DocTest n=6 resp.). Acetylated-α-tubulin signal intensity was 
obtained by immunoblotting individual tumor samples and normalized to GAPDH loading control. 
Statistical comparison was performed by a two-sided T-test. B) Quantification of TUNEL stainings in 
short-term docetaxel treated PC346C-DCC-K tumors from castrate and testosterone supplemented 
mice (DocCx n=6 and DocTest n=6 resp.). TUNEL signal was compared to three tumors obtained 
from castrate mice (Cx) with no/low docetaxel accumulation (≤0.1 ng/mg tumor) after short-term 
treatment. Fraction of TUNEL positive pixels was normalized to Hoechst signal, data plotted is the 
median TUNEL positive pixels of the individual tumor samples. *** indicate P<0.001 and * is P<0.05. 
C) Impact of androgen supplementation (R1881; orange data points) on docetaxel response as 
compared to androgen deprived culture conditions (DCC; blue data points). Docetaxel sensitivity 
was assessed in the AR positive CRPC cell lines PC346C-DCC-K (top panel) and VCaP-DCC-E (lower 
panel) (both n=3). Docetaxel response was normalized to cell density at start of docetaxel treatment 
(dashed line) and plotted as relative cell expansion. Data was fitted using a non-linear curve fit to 
compare the two culture conditions, P-values are displayed. D) Individual tumor-growth curves of 
docetaxel treated PC346C-DCC-K tumors under castrate conditions (from day 0, n=7). Sixty days 
after docetaxel treatment, mice were supplemented with a testosterone implant (red data-points) 




In this study we investigated the impact of testosterone and AR-pathway stimulation on the 
anti-tumor efficacy of docetaxel in CRPC xenografts and cell lines. Testosterone impaired 
docetaxel anti-tumor activity through two different modes of action; interference with 
docetaxel tumor accumulation thereby reducing tubulin stabilization and AR-pathway 
activation protecting cells from docetaxel induced cell-death (Figure 1B). Reduced levels 
of docetaxel tumor accumulating by testosterone is, at least partially, mediated through 
competition for OATP1B3 uptake (Figure 1C). OATP1B3 is an influx transporter of particular 
interest, because it is frequently overexpressed in CNPC and mCRPC compared to normal 
adjacent prostate.18-20 Moreover, OATP1B3 seems to have a dual character in PCa, while 
SLCO1B3 overexpression has been linked to testosterone uptake, downregulation was 
correlated with docetaxel resistance in vivo.13,21 We previously showed that cabazitaxel 
efficacy and tumor accumulation are also impaired by testosterone, indicating that 
testosterone impacts taxane efficacy in general.8 
The current study explored the impact of reduced taxane tumor accumulation on tubulin 
target engagement. The absence of acetylated α-tubulin has previously been described as 
a biomarker of paclitaxel resistance, and was shown to be restored upon re-sensitization.17 
Here, we found that docetaxel accumulation strongly correlated with acetylated α-tubulin 
signal in short-term docetaxel treated tumors. Moreover, tubulin acetylation tended to be 
decreased in mice receiving docetaxel together with testosterone (Figure 2A). Although 
CRPC xenografts from testosterone-supplemented docetaxel-treated mice still displayed 
substantial tubulin stabilization, this did not translate into increased cell-death induction 
(Figure 2B). These results led us to conclude that testosterone-activation of the AR pathway, 
compromised the anti-tumor activity of docetaxel. This was in part demonstrated by the 
impact of R1881 supplementation on docetaxel sensitivity in vitro in two AR expressing 
CRPC cell lines. Of note, the VCaP-DCC-E cell line is positive for AR-V7 while PC346C-DCC-K 
does not express AR-variants (supplementary figure 1)8 this implicates that regardless of 
variant expression, AR pathway activity interferes with taxane efficacy. Additionally, AR 
pathway activation by testosterone stimulated regrowth of docetaxel-treated dormant 
tumors (Figure 2D). Recent clinical findings, albeit retrospective analyses, also suggest an 
interaction between taxane efficacy and testosterone. These studies showed that CRPC 
patients with suboptimal testosterone serum levels had significantly shorter progression 
free survival following docetaxel treatment.22,23
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Our data strongly suggests that taxane efficacy can be optimized by maintaining 
suppression of testosterone levels in order to minimize interference with docetaxel tumor 
accumulation and block AR-driven pro-survival signaling. Several phase II/III trials are 
currently combining (novel) AR targeted therapies with taxanes in mCRPC.24 Our findings 
lend support to investigate such potential benefit of combining docetaxel with additional 
blocking of AR signaling in mCRPC. 
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Supplementary figure 1: Expression of relevant genes in prostate cancer cell line models used. 
Gene expression of the AR, AR-target genes and SLCO1B3 in PC346C-DCC-K, VCaP-DCC-E and the 
corresponding parental cell lines as assessed by qRT-PCR. Additionally the expression of the drug 
transporter ABCB1 was assessed, for which a positive control (DU145-DR) was included. The hinges 
of the boxplots represent the 25th and 75th percentile with the median and the whiskers represent 
1.5x the interquartile range (IQR). For each gene three technical replicates were included and 
expression was normalized to two household genes using the 2-ΔCt method.
Supplementary figure 2: Testosterone supplementation in mice leads to increased plasma 
testosterone, prostate specific antigen levels, AR target gene expression and cancer cell 
proliferation. A) Testosterone plasma levels in short-term docetaxel treated castrate and 
testosterone supplemented tumor bearing mice (DocCx n=6 and DocTest n=6 resp.). Plasma 
samples were collected four days after mice received silastics implants containing testosterone or 
empty controls. The hinges of the boxplots represent the 25th and 75th percentile with the median 
and the whiskers represent 1.5x the interquartile range (IQR), ** indicates P<0.01. B) Normalized 
PSA plasma levels in short-term docetaxel treated castrate and testosterone supplemented tumor 
bearing mice (DocCx n=6 and DocTest n=6 resp.). Plasma samples were collected four days after mice 
received silastics implants containing testosterone or empty controls. PSA values were normalized 
to tumor volumes. The hinges of the boxplots represent the 25th and 75th percentile with the median 
and the whiskers represent 1.5x the IQR, ** indicates P<0.01. C) Gene expression of the AR and AR-
target genes expressed in PC346C-DCC-K tumors after short-term docetaxel treatment in castrate 
and testosterone supplemented mice (both n=6). Heatmap depicts gene expression as assessed by 
qRT-PCR of the individual genes, with each row being one tumor sample. Plotted is the geomean 
of three technical replicates, normalized to two household genes and gene expression in tumors 
from castrate mice, using the 2-ΔΔCt method. D) Representative immunohistochemistry images of 
PC346C-DCC-K tumors, obtained three days after docetaxel treatment in castrate or testosterone 
supplemented mice (DocCx and DocTest resp.). Tumor sections were stained for the AR and cell 
cycle marker Ki67, scale-bars represent 20 µm and 10 µm for the enlarged images. Images were 
scored by two independent viewers for Ki67 (E) percentage positive cells and AR (F) percentage 
positive cells which was multiplied by the AR staining intensity (scale 0-3).
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Supplementary figure 3: Docetaxel is a substrate for OATP1B3 mediated uptake. Uptake of C14-
Docetaxel and 3H-estradiol-17β-D-glucuronide (3H-EbG) in Hek293T cells transiently expressing 
SLCO1B3 and normalized to cells expressing the vector backbone. 3H-EbG uptake was used as a 
positive control for OATP1B3 uptake. Shown are the individual normalized uptake levels (Docetaxel 
n=18 and EbG n=21) obtained from six or seven individual experiments. The hinges of the boxplots 
represent the 25th and 75th percentile with the median and the whiskers represent 1.5x the 
interquartile range (IQR), *** indicates P<0.001.
Supplementary figure 4: Docetaxel tumor accumulation levels correlate with α-tubulin 
acetylation. A) Immunoblots stained for acetylated α-tubulin in short-term docetaxel treated 
tumors. Shown are six biological replicates of PC346C-DCC-K tumors with varying levels of docetaxel 
tumor accumulation. Individual docetaxel concentrations are indicated above each lane. Lane 
marked by * was excluded from analysis due to low GAPDH signal. B) Correlation between signal 
intensity of acetylated-α-tubulin, and docetaxel tumor accumulation in PC346C-DCC-K. Samples 
correspond to immunoblots depicted in Supplementary figure 4A, correlation was assessed by 
linear regression analysis. C) Immunoblots corresponding to Figure 2A, in which the impact of 
testosterone supplementation on α-tubulin acetylation was examined. Shown are the biological 
replicates of short-term docetaxel treated PC346C-DCC-K tumors obtained from castrate and 
testosterone supplemented mice.
Supplementary figure 5: Docetaxel induced cell death is impaired by testosterone. Representative 
confocal images of TUNEL staining in short-term docetaxel treated tumors obtained from castrate 
or testosterone supplemented mice (DocCx and DocTest resp.). Blue nuclear staining is Hoechst and 
green is TUNEL, scale bars represent 20 µm. The lower panels show an enlarged view.
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Supplementary figure 6: AR stimulation does not affect docetaxel response in an AR negative 
prostate cancer cell line. Impact of androgen supplementation (0.1 nM R1881) on docetaxel 
response as compared to androgen deprived culture conditions (DCC) in the AR-negative PCa cell 
line PC339C (n=3). Docetaxel response was normalized to cell density at start of docetaxel treatment 
(dashed line) and plotted as relative cell expansion. Data was fitted using a non-linear curve fit, 
represented by the solid line.
Supplementary figure 7: Testosterone mediated AR-pathway activation overcomes docetaxel 
induced long-term tumor regression in vivo. A) Representative immunohistochemical stainings 
of the AR in tumors obtained after testosterone re-introduction, compared to docetaxel treated 
tumors in castrate mice (left panels). Scale bars represent 20 µm and 10 µm for the enlarged images 
(lower panels). Images were scored by two independent viewers for AR (B) percentage positive cells 
which was multiplied by the AR staining intensity (scale 0-3). C) Gene expression of the AR and 
AR-target genes expressed in PC346C-DCC-K dormant tumors after docetaxel treatment in castrate 
(n=4) and after testosterone re-introduction (both n=6). Heatmap depicts gene expression as 
assessed by qRT-PCR of the individual genes, with each row being one tumor sample. Plotted is the 
geomean of three technical replicates, normalized to two household genes and gene expression in 
tumors from castrate mice, using the 2-ΔΔCt method. 
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Supplementary Material and Methods
Cell culture
The human AR-positive CRPC cell line PC346C-DCC-K was derived from the human 
prostate cancer cell line PC346C, through long-term propagation in prostate growth 
medium (PGM) with 2% steroid stripped fetal calf serum (FCS) and in the absence of 
R1881.1,2 The human AR-positive CRPC cell line VCaP-DCC-E was derived from the VCaP 
cell line through long-term propagation in RPMI with 10% steroid stripped FCS. DU145 
docetaxel resistant cells (DU145-DR) were kindly provided by Zoran Culig and maintained 
as previously described.3 Cell lines were characterized for the expression of prostate 
(cancer) transcripts (Supplementary figure 1), in short total RNA was isolated using RNA-
Bee (Tel-Test, Friendwood, Texas, USA) according to the manufacturer’s protocol. qRT-PCR 
was performed as described previously2, and gene-expression of the following targets 
was assessed; AR, AR-V7, KLK3 (PSA) (using custom assays)2, SLCO1B3, ABCB1, TMPRSS2 and 
FKBP5 and normalized to household genes GAPDH and HMBS (ThermoFisher Scientific, 
Hs00251986, Hs00184500, Hs01120965, Hs01561006, Hs99999905 and Hs00609296 
resp.). Gene expression was normalized using the 2-ΔCt method, DU145-DR was used as 
a positive control for ABCB1 expression. Mycoplasma testing was performed every 6 
months, cell line authentication was performed by short tandem repeat analysis by the 
Promega PowerPlex 16 kit. PC346C-DCC-K cells were kept into culture for a maximum 
of 25 passages after initiating the castrate resistance phenotype, while the VCaP-DCC-E 
clone was kept in culture for 50 passages.
Docetaxel uptake in SLCO1B3 expressing cells
For Docetaxel uptake assays we used Hek293T to over-express SLCO1B3. Hek293T cells were 
maintained in DMEM with 5% FCS. For drug uptake experiments, 1*105 cells were plated in a 
24-wells plate in phenol-red free medium (DMEM, ref # 31053-028, ThermoFisher Scientific, 
Waltham, Massachusetts, USA). After overnight incubation, cells were transfected with 0.5 
µg of SLCO1B3 plasmid DNA (GenScript, New Jersey, USA) or control vector (pCMV6-AC-
IRES-GFP) using Lipofectamin 3000 (1 µl/µg DNA, ref # L3000015, ThermoFisher Scientific). 
Transfection efficiency was monitored visually by GFP expression, and uptake experiments 
were performed 24-48h after transfection. For competition assays, cells were incubated 
with phenol-red/FCS free media containing 200 µM testosterone or vehicle control for 15 
minutes. Media was removed and cells were incubated with C14-Docetaxel (1 µM, 56.27 
µCi/mM) or 3H-estradiol-17β-D-glucuronide (EbG; 0.2 µM) with or without testosterone 
for 10 minutes. After drug uptake, cells were washed three times with ice-cold PBS and 
lysed using 1 M NaOH at 4°C overnight. Cell lysates were neutralized using 2 M HCl and 
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radioactivity measured using a scintillation counter (LS 6500 Counter, Beckman Coulter, 
Brea, California, USA). Radioactivity was corrected for protein concentration and activity 
of the drug solutions used. Uptake levels were normalized to vector control, or uptake in 
the absence of testosterone (vehicle control).
Animal Welfare
All animal experiments were approved by the Animal experiment committee under the 
Dutch experiments on Animal Act, with the reference number AVD101002017867. The 
current study is in compliance with the Arrive guidelines. Group size and experimental 
set-up was based on a previous study.2 All operations (tumor inoculation, castration, blood 
sampling) are conducted under adequate anesthesia to minimize animal discomfort. 
Subcutaneously growing tumors only cause mild discomfort. 
Docetaxel activity in vivo
Forty, six weeks old, NMRI nu/nu male mice (Janvier, Le Genest Saint Isle, France) were 
subcutaneously inoculated with 5*10⁶ PC346C-DCC-K cells, while being anesthetized 
with isoflurane/O2. Tumor growth was observed after 2-4 weeks in ~95% of the mice. 
Once tumors reached a volume of 150 mm3, mice were surgically castrated. Anaesthesia 
was provided by with Ketamine/Medetomidine (75 mg/kg and 1 mg/kg) and analgesia 
by Carprofen (5 mg/kg). After one week, mice were split into in two groups (based on 
tumor volume), to receive either a silastic implant with 40 mg of testosterone (ref 
#A0671, AppliChem, Darmstadt, Germany) or an empty implant to serve as control. 
During implantation of the silastic pellets, mice received anesthesia by isoflurane/
O2. The following day, mice were given an intravenous administration of docetaxel (33 
mg/kg; 10% ETOH, 10% Tween-80 and 80% glucose solution, Sanofi, Paris, France) or 
NaCl as treatment control (inclusion was based on tumor volume). Overall we had four 
treatment groups with six mice each, docetaxel treatment or placebo control in castrate 
or testosterone supplemented mice. The experiment was repeated in 16 castrate mice, 
comparing docetaxel efficacy to placebo controls. Tumor volume was measured twice 
weekly by calipers and mice were followed until tumors exceeded a volume of 1500 
mm3, or a maximum follow up of 60 days after docetaxel treatment. At tumor volume 
1500 mm3 no tumor-related discomfort is observed, mice were euthanized by cervical 
dislocation. Other reasons for euthanizing the mice included continued weight loss, >15% 
loss in bodyweight in two days or >20% compared to start, and abnormal behavior. Mice 
were maintained in an individually ventilated cage at 2-4 mice per cage, on a 12h dark/
light cycle and cage enrichment was provided. Treatments or surgical procedures were 
initiated in the morning and food and water were provided ad libitum. Blood was sampled 
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for prostate specific antigen (PSA) and testosterone analysis at tumor take, one week 
after testosterone (or empty control) supplementation and at end of the study. Blood 
plasma was isolated by centrifugation at 6800 RCF for 10 min and PSA was analysed by an 
electrochemiluminescence immunoassay (Cobas 8000, Roche, Basel, Switzerland). Plasma 
testosterone levels were analyzed using a ChemiLuminescent Enzyme Immunoassay 
(Lumipulse G1200, Fujirebio, Gent, Belgium).
Docetaxel accumulation in vivo
Sixteen NMRI nu/nu male mice were inoculated subcutaneously with 5*10⁶ PC346C-
DCC-K cells. When tumors reached a volume of 150 mm3, mice were surgically castrated 
and after one week supplemented with testosterone-containing or empty silastic implant 
(based on tumor volume). Three days after intravenous administration of docetaxel (33 
mg/kg), mice were sacrificed to determine docetaxel tumor accumulation. At least 40 mg 
of tumor sample was snap-frozen and used to determine docetaxel accumulation, which 
has been described previously.4,5
Immunohistochemistry 
Tumor tissue was formalin fixed paraffin embedded (FFPE) and 4 µm sections were 
stained  for presence of the AR (1:200, SP107, Cell Marque, Rocklin, California, USA) 
and the cell cycle marker Ki67 (1:100, MIB-1, Agilent, Santa Clara, USA) using validated 
antibodies.6,7 The secondary antibodies used were Goat anti-Rabbit and Goat anti-Rabbit/
Mouse for the AR and Ki67 resp. (#P0448 and #K5007, Envision Dako Santa Clara, USA). 
Expression was visualized with DAB/H2O2 (EnVision kit, #K5007 Dako ) and sections 
were counterstained with haematoxylin. For all tissue sections stained we included 
one sample with the secondary antibody (goat anti-Rabbit/Mouse) only, to visualize 
potential a-specific staining. Images were obtained using the Olympus BX41 microscope 
equipped with 2x, 10x, 20x and 40x UPlanFL N objectives, a ColorView III camera and CellB 
imaging software (version 3.4, Olympus, Shinjuku, Tokyo, Japan). All IHC stainings were 
blinded for treatment and quantified by two independent persons based on two or three 
representative images. Ki67 was scored based on percentage positive tumor cells only 
while AR score was calculated by multiplying percentage positive tumor cells with the 
staining intensity score (0-3).
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TUNEL staining
Cell-death was assessed using TdT-mediated dUTP-X nick end labelling (TUNEL). Four 
µm FFPE sections were stained according to manufacturer’s protocol (ref #11684795910, 
Merck, Darmstadt, Germany), and counterstained with Hoechst (ref # H3570, ThermoFisher 
Scientific). Tumor sections were blinded to treatment group and imaged using a Leica 
fluorescent microscope (DM4000b, Nussloch, Germany). Ten fields per tumor sample were 
imaged at a 400x magnification and quantification was performed as described previously.8 
Representative images were obtained using the SP5 Leica confocal microscope at a 630x 
magnification (HCX PL APO CS objective with Photo Multiplier Tube detector and LAS X 
imaging software).
AR-pathway expression upon testosterone stimulation in vivo
Tumor tissue was lysed and homogenized in QIAzol (ref #79306, Qiagen, Hilden, Germany) 
using an Ultra-Turrax T25 (Janke & Kunkel, Staufen, Germany). Total RNA was isolated using 
the miRNA-easy mini kit (ref # 217004, Qiagen), and RNA quality was measured using the 
Bioanalyzer RNA 6000 Nano assay (ref #5067, Agilent, Santa Clara, California, USA). All 
RNA samples had a RIN value ≥7. qRT-PCR was performed as described previously, gene-
expression was normalized to household genes (GAPDH and HMBS) and gene expression 
in castrate tumors using the 2-ΔΔCt method. 
Tubulin stabilization by docetaxel treatment in vivo
Tumors tissue was lysed and homogenized in RIPA buffer (0.01 M Tris-HCl, 0.05 M NaCl, 0.05% 
deoxycholate, 0.1% sodiumdodecyl sulfate (SDS), 5 mM ethylenediaminetetraacetic acid 
(EDTA) and 1% Triton x-100) supplemented with protease and phosphatase inhibitors (ref 
#78429, HaltTM Protease Inhibitor Cocktail and ref# 78420 HaltTM Phosphatase Inhibitor 
Cocktail both ThermoFisher Scientific), using an Ultra-Turrax T25. Protein homogenates 
were separated from the nucleic acids by centrifugation (4°C, 15 min at 20.000 g). Protein 
concentration was measured by the Pierce BCA protein assay (ref #23227, ThermoFisher 
Scientific), and 10 µg of protein lysate was used for immuno-blotting. Tubulin stabilization 
was visualized by staining for acetylated-α-tubulin (1:1000, ref #6-11B-1, Santa Cruz, 
Dallas, USA) and imaged using chemiluminescence (ref #11500694001, Merck). Staining 
intensity was assessed by the Odyssey Li-COR (C-Digit model 3600, Lincoln, Nebraska, 




For cell viability assays PC346C-DCC-K and VCaP-DCC-E cells were plated at a cell density 
of 5*103 cells per well in a 96-wells plate. VCaP-DCC-E cells were maintained in RMPI 
containing 10% DCC serum, while PC346C-DCC-K cells were maintained in PGM-basic 
medium.9 After overnight incubation, cells were exposed to a dose-range of docetaxel 
(0-100 nM, Sanofi) with or without the addition of 0.1 nM R1881, using six replicates per 
condition. After 10 days cell viability was measured by MTT assay, as described previously9, 
and normalized to values of six untreated wells at day one. The docetaxel sensitivity of 
the non-adherent, AR and SLCO1B3 negative cell line PC339C was examined using the 
PrestoBlue assay (ref #A13261, ThermoFisher Scientific).10  The experimental set-up was 
similar to the MTT assay described above, with the following alteration, cells were plated 
at a cell density of 2.5*103 and docetaxel response was measured after 7 days.
Statistical analysis
Kaplan-Meier plots and log-rank survival analysis as depicted in Figure 1A, were performed 
using the survival package version 3.1-6 in Rstudio Version 1.1.463.11,12 A pairwise 
comparison with Bonferroni correction was used to compare survival in the independent 
groups. The boxplot graphs shown throughout the manuscript were produced using 
ggplot2 version 3.2.1 in Rstudio13, the hinges of the boxplots represent the 25th and 
75th percentile with the median and the whiskers represent 1.5x the interquartile range, 
individual data points were plotted on the boxplots using ggbeeswarm.14 Statistical 
analysis of uptake and subsequent competition assays was performed using an one-way 
Anova with Dunn’s post-test for multiple comparisons using Rstudio15. The frequency of 
TUNEL positive cells after treatment (Figure 2B) was analyzed using an one-way Anova with 
Tukey post-test for multiple comparisons using Rstudio. The relation between acetylated-
α-tubulin staining intensity as obtained by immunoblotting and docetaxel tumor 
accumulation was analyzed using linear regression analysis in GraphPad Prism (version 
5.01, GraphPad Software, San Diego, California, USA ). The cell viability data was analyzed 
using non-linear fit in GraphPad, we used a log(inhibitor) versus response and variable 
slope to compare EC50 and maximum effect in castrate and androgen supplemented 
conditions. The impact of testosterone supplementation on plasma PSA, testosterone 
levels, docetaxel tumor accumulation and AR nuclear localization or Ki67 expression was 
assessed using a two-sided T-test in Rstudio.
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Abstract
The use of taxanes has for decades been crucial for treatment of several cancers. A major 
limitation of these therapies is inherent or acquired drug resistance. A key to improved 
outcome of taxane-based therapies is to develop tools to predict and monitor drug 
efficacy and resistance in the clinical setting allowing for treatment and dose stratification 
for individual patients. To assess treatment efficacy up to the level of drug target 
engagement, we have established several formats of tubulin-specific Cellular Thermal Shift 
Assays (CETSAs). This technique was evaluated in breast and prostate cancer models and 
in a cohort of breast cancer patients. Here we show that taxanes induce significant CETSA 
shifts in cell lines as well as in animal models including patient-derived xenograft (PDX) 
models. Furthermore, isothermal dose response CETSA measurements allowed for drugs 
to be rapidly ranked according to their reported potency. Using multidrug resistant cancer 
cell lines and taxane-resistant PDX models we demonstrate that CETSA can identify taxane 
resistance up to the level of target engagement.An imaging-based CETSA format was 
also established, which in principle allows for taxane target engagement to be accessed 
in specific cell types in complex cell mixtures. Using a highly sensitive implementation 
of CETSA, we measured target engagement in fine needle aspirates from breast cancer 
patients, revealing a range of different sensitivities. Together, our data support that CETSA 
is a robust tool for assessing taxane target engagement in preclinical models and clinical 
material and therefore should be evaluated as a prognostic tool during taxane-based 
therapies.
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Introduction
The use of taxanes has been a cornerstone in the treatment of cancers for several decades. 
Today taxanes are used in several cancer types and are a part of first line treatment in 
breast, non-small-cell lung cancer, castration-resistant prostate cancer, esophageal, head 
and neck cancers, and Kaposi sarcoma.1-3
   Taxanes are particularly important in the treatment of both early-stage and metastatic 
breast cancer patients where robust improvements of overall survival have been shown.4,5 
Both paclitaxel, a substance isolated from the Pacific yew tree (Taxus brevifolia), and 
docetaxel, a more potent semisynthetic derivate of paclitaxel, derived from the European 
yew tree (Taxus baccata), are standard treatment in breast cancer. Taxanes are also used for 
prostate cancer patients and are currently the only type of chemotherapy used for this type 
of cancer. Athough the mainstay therapy for metastatic prostate cancer has been hormone 
depletion, no effective therapy was available for patients who had progressed under 
androgen deprivation therapy until the introduction of docetaxel in 2004.6 Currently the 
treatment landscape for patients with castrate-resistant prostate cancer (CRPC) has vastly 
expanded, including cabazitaxel. This novel taxane has been shown to remain effective 
in docetaxel-resistant CRPC patients.7 Of note, the addition of docetaxel in parallel to 
androgen deprivation therapy was recently shown to increase overall survival, suggesting 
that an earlier switch to taxane regime might be favorable in these cases.8 The taxanes 
exert their effect by binding to β-tubulin on the luminal side of microtubules leading to 
the stablization of microtubules via inhibition of depolymerization.9 Therefore taxanes 
suppress microtubule dynamics, with the major mechanism for cell toxicity being the 
effect on the mitotic spindle, which leads to cell cycle arrest typically in G2- and M-phase, 
followed by cell death in rapidly dividing cells.10 Vinca alkaloids is another family of tubulin 
modulators, including vinorelbine and vincristine, which act by inhibiting microtubule 
polymerization, also arresting cells in G2- and M-phase.
   Taxanes are widely used for both early- and late-stage disease, but as for other cytotoxic 
cancer drugs, inherent or acquired resistance is often seen, leading to lack of efficacy or 
time-limited responses, and eventually progressive disease and mortality. There have 
been multiple mechanisms attributed to taxane resistance where a specific focus has 
been on the overexpression of efflux pumps, for example P-glycoprotein 1 (MDR1) or 
down-regulation of influx transporters.11 The activation of efflux pumps leads to depletion 
of the intracellular pool of the taxane, which affects the extent of binding to β-tubulin, 
i.e. decrease the target engagement (TE). Attenuated TE has also been suggested to 
occur due to point mutations or post translational modifications of β-tubulin, modified 
expression levels of microtubule-associated proteins (MAPs) or altered levels of tubulin 
isoforms such as up-regulation of TUBB3.12-14 However, the mechanisms for how TUBB3 
overexpression overcomes cell cycle arrest remains only partially defined. Other general 
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mechanisms for resistance to cytotoxic drugs have also been suggested to affect taxane 
sensitivity such as altered expression of anti-apoptotic proteins (e.g. Bcl-2 and Bcl-xL)15,16 
and NFkB modulation.17
   However, although several potential mechanisms and biomarkers for cellular drug 
efficacy and resistance have been proposed, none of these have been proven predictive 
for efficacy in the clinical setting. This is unfortunate since different taxanes appear to 
have different efficacy profiles, as well as different adverse effects, and thus biomarkers 
and predictive assays could potentially help in stratifying drug or drug combinations at 
different stages of taxane-based combination therapy.
   A basic requirement for taxane efficacy is sufficient TE of β-tubulin. After the drug 
has reached the tumor environment, TE is mainly determined by cellular influx, efflux, 
and drug catabolism, yielding the effective intra- cellular drug concentration. During 
therapy the pharmacokinetic (PK) profile in the individual patient will also affect TE by 
determining the amount of taxanes reaching the tumor environment. To optimize PK, 
drug monitoring is sometimes used during taxane therapy to demonstrate appropriate 
serum concentrations of the drug.18
   Considering the critical role of TE for drug efficacy, information on absolute and relative 
TE for different drugs in patient-derived samples could potentially help in stratification of 
cancer therapies with taxanes. However, direct measurements of TE in cells and tissues have 
previously been very challenging when no general technique for such measurements has 
been available. To meet this challenge, our lab has introduced the Cellular Thermal Shift 
Assay (CETSA), a biophysical assay which allows for TE to be measured in intact cells and 
tissues.19 CETSA can directly assess drug binding at the target protein level (the protein 
reports) by applying the critical heating step while cells are still intact and the target 
protein is in its proper cellular environment. After determining overall melting behavior 
of a target protein, isothermal dose response (ITDR) curves can be determined with CETSA 
to assess relative doses needed to obtain TE. Combined with mass spectrometry (MS-
CETSA) the method has allowed for comprehensive characterization of both direct drug 
binding, and protein interaction state changes induced by downstream and stress effects 
introduced by drugs.
   Although CETSA is most often explored to study TE in cell cultures, single protein CETSA 
experiments on tissue samples have previously been done for drug treated mice, for 
example, in the initial CETSA study for METAP219 and in several mice tissues for RIPK1.20 
Proteome wide MS-CETSA experiments have also recently been performed in multiple 
tissues of drug treated mice (ref. https://www.biorxiv.org/content/10.1101/500306v1). 
In the present work we implemented different formats of tubulin-specific CETSA and 
used these to study taxane TE in cell lines of breast and prostate cancer as well as mouse 
xenografts. Using cognate pairs of sensitive and resistant cell lines we show that CETSA can 
efficiently reveal the presence of drug resistance mechanisms. Finally, using miniaturized 
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CETSA we demonstrate that TE responses can be measured in fine needle aspirates from 
breast cancer patients and therefore can be used to validate tubulin CETSA as a potential 
prognostic biomarker for taxane sensitivity in clinical trials.
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Results
Tubulin melting behavior and drug stabilization in western blot-based 
CETSA.
To validate the applicability of CETSA to assess TE for tubulin-targeted drugs we 
implemented several CETSA formats as shown in Fig. 1A. We first developed a western 
blot-based assay to investigate the feasibility of tubulin-based CETSA. Initially melt curves 
for a- and ß-tubulin were generated in K562-cells, a suspension cell line originating from 
myelogenous leukemia. Both α- and β-tubulins had relatively high melting temperatures, 
around 61-63 °C, compared to 52 °C as the average melting temperature of proteins of the 
human proteome.21 The high melting temper- atures of tubulins might be due to stabilizing 
effects of the extensive protein-protein interactions made within the microtubule polymer. 
This is consistent with the finding that the non-polymerized subunits of tubulin, in lysates, 
melt more than 10 °C earlier (Fig. S1A, B).
   In addition to paclitaxel, which preferentially binds to a site on β-tubulin localized in the 
lumen of microtubules leading to stabilization of microtubules, we used vinorelbine, that 
binds to the vinca-binding domain, a site on β-tubulin distinct from the taxane-binding 
domain and which inhibits tubulin polymerization.22-24 Treatment of K562-cells for 1 h with 
both drugs produced a significant stabilization of β-tubulin with the largest difference 
between vehicle and treated seen around 63 °C (Fig. 1B and Table 1). A significant shift 
was also observed for α-tubulin following treatment with paclitaxel (Fig. 1C and Table 
1). However, no shifts were observed in cell lysates (Fig. S1A, B), consistent with the 
fact that drug binding is considered to occur only with intact microtubules.12 In lysate, 
microtubules are depolymerized and tubulin is only present as soluble dimers. Although 
the drugs used bind specifically to the β-tubulin subunit, both the α- and β-subunits show 
shifts in CETSA melt curves (Fig. 1B-E and Table 1). We recently described the correlation of 
CETSA melt curves of interacting proteins and named this phenomena thermal proximity 
co-aggregation (TPCA)25,26, which is the likely explanation for the correlated shifts of the 
tubulin subunits. CETSA melt curves were also generated in MCF-7 cells, a commonly used 
model system for hormone-positive breast cancer.
Paclitaxel generated clear shifts in both α- and β-tubulin in these cells, while docetaxel 
produced even larger shifts (Fig. 1D, E and Table 1). As negative controls we have generated 
melt curves for MCF-7 cells treated with the anthracycline daunorubicin, or with the 
pyrimidine analogue cytarabine which, as expected, produced no shifts in neither α- nor 
β-tubulin (Fig. 1F, G). Since the temperatures needed to generate tubulin melting are 
high, there might be a risk of losing cell membrane integrity during heating. We therefore 
tested the temperature and time dependent effects on the cell membranes in K562 and 
MCF-7 cells using a trypan blue assay (Fig. S1C-F).
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Figure 1. CETSA shows distinct melt curves for α- and β-tubulin that shift upon drug binding in 
cancer cells. Schematic overview of the CETSA method (A). Western blot-CETSA shows that the 
tubulin-binding drugs paclitaxel and vinorelbine (20 µM) produce clear shifts for β-tubulin in K562-
cells (B and C). In MCF-7 cells, the two taxanes, paclitaxel and docetaxel (20 µM), produce significant 
CETSA shifts for both β-tubulin and α-tubulin (D and E). Daunorubicin and cytarabine (negative 
controls) produced no shift in both β-tubulin and a-tubulin (F and G). All data represent the mean 
± S.E.M from independent experiments (n = 5-6 in D and E, and n = 3 in B, C, F and G) and are 
presented as a percentage of the signal detected at the lowest temperature in each melt curve.
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 Although some cell lysis was induced above 60 °C, the majority of cells remained intact 
up to 63 °C. In a time dependent experiment, the cell lysis occurred mainly after 1 minute 
of the total 3 minutes heating time (Fig. S1E,F), which is beyond the time point when the 
most prominent effects on protein stability are expected (the remaining heating time is 
expected to mainly drive the efficient precipitation of unfolded protein). 
Importantly, when the melting temperature of tubulin in lysates is much lower than in 
cells, proteins from lysed cells will not be seen above 60 °C. Furthermore, no stabilizing 
effect by taxanes can be observed on tubulin in lysed cells when tubulin is then present 
only as soluble dimers, as discussed above. Therefore, the heat-induced lysis of a fraction 
of the cells is not likely to quantitatively affect the TE measurements with tubulin CETSA.
Table 1. Overview of melting temperatures (Tm), CETSA shifts (ΔTm), with associated standard 
errors and statistical significance of the measured CETSA shift for the data presented in Fig. 1B-
G. *The significance of the CETSA shifts was calculated using one-way ANOVA for Tm values from 
independent experiments. Adjusted P-values ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0,001, ****P < 
0,0001 compared to vehicle.
K562 cells
β-tubulin α-tubulin
Tm (°C) ΔTm (°C) Significance* Tm (°C) ΔTm (°C) Significance*
Vehicle 61,0 ± 0,6 — — 54,0 ± 2,1 — —
Paclitaxel (20 µM) 66,1 ± 0,8 5,1 ± 1,0 *** 63,0 ± 1,0 9,0 ± 3,1 *
Vinorelbine (20 µM) 64,7 ± 0,8 3,7 ± 1,1 * 62,5 ± 0,5 8,5 ± 3,8 ns
MCF-7 cells Tm (°C) ΔTm (°C) Significance* Tm (°C) ΔTm (°C) Significance*
Vehicle 61,2 ± 0,2 — — 58,9 ± 0,3 — —
Paclitaxel (20 µM) 64,9 ± 0,2 3,7 ± 0,3 **** 63,8 ± 0,7 4,9 ± 0,6 ***
Docetaxel (20 µM) 68,9 ± 0,4 7,7 ± 0,4 **** 68,5 ± 0,6 9,6 ± 0,6 ****
Daunorubicin (20 µM) 61,9 ± 0,3 0,7 ± 0,4 ns 57,7 ± 0,3 −1,2 ± 0,6 ns
Cytarabine (20 µM) 61,7 ± 0,3 −0,5 ± 0,4 ns 58,1 ± 0,3 −0,7 ± 0,6 ns
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Miniaturization of CETSA for β-tubulin using AlphaLISA. 
Since measurements on clinical samples typically are limited by the amount of available 
cells, and screening studies using cell lines can require high sample throughput, we 
established a miniaturized tubulin CETSA based on AlphaLISA (overview of method in 
Fig. 2A). Antibody pairs can be chosen to only detect native protein in these assays with 
the advantage that, after heating, centrifugation of the lysate is not needed to remove 
aggregated protein (Figs. 2C, D and S2B, C). Several combinations of antibodies were tested 
and two pairs were found to give a robust signal: pair 2 consisting of ab6046 (Abcam) in 
combination with sc-398937 (Santa Cruz) and pair 8 consisting of ab6046 (Abcam) and 
T5201 (Sigma). Both pairs could detect CETSA melt curves and target stabilization in 
response to docetaxel and vinorel- bine with very similar shape as detected with western 
blot (Fig. 2C, D, Table 2, and Fig. S2B, C). Also CETSA ITDR experiments performed at 64 °C 
showed very similar curves with both detection methods (Fig. S2A).
   In order to optimize the cell numbers required for these assays different amounts of 
lysate were analyzed with both antibody pairs (Figs. 2E and S2D). The two pairs showed 
similar curves with pair 8 being somewhat more sensitive and having slightly shorter 
linear range. To increase the sensitivity even further, the pair 8 antibodies were directly 
conjugated to the AlphaLISA beads (Figs. 2B and S2E). Also a polyclonal SOD-1 antibody 
(R&D systems AF3418) was used in a conjugated AlphaLISA assay to function as loading 
control since SOD-1 is stable also at higher temperatures (Fig. S2G).27 The SOD1 assay had 
a linear range up to 500 cells (Fig. S2H). Interestingly, a time course experiment showed 
the stabilization of tubulin by docetaxel in K562 cells to be fully saturated already after 5 
min drug treatment (Fig. S2F).
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Figure 2. Miniaturization of the β-tubulin CETSA assay. Schematic drawing of the principle of 
standard and conjugated AlphaLISA (A and B). CETSA melt curves in K562 cells treated with docetaxel 
or vinorelbine (20 µM). β-tubulin was detected in total and clarified cell lysate with AlphaLISA pair 2 
(C and D). Cell density titration for AlphaLISA pair 2 in lysate from K562 cells treated with docetaxel 
(20 µM) or vehicle and heated to 37 or 63 °C (E). The data represent the mean ± S.E.M from technical 
replicates and are presented as a percentage of the signal detected at the lowest temperature in 
each melt curve.
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Detection of acquired drug resistance at the TE level using CETSA. 
To investigate the feasibility of using CETSA for assessing acquired drug resistance, 
multidrug-resistant K562-R cells were studied. The K562-R cells are previously described 
as vincristine-resistant due to overexpression of P-gp.28 We used AlphaLISA as readout 
method for ITDR-CETSA in order to compare the dose dependence of different taxanes 
in K562-R and the parental counterpart K562-P after a 1 h 45 min exposure to drugs. The 
ITDR-CETSA data showed that K562-R cells required in the range of 5,3x higher paclitaxel 
or docetaxel concentrations to establish the same TE response as in the parental cells 
(Fig. 3A, E, and Table 2) despite no difference in the total amount of tubulin (Fig. 3K). 
Measurements of cell viability after 72 h using the resazurin viability assay confirmed 
resistance in the K562-R cells compared to K562-P (Fig. 3B, F, and Table 2). Interestingly, 
the differences in both cell survival and CETSA shifts were abolished by the potent P-gp-
inhibitor tariquidar (Fig. 3C, D, G, H, and Table 2), directly supporting that the resistance 
mechanism is indeed due to up-regulation of P-glycoprotein. Furthermore, these cells 
were exposed to epothilone B, a tubulin targeting drug which is not a P-glycoprotein 
substrate. 
Table 2. Overview of EC50 values with associated standard errors and 95% confidence intervals 
(CI), and statistical significance calculated for the ITDR-CETSA curves in Fig. 3A-J. *The significance 
was determined for K562-R vs. K562-P using a two-tailed T-test for EC50 values from independent 
experiments. P-values ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0,001, ****P < 0,0001 compared to K562-P.
CETSA
K562-P K562-R
EC50 and St. 
Error (µM)
95% CI EC50 and St. 
Error (µM)
95% CI Significance*
Docetaxel 0,30 ± 0,08 0,18-0,5 1,54 ± 0,25 1,10-2,20 ***
Docetaxel + 0,5 µM Tariquidar 0,37 ± 0,09 0,23-0,58 0,26 ± 0,07 0,16-0,42 ns
Paclitaxel 1,55 ± 0,3 0,96-2,51 8,34 ± 1,63 5,90-11,81 ***
Paclitaxel + 0,5 µM Tariquidar 1,06 ± 0,21 0,66-1,72 1,2 ± 0,27 0,80-1,78 ns
Epothilone B 0,08 ± 0,02 0,06-0,13 0,1 ± 0,01 0,08-0,14 ns
Viab. Assay (nM) (nM)
Docetaxel 0,64 ± 0,08 0,50-0,85 150 ± 30 106-213 ****
Docetaxel + 0,5 µM Tariquidar 1,64 ± 0,32 1,16-2,32 1,65 ± 0,35 1,13-2,43 ns
Paclitaxel 0,58 ± 0,14 0,37-1,02 457 ± 106 306-680 **
Paclitaxel + 0,5 µM Tariquidar 3,18 ± 0,76 2,14-4,72 3,29 ± 0,69 2,30-4,72 ns
Epothilone B 1,1 ± 0,17 0,83-1,44 1,2 ± 0,16 0,92-1,53 ns
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Figure 3. CETSA TE measurements correlate to sensitivity to taxanes and report on the mechanism 
of resistance. ITDR-CETSA for β-tubulin at 63 °C and viability assays in multidrug-resistant (K562-R) 
and the corresponding parental cells (K562-P) in response to increasing concentrations of docetaxel 
(A-D) or paclitaxel (E-H) and in the absence or presence of the Pgp-inhibitor tariquidar (C,D,G,H). ITDRs 
at 63 °C and viability assays performed in response to the non-Pgp-substrate epothilone B (I and J). 
β-tubulin was detected with AlphaLISA in the ITDR-CETSA experiments. Pgp- and β-tubulin-expression 
in the two cell lines was detected with western blot (K,L). ITDR-CETSA data are presented as relative to 
the compound concertation where maximum stabilization is achieved. Cell viability data is relative to 
the untreated samples. All data represent the mean ± S.E.M from independent experiments (n = 3-4).
Epothilone B induced almost identical CETSA curves in K562-R as in K562-P and did not 
show any difference in the resazurin assay, further supporting that the observed difference 
between the two cells lines is mainly P-gp-dependent. Consistent with these findings, the 
protein levels of P-gp were found to be high in K562-R and barely detectable in K562-P as 
examined by western blot (Fig. 3L). Together these data illustrate that CETSA can be used 
to detect development of acquired drug resistance, as well as report on the mechanism of 
resistance in specific cases.
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Image-CETSA to monitor TE in specific cell types in heterogeneous samples.
 
For clinical applications, the analysis of TE in individual cells is of high interest since it would 
facilitate assessment of TE in specific cell types within a heterogeneous cell population 
existing in one tumor sample. One potential way to accomplish single cell resolution in 
CETSA is to quantify stabilization by antibody-based cell imaging, using an antibody that 
specifically recognizes the folded form of the protein. We developed an imaging CETSA 
format where we investigated several tubulin-directed antibodies and optimized the 
protocols, resulting in the experimental scheme as shown in Fig. S4A. Starting from cells in 
suspension, after drug treatment and subsequent CETSA heating in PCR-tubes, cells were 
washed and collected by centrifugation before being transferred to clear bottom plates 
where they were fixed and stained (anti-tubulin and Hoechst). After we had developed 
this CETSA imaging format, two articles describing related methods were published on 
CETSA drug screening on adherent cells, demonstrating the feasibility of the image-based 
detection of target engagement.29,30 Our method is, however, more versatile and allows 
for studies of clinical samples of cell suspensions such as fine needle aspirates. Moreover, 
our protocol allows the use of different temperatures to generate melt curves.
To test our tubulin Image-CETSA implementation for assessing drug efficacy, we first 
generated melt curves by exposing K562 cells to different temperatures after incubation 
with and without docetaxel or paclitaxel (Fig. 4A and Table 3). The Image-CETSA melt curves 
were similar to melt curves produced by western blot CETSA from the same samples and 
both drugs have apparent stabilization (Figs. S4B and 4A). We then performed ITDR-CETSA 
experiments, showing that the imaging protocol was able to generate dose response 
curves (Figs. S4C and 4B). ITDRs with docetaxel were also performed in the resistant 
K562-R cells comparing them with their parental counterparts K562-P. A shift towards a 
higher EC50 value was observed in the ITDR-CETSA curve corresponding to K562-R cells 
for both paclitaxel and docetaxel, supporting that Image-CETSA can indeed be used to 
monitor drug sensitivity (Fig. 4B,C and Table 3). In Fig. 4D, representative images show 
that Image-CETSA in principle can reveal TE information in individual cells and should be 
applicable to monitor TE in individual cell types in heterogeneous samples.
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Figure 4. Imaging-CETSA has the potential of quantifying TE in individual cells and report on cellu-
lar resistance. Imaging-CETSA melt curves for β-tubulin in response to docetaxel and paclitaxel (5 
µM) (A). ITDR- CETSA in multidrug-resistant (K562-R) and parental (K562-P) cells after exposure to 
different concentrations of docetaxel (B) or paclitaxel (C) and heating at 56 °C. Representative imag-
es of K562-P and K562-R cells treated with docetaxel or vehicle (D). Hoechst staining of the nuclei is 
shown in blue while β-tubulin staining is shown in yellow. All data represent the mean ±S.E.M from 
independent experiments (n = 3-4) and are presented as a percentage of the signal detected at the 
lowest temperature in each melt curve (A) or maximum stabilization detected in each series (B and 
C).
Table 3. Overview of EC50 values with associated standard errors and 95% confidence intervals 
(CI), and statistical significance calculated for the ITDR-CETSA curves in Fig. 4B,C. *The significance 
was determined for K562-R vs. K562-P using a two-tailed T-test for EC50 values from independent 




EC50 and St. Error (µM) 95% CI Significance*
K562-P 0,12 ± 0,02 0,09-0,16 —
K562-R 0,83 ± 0,12 0,60-1,17 **
Paclitaxel EC50 and St. Error (µM) 95% CI Significance*
K562-P 0,08 ± 0,04 0,03-0,20 —
K562-R 2,00 ± 0,83 0,73-5,41 **
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Taxane TE in mouse xenografts in ex vivo and in vivo settings. 
An advantage of CETSA is that the same measurement principle for target engagement 
can be used in both cell lines and tissues samples. To explore the use of tubulin CETSA in 
animal models, we used xenografts in mice for ex vivo and in vivo treatment. First, mice 
with MCF-7 derived xenografts were injected i.v. with drug or vehicle 30 min before 
euthanasia, directly followed by tumor sampling and preparation for CETSA analysis. In 
this first experiment a dose of 50 mg/kg was used, which is equivalent to 150 mg/m2 for 
humans,31 a dose that is somewhat higher than routinely used in the clinic. A significant 
stabilization of β-tubulin was observed for β-tubulin at 60 °C (Fig. 5A and Table 4).
In a second experiment we therefore repeated the treatment with 50 mg/kg docetaxel in 
mice bearing MCF-7 xenografts and included two additional docetaxel doses (33 mg/kg 
and 16,5 mg/kg) and two additional temperatures for the melt curves. This is equivalent to 
human doses of 100 mg/m2 and 50 mg/m2, which are commonly used in monotherapy and 
combination treatment respectively. A significant stabilization of tubulin was observed 
also with lower doses of docetaxel, demonstrating that CETSA-based TE can potentially 
be detected at clinically relevant doses (Fig. 5B and Table 4).
   For comparing local tumor cell effects of different drugs, an ex vivo setting experiment 
is preferred, since this format would allow to evaluate target binding of multiple drugs 
in e.g. the same patient biopsy. To test this setting and an additional xenograft model, 
ex vivo experiments were performed in MDA-MB-231 (triple negative breast cancer cell 
line) derived xenograft tumors. Ex vivo exposure to 50 µM docetaxel also showed a very 
prominent shift, albeit with larger standard deviations than in the in vivo treated MCF-7 
samples (Fig. 5C and Table 4). Possibly, the larger standard deviations could be due to 
poorer drug penetration in the solid tumor MDA-MB-231 pieces in the ex vivo setting 
and indicate that analysis of tissue samples with ex vivo drug treatment should be done 
using cell suspensions obtained by digesting solid biopsies, rather than by treating pieces. 
Alternatively, to avoid digestion of tumor tissue, a process that could potentially affect cell 
characteristics, the tissue could be freshly sliced using a vibratome before incubating with 
drug.
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Figure 5. Docetaxel produces CETSA shifts for β-tubulin in both in vivo and ex vivo mice models. 
SCID-mice bearing MCF-7 xenograft tumors were treated in vivo for 30 min with docetaxel at a dose 
of 50 mg/kg before being sacrificed and the tumors taken for β-tubulin analysis with western blot-
CETSA (A). SCID-mice bearing MCF-7 xenograft tumors were treated in vivo with different doses of 
docetaxel and samples were analyzed with AlphaLISA (B). Pieces of MDA-MB-231 xenografts were 
treated ex vivo with Docetaxel (50 µM) before β-tubulin analysis with western blot-CETSA (C). All 
data represent the mean ±S.E.M from different tumors in each condition (n = 2-3 in A, and n = 4 in B 
and C) and are presented as a percentage of the signal detected at the lowest temperature in each 
melt curve.
Table 4. Overview of the statistical significance of the measured CETSA shift for the data presented 
in Fig. 5A-C. *The significance of the CETSA shifts was calculated using one-way ANOVA. Adjusted 
P-values ns P > 0.05, *P < 0.05, **P < 0.01, ***P < 0,001, ****P < 0,0001 compared to vehicle.
MCF-7 Xenografts β-tubulin
in vivo (60 °C) Significance*
Vehicle —
Docetaxel (50 mg/kg) *
in vivo (60 °C) Significance*
Vehicle
Docetaxel (16,5 mg/kg) *
Docetaxel (33 mg/kg) ns
Docetaxel (50 mg/kg) **
ex vivo (62 °C) Significance*
Vehicle —
Docetaxel (50 µM) *
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Characterization of resistance in prostate cancer PDX models. 
As previously mentioned, an attractive setting to predict clinical outcome of drug 
treatment is to examine drug response ex vivo in biopsy samples. To investigate if drug 
TE measured with CETSA in ex vivo experiments could predict in vivo biology of the same 
drug, we performed experiments using patient-derived xenograft (PDX) based models of 
tumors drug resistance in castration-resistant prostate cancer. To study taxane sensitivity 
in resistant models we used two PDX models, PC346C and PC339, and their docetaxel-
resistant counterparts PC346C-DOC and PC339-DOC, previously described by de Morrée 
et al.32 Relevant details regarding the abovementioned PDX models are summarized 
in Table S1A. We first compared the effect of docetaxel, cabazitaxel, paclitaxel,  and 
vinorelbine in cell lines corresponding to the PDX models PC346C and PC339. We found 
a pronounced difference in potency between the drugs in both cell lines with cabazitaxel 
as the most potent drug, followed by docetaxel, paclitaxel, and vinorelbine as the least 
potent drug (Figs. 6A, S5A and Table S1B). The observed ranking correlates with previous 
studies showing cabazitaxel is more efficient than docetaxel in inhibiting cell proliferation 
and suppression of microtubule dynamics.33
 Studies of the PC346C and PC346C-DOC cell lines support that the taxane-resistant cells 
have attenuated TE in response to docetaxel, cabazitaxel, and paclitaxel (Fig. 6B-D and 
Table S1D) when both EC50s and maximum response levels are affected, reiterating the 
published in vivo results showing that taxane uptake is strongly impaired in the PC346C-
DOC model.
PC346C-DOC express less of the influx transporter SLCO1B3, as compared to the parental 
counterpart PC346C, which is shown to result in almost fully depleted intratumoral taxane 
levels.34 The effect of cabazitaxel on TE was more pronounced than that of docetaxel in 
both PC364C and PC346C-DOC tumor slices, which is in line with its reported higher 
efficacy.35
Similar studies of PC339C and PC339C-DOC do not show any significant difference between 
the cell lines, consistent with that processes effecting residual target engagement are not 
altered in this model.
Subsequently, ex vivo treatments of PC346C and PC339 PDX tumors (freshly sliced using a 
vibratome) with increasing concentrations of docetaxel and cabazitaxel were performed. 
Standard deviations were high for these experiments for technical reasons, as discussed 
below, but the results support that maximum β-tubulin TE in PC346C-DOC compared to 
the parental counterpart PC346C after both docetaxel and cabazitaxel treatment (Fig. 6E) 
is changed in a similar manner as in the cell lines. In contrast, PC339 and the docetaxel 
resistant variant PC339-DOC did not show effects on TE (Fig. S5E). Previous data show 
PC339-DOC to remain sensitive to cabazitaxel and that the docetaxel resistance in this 
model is possible to overcome by increased dosing of docetaxel.32 These results support 
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that the mechanism of resistance in PC339-DOC is to be downstream of, or alternatively 
bypassing, target engagement. Taken together, our data support that CETSA TE studies 
can differentiate between sensitive and resistant tumors in the cases where taxane 
resistance occurs up to the level of TE, for example in the case of altered expression of 
membrane transporters.
Figure 6. CETSA TE levels correlate with sensitivity to taxanes and reported resistance mechanisms 
in mouse PDX models of prostate cancer. PDX-derived cell line PC346C was treated with different 
concentrations of tubulin-binding drugs and ß-tubulin TE was analyzed with AlphaLISA (A) 
PC346C cells and the corresponding resistant cell line PC346C-DOC were treated with different 
concentrations of taxanes (B-D). Tumors from the PDX model PC346C and the resistant counterpart 
PC346C-DOC were treated ex vivo with increasing doses of docetaxel and cabazitaxel (E). Data from 
tumors slices were normalized to SOD-1 levels. All data represent the mean ±S.E.M from either 
different tumors in each condition (E) or from independent experiments (n = 3 in A-D).
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Drug TE measurements in fine needle aspirates from breast cancer patients. 
As shown above in several model systems, tubulin CETSA for taxanes generally correlates 
with drug sensitivity. To establish and evaluate the method for clinical samples we used 
fine needle aspirates (FNAs), since previous data indicates that measurements in cell 
suspensions tend to have lower variation than tissue pieces and that tumor cells are highly 
enriched in FNA samples.36 We first tested the amenability of using FNAs by taking such 
samples from mouse xenografts. CETSA stabilization upon ex vivo treatment with 25 µM 
docetaxel of FNAs from MCF-7 xenografts was detected by AlphaLISA and shown to be 
linear for several cell concentrations (Fig. 7A).  Next, the applicability of CETSA for patient 
material was assessed by performing experiments on FNAs collected from surgically 
resected primary tumors from breast cancer patients that have not received any previous 
treatment. All FNAs were exposed to docetaxel for 15 min, an incubation time that was 
shown to be sufficient to give full stabilization (Fig. S2F) and yet short enough to have 
minimal impact on cell viability as well as minimizing potential effect of transcription 
or other alterations that might occur in cells after being removed from their original 
environment. A major challenge with this approach was however the low cell number 
and viability typically obtained from the FNAs, although this varied very significantly 
between samples (Fig. S6). FNAs containing enough material (at least 10 000 live cells per 
experiment for detection with conjugated beads, and 100 000 per experiment for detection 
with standard AlphaLISA) were subjected to docetaxel treatment and subsequent CETSA 
analysis. Clear stabilization of β-tubulin could be detected in most samples analyzed 
and variability was acceptable between technical replicates. In cases where a sufficient 
number of viable cells were obtained, FNA samples were incubated with several doses of 
docetaxel. Surprisingly, these experiments revealed large differences at TE level between 
patients, up to 100 times (Fig. 7B and Table S2).
   FNAs were also collected by cytological aspiration directly from the untreated primary 
tumors of breast cancer patients. In this case, the viability of the cells was somewhat 
higher with a mean of 43% cell viability compared to 16% in the FNAs from surgically 
removed tumors (Fig. S6). This improvement in cell viability may have been the result of 
the shorter time between FNA collection and performing the CETSA analysis. When FNAs 
were collected from surgically removed tumors this was typically done at least 1 hour 
after time of ischemia, which could have contributed to the differences in viability. The 
assay quality was, however, similar when analyzing samples taken directly from patients 
and from surgically removed tumors. Again, samples showed a dose dependent response 
to docetaxel but the efficacy varied between patients (Fig. 7C). K562 cells were treated 
and analyzed in parallel in each experiment as a technical control of the experiment and 
for confirming the reproducibility of the AlphaLISA assay. The K562 control experiments 
resulted in ITDR-CETSA curves for docetaxel with very similar EC50 values for all tested 
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samples (data not shown).
Figure 7. CETSA for assessing TE for taxanes in ex vivo-treated breast cancer patient FNAs. Fine needle 
aspirates (FNAs) were taken from freshly removed MCF-7 xenografts and treated with docetaxel (25 
µM) for 15 min before CETSA-heating at 37 or 63 °C. β-tubulin for different lysate concentrations was 
analyzed with AlphaLISA (A). Fine needle biopsies from surgically removed tumors (B) or directly 
from patients (C) were treated with different concentrations of docetaxel for 15 min before CETSA-
heating at 63 °C and β-tubulin analysis with AlphaLISA. The data represent the mean ± S.E.M from 




In the present work we establish different formats of CETSA to assess target engagement 
of taxanes, and other tubulin directed drugs, to microtubules in cells and tissues, 
including breast cancer patient FNAs. The different CETSA formats give consistent 
measurements of melting behavior and ITDRs, although some quantitative differences 
are seen in melting curve shapes. We show that melt curves are stabilized by several 
tubulin modulators binding at both the vinca and the taxane site on β-tubulin. The very 
stabilization by vinorelbine is surprising and indicates that this family of drugs, in addition 
to inhibiting tubulin polymerization, also have a dramatic effect in intrinsic microtubule 
stability, which might add significantly to their cytotoxic mechanism. The optimized 
AlphaLISA assays provide a miniaturized and sensitive format allowing for measurements 
using relatively small number of cells (1000 cells per measurement point). Miniaturized 
and sensitive CETSA measurements are particularly valuable when many measurements 
points (replicates, doses, time points, etc.) are assessed in model studies, and sensitivity 
is essential for measurements on biopsy material where low cell number is often the 
limiting factor. The imaging CETSA implementation provides an interesting alternative, 
when different cell types can be selected from images, and TE can in principle be assessed 
in each cell type (although this was not directly tested in this study).
   A specific challenge of the tubulin specific assay is the unusually high melting temperature 
of tubulin in intact cells, being in the range where some cells are prone to heat induced 
lysis. Fortunately, tubulins are depolymerized when cells lyse and do not bind taxanes. 
Furthermore, tubulin in lysed cells melt some 10 °C earlier than in intact cells, so no protein 
from lysed cells is detected at the temperature used for most of the ITDRs (63 °C).
   Most studies of cancer drug sensitivity is done using cell viability assays with durations 
of 48-72 h, but such assays are typically hard to establish in reproducible formats for 
material from solid tumors. Also, different cell programs and distribution of different 
cancer cell clones in the sample can change very significantly during extended culturing, 
as compared to the situation in the tumor. An advantage with the ex vivo CETSA assay is 
that it allows for rapid measurement of TE, where fresh tumor samples are incubated with 
different drugs for short time periods (15-120 minutes), during which cell programs and 
cell clone distributions are less affected. On the other hand, CETSA only assesses cellular 
responses up to the target engagement level. For tubulin-directed drugs, however, 
several mechanisms proposed so far for drug resistance include the level of effective 
intracellular drug concentrations (through changes in influx, efflux, or catabolism) as well 
as modulation of tubulin structure (e.g. tubulin mutations or overexpression of beta-III-
tubulin),12-14 which should be directly accessible with CETSA measurements.
   In support that CETSA-derived measurement of tubulin binding correlates well with cell 
toxicity we show that CETSA ITDRs reflect known ranking of toxicities of different tubulin 
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binding drugs in cell lines. When toxicity of tubulin inhibition is primarily expected in 
M-phase, this suggests that drug binding and buildup of effective drug concentration 
in other cell cycle phases, that dominate our samples, correlates well with the situation 
in M-phase. Importantly, CETSA directly reflects the difference between parental and 
resistant cells as shown for the multidrug resistant K562 cells as well as for PC346C-DOC 
taxane-resistant prostate cancer.
   In the PC339-DOC PDX model TE was retained, consistent with the known increased drug 
accumulation of cabazitaxel in the resistant cells. This supports a bypass, or downstream 
mechanism of acquired resistance for this PDX model which remains to be characterized. 
This illustrates that even in cases were CETSA reveals TE not to be affected, such 
information will be valuable for dissecting resistance mechanisms for cancer drugs, since 
CETSA captures both effective intracellular drug concentrations and target modifications. 
In cases where TE is not changed in resistant cells, focus can instead be put on discovering 
downstream mechanisms for resistance. The mass-spectrometry implementation of CETSA 
(MS-CETSA) now provides a novel mean to dissect down- stream/bypass mechanisms for 
drug resistance involving modulations of protein interaction states.26
   Clinical evaluation of tubulin CETSA is outside the scope of this work and remains to be 
done for the validation of the usefulness of the assay to predict clinical outcome and to 
stratify drug selection. The present work does, to the best of our knowledge, for the first 
time present CETSA data for patient samples revealing variations in dose response. When 
tubulin CETSA data show correlation with drug toxicity in models it has the potential to be 
useful as an early prognostic biomarker to detect the emergence of resistance for different 
drugs up to the TE level in patient biopsies, where the cross resistance to alternative 
tubulin directed therapies can also be accessed. It is likely that drug targets for many other 
clinical drugs are similarly applicable for CETSA and that the resistance of other classes of 
drugs in combination therapies can be accessed in parallel with tubulin-specific acquired 
resistance. In the clinical situation, it has previously been difficult to pin down acquired 
resistance for individual drugs in combination regimes, except in cases where information 
on specific mutational patterns leading to target protein modifications has been available.
 In conclusion, we have established and validated several protocols for measuring tubulin-
specific CETSA of taxanes in cell lines and mouse models, demonstrating that drug effects 
up to the level of TE can be rapidly assessed in cells and tissues. Correlation of CETSA-
based detection of TE with cell toxicity in several of the tested models support that 
CETSA measurements can provide a novel and valuable alternative in the clinical setting 
to rapidly generate actionable information for therapeutic decisions. Experiments on 
FNAs from breast cancer patients demonstrate that CETSA TE can indeed be measured 
in some patient samples with sufficient accuracy in the ex vivo setting. The relatively 
broad range of responses on the TE level seen in these non-treated patients, suggest 
varying drug sensitivity and potentially that initial resistance can be detected in patients. 
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To rapidly assess the relative efficacy of several tubulin directed drugs could therefore 
help in stratification of next line therapies. However, in spite of the high sensitivity of the 
miniaturized assays, for many patients the number of viable cells were not sufficient from 
a single FNA (Fig. S6) suggesting that e.g. core biopsies, and more sensitive detection 
methods are needed for CETSA measurements in a majority of patients.
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Materials and Methods
Drugs. 
Docetaxel (S1148), paclitaxel (S1150), vinorelbine (S4269), epothilone B (S1364), 
daunorubicin (S3035), and cytarabine (S1648) were obtained from Selleckchem. All drugs 
were solubilized in DMSO at a con- centration of 50 mM and stored frozen until use. Drugs 
were generally diluted 4 times in DMSO before further dilution in HBSS or media.
Cell culture. 
All cell lines were cultured in 5% CO2 and 37 °C. K562 (ATCC-CCL-243) was grown in 
RPMI (Sigma R8768), SK-BR-3 (ATTCC-HTB-30) in McCoy’s 5a media (Sigma), and MCF-
7 (ATCC-HTB-22) and MDA-MB-231 (ATCC-HTB-26) were grown in DMEM high glucose 
(Sigma D6429). All media were supplemented with 10% heat inactivated fetal bovine 
serum (FBS) (Gibco 10500-064) and antibiotic-antimycotic (Life technologies 15240-062). 
Multidrug-resistant and parental K562 cells were kindly provided by Sören Lehmann and 
Christer Paul at the Karolinska Institute. Cells were passaged every second to third day. For 
adherent cells passaging included washing the cells in HBSS (Life technologies 14175-053 
-CaCl2, -MgCl2) and detaching in TrypLE (Life Technologies 12563-029). The PC346C and 
PC339C cell lines were cultured in prostate growth media (PGM) as described37 and the 
docetaxel-resistant counterparts were cultured in the presence of 0.1 nM docetaxel. The 
multidrug-resistant K562-cells were incubated for 72-96 hours with 150 nM vincristine (or 
DMSO for the parental cells) once a week.
CETSA melt curves and ITDR-CETSA with intact cells. 
Cells were harvested, washed, and diluted in HBSS (Life technologies 14025100 + CaCl2, 
+ MgCl2) to 4 million cells/ml for western blot and 3,33 million cells/ml for AlphaLISA. The 
cell suspension was mixed with drug or vehicle before aliquoting into PCR-tubes and kept 
at 37 °C for 1 h unless otherwise indicated. During longer incubations, tubes were rotated 
every 20 min. CETSA heating for 3 min, unless otherwise stated, was performed in a Veriti 
Thermal cycler (Applied Biosystems), either at a range of temperatures for melt curves or at 
63 °C for ITDRs unless otherwise specified. Cells were subsequently lysed by three rounds 
of freeze-thawing by alternating exposure of the samples to liquid nitrogen and 20 °C in 
a PCR-machine. For western blot experiments the aggregated proteins were removed by 
centrifugation at 20 000 g for 20 min at 4 °C and the supernatant was collected. Samples 
were either analyzed directly or stored at -80°.
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CETSA melt curves with cell lysate. 
Cells were harvested, washed, and diluted in HBSS (Life technologies 14025100 + CaCl2, 
+ MgCl2) to 40 million cells/ml and freeze-thawed three times, as described above, with 
vortexing in between for proper cell lysis. The high cell density was used in order to 
obtain a protein concentration more similar to that inside intact cells. The lysates were 
centrifuged at 20 000 g for 20 min at 4 °C, the supernatant collected, and the clarified 
lysate was stored at -80° until use. For the experiments, the lysate was mixed with drug 
or vehicle and incubated in PCR-tubes for 10 min at RT. CETSA heating and centrifugation 
were performed as described above. Before western blot analysis the samples were 
diluted to 5x in HBSS before mixing with the western blot loading buffer in order to get 
the same protein concentration in the samples as used for the intact-cell experiments.
Western blot. 
Samples were mixed with NuPage loading buffer consisting of NuPage LDS sample 
buffer (Life technologies NP008) and reducing agent (Life technologies NP009) and 
vortexed. Proteins were separated on a Bis-Tris 4-12% polyacrylamide midi gel (Invitrogen 
WG1403BX10) for 45-50 min at 200 mV. Directly after the run the gels were washed in 
deionized water and transferred to nitrocellulose membranes using the iBlot 2 system 
(Invitrogen) and iBlot 2 NC Regular stacks (Invitrogen IB23001). Membranes were washed 
for 10 min in TBS with 0,05% Tween 20 (Medicago 09-7510-100) (TBS-T) and blocked in 5% 
(w/v) non-fat milk (Semper AB) in TBS-T for 1 h before incubation with primary antibody 
over night at 4 °C with gentle shaking. After washing in TBS-T for 5 × 5 min, membranes 
were exposed to secondary antibodies for 1 h, washed again 5 × 5 min in TBS-T and 
developed using Clarity Western ECL Substrate (BioRad #170-5061). The chemiluminescent 
signal was detected using the ChemiDocTM XRS + imaging system from BioRad and band 
intensities were quantified using ImageLabTM software (BioRad).
   Primary antibodies used were T5201 from Sigma for ß-tubulin, sc-32293 from Santa 
Cruz for a-tubulin, and HPA001401 from Sigma or sc-11407 from Santa Cruz for SOD-1. 
When comparing western blot with Image-CETSA the ß-tubulin antibody #2128 from Cell 
Signalling was used since that is the same clone (9F3) as the Alexa Fluor 488 conjugated 
antibody #3623 that was used for Image-CETSA.
   Secondary antibodies used were either sc-2055 from Santa Cruz or W402B from Promega 
for mouse and sc-2374 from Santa Cruz or W401B from Promega for rabbit. All antibodies 
were diluted in 5% (w/v) non-fat milk in TBS-T.
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Trypan blue exclusion. 
In order to monitor membrane integrity after heating, cells were harvested according 
to the same protocol as for the CETSA experiments (see above) and heated in the Veriti 
Thermal cycler according to the indicated temperatures and time points. After heating, a 
10 µl aliquot was immediately taken and mixed with 10 µl 0.4% Trypan Blue stain (Gibco/
Life Technologies 15250-061). 10 µl of this mix was directly loaded on a counting slide 
(BioRad #145-011) and read in an automated cell counter (BioRad TC20).
Standard AlphaLISA assay.  
For detection with AlphaLISA, 3 µl of each sample was loaded in duplicates in an 
AlphaPlate (Perkin Elmer 6008350) followed by addition of 2 µl antibody mix. Two different 
combinations of antibodies were used: either the mouse-anti-tubulin antibody sc-398937 
(raised against amino-acids 209- 305 within an internal region of human β4-tubulin, 
Santa Cruz) in combination with the rabbit-anti-tubulin antibody ab6046 (raised against 
a synthetic peptice corresponding to human beta tubulin amino-acids 1-100, Abcam) 
referred to pair 2, or pair 8 where the mouse antibody was changed to T5201 (recognizes 
all five isoforms of beta-tubulin and binds to the carboxy-terminal part, Sigma). Sc-389837 
was diluted to 45 nM in order to get the final concentration of 1 nM, T5201 to 135 nM to 
get final concentration of 3 nM, and ab6046 was diluted to 450 nM to get 10 nM in the 
final mix. All dilution was made in AlphaLISA Immunoassay Buffer (Perkin Elmer AL000F). 
Anti-rabbit acceptor beads (Perkin Elmer AL104M) and anti-mouse donor beads (Perkin 
Elmer AS104D) were diluted in the same AlphaLISA buffer to 22.5 µg/ml and 90 µg/ml 
respectively to get 10 µg/ml and 40 µg/ml as final concentration when adding 4 µl of the 
mix to each well. All handling of the beads was done in a room with green light. Plates 
were sealed with sticky film, covered in foil, and spun at 177 rcf for 1-3 min. After overnight 
incubation in the dark, plates were spun briefly at 300 rcf and read in an Enspire 2300 
(Perkin Elmer).
Conjugation of AlphaLISA beads. 
Two antibody pairs were conjugated: ab6046 (abcam) and T5201 (Sigma) for tubulin (pair 
8) and the polyclonal AF3418 for SOD-1. The SOD-1 antibody AF3418 (R&D Systems) was 
divided in two aliquots of which one was biotinylated and one was conjugated to the 
Acceptor beads (Perkin Elmer 6772001). For β-tubulin ab6046 (abcam) was biotinylated 
and T5201 (Sigma) was used for conjugation to Acceptor beads. Biotinylation of respective 
antibody were performed using an antibody biotinylation kit (Pierce/ Thermo scientific 
90407).
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   Before performing biotinylation, the buffer of ab6046 needed to be exchanged to PBS 
which was done using Zeba spin column (Thermo Scientific 89882) according to the 
manufacturer’s instructions. Then 100 µl PBS was added to one tube of NHS-PEG4-Biotin 
and mixed by pipetting. A 40-fold excess of biotin was added to the anti- bodies, mixed, 
and incubated for 30 min at RT. After incubation, the buffer was exchanged using the Zeba 
spin column (Thermo Scientific 89882) according to manufacturer’s protocol. Biotinylated 
antibodies were aliquoted and stored at -20 °C before use.
   The antibodies T5201 and AF3418 were conjugated to Acceptor beads (Perkin Elmer 
6772001). 0.033 mg beads were used for 0.333 mg antibody. First, the Acceptor beads were 
washed by adding 17 µl PBS (Life technologies 10010), centrifuged at 16 000 rpm for 15 
min, supernatant discarded, and the pellet dissolved in at mix with 0.033 mg antibody and 
130 mM sodium phosphate puffer (pH 8.0) in a final volume of 67 µl. In later conjugations, 
this volume was reduced to half in order to increase the yield. To this mix 0.43 µl of 10% 
Tween-20 (P1379) and 3.33 µl of 400 mM NaHB3CN (Sigma Aldrich 296945) was added, 
mixed gently by pipetting and incubated for 18-24 h at 37 °C with mild agitation (~60 
rpm).
   The next day 3.33 µl of 65 mg/ml Carboxymethoxylamine (Sigma C13408) in 800 mM 
NaOH was added and incubated for 1 h at 37 °C with mild agitation to stop the reaction. 
After incubation the tubes were centrifuged for 15 min at 16 000 rpm at 4 °C and the 
supernatant discarded. The pellet was resuspended in 67 µl 100 mM Tris-HCl (pH 8.0), 
centrifuged again and was resuspended in 200 µl PBS with 0.05% Proclin-300 (Sigma 
Aldrich 48912). The antibodies were vortexed briefly, spun down, and sonicated with 10 
pulses before stored at + 4 °C until use.
AlphaLISA assay with conjugated beads. 
Samples were diluted in HBSS for optimal linearity for each antibody pair. For human 
samples, 300 cells/well were used for SOD-1 and 3000 cells/well for ß-tubulin. The PDX-
samples were diluted 10 x for tubulin and 500 times for SOD1. 3 µl of each sample was 
loaded in AlphaPlate (Perkin Elmer 6008350), in duplicate when possible. 2 µl biotinylated 
antibody was added to each well and the plate were then briefly spun down before 
addition of Acceptor beads. For both β-tubulin and SOD-1 the biotinylated antibody 
(biotin-AF3418 and biotin-ab6046 respectively) were used at a final concentration of 3 
nM.
   Acceptor breads (2 µl) were added and the plate was spun briefly and incubated on a 
shaker for 1 h at 60 rpm. For SOD-1, Acceptor beads were diluted to 45 µg/ml for a final 
concentration of 10 µg/ml and for β-tubulin T5201-conjugated Acceptor beads were used 
at a concentration of 180 µg to get at final concentration of 40 µg/ml. Then 2 µl Donor 
beads (Perkin Elmer 6760002S) was added at a concentration of 180 µg/ml for get at final 
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con- centration of 40 µg/ml. Handling of beads was only done in a room with green light. 
Plates were sealed with sticky film, covered in foil, briefly spun down, and incubated in the 
dark over night before being read in an EnSpire 2300 (Perkin Elmer).
ITDR-CETSA in multidrug-resistant K562 cells. 
For the intact cell ITDR-CETSA experiments, studied compounds (docetaxel, paclitaxel, 
or epothilone B) were prepared in RPMI supplemented with 5% FBS at double the final 
compound concentration and with or without the addition of tariquidar (also at double 
the final concentration). Multidrug-resistant and parental K562 cells were harvested, 
washed in + 5% FBS, and resuspended at 6,66 million cells/ml in RPMI + 5% FBS. Cells 
were then mixed 1:1 in PCR tubes with the previously prepared compound dilutions so 
that the final cell density was 3,33 million cells/ml in 50 µl total volume. The final tariquidar 
concentration in the allocated samples was 0,5 µM. Vehicle-treated samples were also 
included at a final concentration of 0,4% DMSO. The treated cells were incubated at 37 °C 
for 1 h 45 min followed by heating for 3 minutes at 63 °C in a Veriti thermal cycler (Applied 
Biosystems). Unheated samples were also included. Immediately after the heating, all 
samples were freeze-thawed three times using liquid nitrogen. The samples were vortexed 
after every freeze-thaw cycle. The remaining soluble β-tubulin was analyzed in the total 
lysate using AlphaLISA pair.8
Resazurin cytotoxicity assay.  
For assessment of drug toxicity, multidrug-resistant and parental K562 cells in duplicates 
of 10 000 cells/well, were seeded in black 96-well clear bottom polystyrene microplates 
(Sigma) containing various drug concentrations diluted in RPMI supplemented with 5% 
heat inactivated FBS. Following, 72 h incubation at 37 °C, 10 µg/ml resazurin sodium 
salt (Sigma) was added to each well and further incubated for 2 h at 37 °C. Resorufin 
fluorescence was measured at a wavelength of 590 nm using an Enspire plate reader 
(Perkin Elmer).
Image-CETSA. 
Multidrug-resistant and parental K562 cells were propagated in RPMI-1640 medium 
supplemented with 10% heat inactivated FBS and continuously maintained at a cell 
density of 2 × 105 cells/ml. Drug resistance was preserved with 150 nM vincristine or 
vehicle DMSO, in the resistant and parental K562 cells respectively, by selection for 72-
96 h. Prior to each experiment, cells were washed once in HBSS before transfer to PCR 
tubes with RPMI-1640 medium containing 5% heat inactivated FBS and various drug 
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concentrations at a density of 4 million cells/ml. After 2 h incubation at 37 °C, CETSA 
heating was performed at 56 °C in a Veriti Thermal Cycler (Applied Biosystems) for 3 min. 
After heating, cells were collected by centrifugation at 200 rcf for 3 min at 4 °C and washed 
twice in HBSS before transfer to black 96-well clear bottom polystyrene microplates 
(Sigma) pre-coated with 1% aqueous Alcian Blue solution (Electron Microscopy Sciences) 
for 15 min for cell adherence. Supernatant was aspirated after centrifugation at 200 rcf 
for 5 min at 4 °C, after which cells were fixed in 4% w/v formaldehyde (Thermo Scientific) 
for 15 min at room temperature. Next, the cells were washed twice in DPBS/Modified (GE 
Healthcare) and permeabilized by incubation with 5% v/v Triton X-100 (Sigma) for 15 min 
at room temperature with gentle agitation. After an additional three washes, blocking was 
performed in 2% w/v bovine serum albumin (Sigma) for 1 h at room temperature with 
gentle agitation. β-tubulin conjugated Alexa Fluor 555 (#3623, Cell Signaling) was diluted 
1:200 in blocking buffer and added for overnight incubation protected from light at 4 °C 
with gentle agitation. Next, the cells were washed twice with 0.1% v/v Tween 20 (Sigma) 
and counterstained with 1 mg/ml v/v Hoechst (Chemometec) diluted in DPBS/Modified 
for 5 min at room temperature with gentle agitation. After an additional two washes, the 
Tween 20 wash buffer was replaced with DPBS/ Modified for subsequent image analysis.
   Images and analysis were acquired with the CytellTM Cell Imaging system (GE Healthcare) 
using a 2-colour BioApp specific for cytoplasmic image analysis. A blue (390/430) and a 
yellow (544/588) channel were applied for nuclear and cytoplasmic imaging respectively. 
Fifty-one fields covering the entire well were captured with a 10x Plan Apo 0.45 NA 
objective. Raw data based on average cellular cytoplasmic intensity for each individual 
well was further analyzed and plotted using GraphPad Prism version 6.
CETSA on in vivo treated xenografts. 
Female NOD-SCID mice were obtained from the breeding unit at the Department of 
Microbiology, Tumor and Cell Biology, Karolinska Institute. All mouse studies were 
approved by the Northern Stockholm Experimental Animal Ethical Committee (Dnr N 
192/13 and Dnr N 2/17) and were performed in accordance with the relevant guidelines 
and regulations. Tumor volumes were measured with a caliper and calculated according 
to the standard formula (length × width2 × 0.52).
   For the in vivo experiments, NOD-SCID mice were injected with approximately 5 × 10⁶ 
MCF-7 cells into a mammary gland. When the tumor sizes reached 0.2-0.3 cm3, the mice 
were injected with either vehicle (EtOH 1:1 in polysorbate 80 and then diluted in 5% 
dextrose) or docetaxel 30 min before they were euthanized by inhalation of a lethal dose 
of CO2 followed by cervical dislocation. Tumors were removed and cut into pieces using a 
scalpel and put in PCR-strips (Applied Biosystems N8010580). 30 µl HBSS (Life technologies 
14025100 + CaCl2, + MgCl2) was added and the samples heated to different temperatures 
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in a Veriti Thermal cycler (Applied Biosystems). After heating samples were frozen in liquid 
nitrogen and then thawed at 20 °C. High salt lysis buffer (50 mM tris-HCl, 300 mM NaCl, 
0.5% NP40, 1 mM EDTA, pH 7.2) and Halt Protease Inhibitor (Thermo Scientific 1861279) 
was added and the freeze-thawing repeated two additional times. The tumor pieces were 
further homogenized by crushing them with bent plastic pipette tips.
   Soluble proteins were isolated by centrifugation at 20000 x g for 20 minutes at 4 °C and 
the tubulin detected with western blot or AlphaLISA pair 2. SOD-1 was used as loading 
control in order to minimize the potential effect of differences in size of tumor pieces, 
this did however only give minimal change to the graph appearance, why we chose not 
to use this in the analysis of xenografts. Total five animals were used for the first pilot 
experiment and 16 mice were used for the second.
CETSA on ex vivo treated xenografts. 
NOD-SCID mice were injected with approximately 5 million MDA-MD-231 cells into a 
mammary gland. At the day of the experiment, four mice were euthanized by inhalation 
of a lethal dose of CO2 followed by cervical dislocation and tumors removed directly. Each 
tumor was divided into 12 pieces, which were incubated in vehicle (DMSO, 0.5%) or 50 µM 
docetaxel in HBSS (Life technologies 14025100 + CaCl2, + MgCl2) supplemented with Halt 
Protease Inhibitor (Thermo Scientific 1861279) for 1 h at 37 °C. After incubation samples 
were heated to different temperatures in a Veriti Thermal cycler (Applied Biosystems). 
After heating samples were frozen in liquid nitrogen and then thawed at 20 °C. High salt 
lysis buffer (50 mM tris-HCl, 300 mM NaCl, 0.5% NP40, 1 mM EDTA, pH 7.2) was added 
and the freeze-thawing repeated two additional times. The tumour pieces were further 
homogenized by crushing them with bent plastic pipette tips. Soluble proteins were 
isolated by centrifugation at 20000 rcf for 20 minutes at 4 °C and tubulin was detected 
with western blot.
CETSA on ex vivo treated PDX-tumors. 
These animal experiments were performed at the Erasmus University Medical Centre in 
Rotterdam and all experiments were approved by the Animal Experiment Committee 
under the Dutch Experiment on Animals Act and adhered to the European Convention for 
Protection of Vertebrate Animals used for Experimental Purposes (Directive 2010/63/EU).
   Sixteen mice were inoculated with one of four prostate cancer cell lines bilaterally at 
5 million cells on each side. The following prostate cancer cell lines were used: PC346C 
and PC339, and the docetaxel resistant lines PC346C-Doc and PC339-Doc. Cells were 
maintained as described previously.37
   Tumor volume was monitored twice weekly by digital calipers, and tumors were excised 
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28-37 days after inoculation (tumor volumes ranged between 125 and 1500 mm3).
   At the day of the experiment, mice were sacrificed (cervical dislocation), the tumors 
removed and fixed on a layer of low melting agarose using cyanoacrylate glue. The tumors 
were sliced using the Leica VT1200S Vibratome at a thickness of 300 µm and the slices were 
transferred to PCR strips containing HBSS (Life technologies 14025100 + CaCl2, + MgCl2) 
and treated with a range of drug concentrations as indicated for 1 h at 37 °C and 5% CO2. 
After incubation, samples were heated in a PCR-machine (Biometra T1 thermocycler) at 
63 °C for 3 min and then snap frozen in liquid nitrogen. All samples were stored at -80 °C 
until detection.
   For detection, all samples were frozen and thawed three times in liquid nitrogen and 
a 20 °C program on a PCR-machine. High salt lysis buffer (50 mM tris-HCl, 300 mM NaCl, 
0.5% NP40, 1 mM EDTA, pH 7.2) was added and samples were vortexed vigorously before 
slices and debris were removed by centrifugation for 20 min at 1000 rpm. Supernatant 
was isolated and analyzed for β-tubulin and SOD-1 content using AlphaLISA. For β-tubulin 
detection antibody pair 2 was used and the samples were diluted 10 times prior to 
AlphaLISA detection, while for SOD-1 samples were diluted 500 times.
Patient fine needle aspirates (FNAs). 
All experiments performed on human material were approved by the Regional Ethical 
Board in Stockholm. Samples were either anonymized (Dnr 2016 957-31) or taken from 
patients who signed informed consent (Dnr 2015/1694-31/1 with approved amendments 
2016/2599-32, 2017/1353-32 and 2017/1267-32). All methods were performed in 
accordance with the relevant guidelines and regulations. FNAs were taken by pathologists 
or cytologists from tumors after surgery or directly from patients and placed in tubes with 
L15 media (Gibco L-15 21083-027). Cells were counted, spun down, and resuspended 
in HBSS (Life technologies 14025100 + CaCl2, + MgCl2) and treated with docetaxel for 
15 min. When 100 000 cells or more were obtained, cells were resuspended to a final 
concentration of 3 million cells/ml and detected with AlphaLISA pair 8. When 20 000 
to 100 00 cells were obtained cells were suspended to 1 million/ml and detected with 
conjugated AlphaLISA pair 8.
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Data analysis. 
The presented data were generated in independent experiments n = 3 except Figs. 
2C-E, S2D-F and Fig. 7, where data correspond to technical duplicates. All graphs were 
generated using GraphPad Prism (versions 6-8). All data are presented as mean with error 
bars representing the standard error of the mean (S.E.M). Error bars that are smaller than 
the displayed data points are not shown by the software e.g. in Fig. 2C.
   ITDR-CETSA and cell viability data are presented as a percentage of the signal 
corresponding to the com- pound concentration where maximum stabilization was 
achieved in each series, with the exception of Figs. 6E and S5E where data are presented 
as normalized to SOD-1, Fig. 6B-D where data are presented as a percentage of the signal 
obtained for the drug-sensitive cells at maximum stabilization, and Fig. 7B,C where data 
are presented as a percentage of the signal detected for the untreated samples in each 
series. Sigmoidal curves were fit in GraphPad Prism using non-linear regression of the type 
[Inhibitor] vs. Response (three parameters) with the function Y = Bottom + (Top-Bottom)/
(1 + (X/IC50)). ITDR-CETSA curves in Fig. 7 were fit using non-linear regression of the type 
[Inhibitor] vs. Response (four parameters) with the function Y = Bottom + (Top-Bottom)/ (1 
+ (IC50/X)^HillSlope). The EC50 values with associated standard errors and 95% confidence 
intervals calcu- lated for the curves are presented in corresponding tables. The statistical 
significance of the difference observed between the dose-response curves in each graph 
was calculated using a T-test for the EC50 values obtained in each individual experiment.
   For CETSA melt curves (Figs. 1B-G, 2C,D, 4A and 5A-C), data are presented as a percentage 
of the signal detected at the lowest temperature in each melt curve and a line connecting 
the data points was automatically generated by the abovementioned software. Melting 
temperatures (Tm) and the size of the CETSA shifts (ΔTm) were also determined in 
GraphPad Prism. One-way ANOVA was used for analyzing the CETSA melt curve data in 
Figs. 1B-G and 5A-C. The significance levels for these statistical analyses are presented in 
corresponding tables.
Data availability
The datasets generated and analyzed during the current study are available from the 
corresponding author on reasonable request.
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The androgen receptor (AR) signaling pathway is a key driver of neoplastic behavior in the 
different stages of metastatic prostate cancer (mPCa). Inhibiting AR signaling therefore 
remains the cornerstone for mPCa treatment. We have previously reported that activation 
of AR signaling affects taxane chemo-sensitivity in preclinical models of castration 
resistant PCa (CRPC). Here, we explored the anti-tumor efficacy of the AR signaling 
targeted inhibitor enzalutamide combined with cabazitaxel. 
Methods
We used the AR positive CRPC model PC346C-DCC-K to assess the in vitro and in vivo 
activity of combining enzalutamide with cabazitaxel. Subsequent validation studies were 
performed using an enzalutamide resistant VCaP model. To investigate the impact of AR 
signaling on cabazitaxel activity we used RNA-sequencing, quantitative live-cell imaging 
of tubulin stabilization and apoptosis related nuclear fragmentation.  
Findings
Enzalutamide strongly amplified cabazitaxel anti-tumor activity in both the PC346C-
DCC-K (median time to humane endpoint 77 versus 48 days, P<0.0001) and VCaP-Enza-B 
tumor model (median time to humane endpoint 80 versus 53 days, P<0.001). Importantly, 
enzalutamide treatment still effectively suppressed AR signaling in PC346C-DCC-K tumors 
as shown by differential gene expression (normalized enrichment score -1.74, false 
discovery rate 0.09). AR inhibition enhanced cabazitaxel induced apoptosis as shown by 
live-cell imaging (P<0.001). 
Interpretation
Our study demonstrates that cabazitaxel efficacy can be improved by simultaneous 
blocking of AR signaling by enzalutamide, even if AR targeted treatment no longer affects 
tumor cell proliferation. These findings support clinical studies that combine AR signaling 
targeted inhibitors with cabazitaxel in CRPC.
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Introduction
The androgen receptor (AR) signaling pathway is a major driver of neoplastic behavior 
in the different stages of metastatic prostate cancer (mPCa). Hence, androgen 
deprivation therapy (ADT), which blocks the production of the AR ligands testosterone 
and dihydrotestosterone levels, is the cornerstone of mPCa treatment. Although ADT 
effectively infers disease regression in the vast majority of patients, disease recurrence is 
inevitable and is classified as castration resistant prostate cancer (CRPC). Multiple studies 
have shown that the AR continues to play a major role in ADT resistance and progression 
to CRPC, as AR amplifications and mutations conferring androgen hypersensitivity and 
ligand promiscuity are frequently identified in samples from CRPC patients.1,2 Large scale 
whole genome sequencing studies showed that AR alterations occur in 80-85% of CRPC 
patients, which are rare in castration naïve patients.3,4 This underlines the importance 
of continued suppression of AR signaling by ADT or targeted inhibitors such as 
enzalutamide in CRPC patients. We have previously reported on the impact of androgens 
and AR pathway signaling on taxane treatment efficacy in CRPC. Taxanes represent a 
vital therapeutic option for CRPC, however, treatment efficacy is limited by intrinsic and 
acquired resistance. We showed that testosterone supplementation impairs the activity 
of both docetaxel and cabazitaxel.5,6 Moreover, stimulating AR signaling by testosterone 
was able to counteract docetaxel induced long-term tumor regression, demonstrating 
that AR signaling directly contributed to taxane resistance. We therefore hypothesized 
that taxane treatment efficacy is enhanced by simultaneous blockade of AR signaling, 
through targeted inhibitors such as enzalutamide. Here, we show that indeed combining 
enzalutamide with cabazitaxel, significantly improved activity in enzalutamide resistant 
patient-derived xenograft models. We demonstrate that targeting of AR signaling 
enhances the rate of cabazitaxel induced apoptosis. Our results support new combination 
treatments for CRPC patients that potentially remains effective after resistance to AR 
signaling targeted agents occurs.
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Material and Methods
Cell culture and treatment sensitivity in vitro
The AR expressing CRPC model PC346C-DCC-K was obtained by long-term exposure 
to steroid stripped cell culture conditions as described previously.5,7 VCaP-Enza-B was 
obtained through long-term propagation of the parental VCaP cell line (RRID:CVCL_2235, 
a kind gift from Dr. Pienta, Baltimore, Maryland, USA) in RPMI (cat. no. BE12-167F, Lonza, 
Basel, Switzerland) supplemented with 10% FCS and 10 µM enzalutamide (cat. no 1613, 
Axon Medchem, Groningen, the Netherlands). Cell line authentication was performed 
by short tandem repeat analysis using the Promega PowerPlex 16 kit and compared to 
the parental cell lines. Absence of mycoplasma contamination was assessed regularly 
(MycoAlert kit, cat. no. LT07-318, Lonza). For cell viability assays, PC346C-DCC-K and 
VCaP-Enza-B cells were plated at a cell density of 5*103 cells per well in 100 µl medium. 
VCaP-Enza-B cells were maintained in RPMI containing 10% steroid stripped (DCC) 
serum, while PC346C-DCC-K cells were maintained in PGM-DCC medium.7,8 The following 
day, cells were exposed to a dose-range of cabazitaxel (0-10 nM, Sanofi-Aventis, Paris, 
France), enzalutamide or the combination of cabazitaxel with 1 µM enzalutamide in the 
presence of 0·1 nM R1881 (cat. no. D5027, Sigma-Aldrich, Saint-Louis, MO). After 7 (VCaP-
Enza-B) or 10 days (PC346C-DCC-K), cell viability was measured by the MTT assay (cat. 
no. M2128, Sigma-Aldrich) as described previously, and normalized to vehicle control.8 
Characterization of the newly acquired VCaP-Enza-B cell line was performed by examining 
the RNA and protein expression of the AR, AR-V7 and several AR target genes. In short, 
RNA was isolated using the RNeasy mini kit (#74104, Qiagen) and qRT-PCR was performed 
as described previously.5 Gene-expression of the following targets was assessed using 
TaqMan assays; AR, AR-V7, KLK3 (PSA) (using custom assays), FKBP5 and TMPRSS2 (using 
commercial kits Hs01561006 and Hs01120965 respectively, ThermoFisher Scientific). 
PBGD and HPRT1 were measured by SYBER Green assay (SensiMix Syber Lo-ROX). The 
custom TaqMan assays and primer sequences used for SYBER Green have been described 
previously.5,9 For protein expression, 20 µg protein lysate was used for immunoblotting 
and blots incubated with the following primary antibodies; rabbit-anti-AR binding 
targeting the N-terminal domain (Sp107, #200R-14, Cell Marque at 1:2000), anti-PSA 
(#A0562, Dako Agilent at 1:1000) and anti-β-actin used as loading control (#A1978, Sigma-
Aldrich, RRID:AB_476692 at 1:10000). 
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Combining enzalutamide with cabazitaxel in vivo
Fifty-two, six weeks old, NMRI nu/nu male mice (Janvier, Le Genest Saint Isle, France) were 
subcutaneously inoculated with 5*10⁶ PC346C-DCC-K cells. Tumor growth was observed 
after 2-5 weeks in ~80% of the mice. Once tumor size surpassed a volume of 150 mm3, 
mice were stratified based on tumor size to receive daily oral enzalutamide treatment 
at 60 mg/kg or vehicle control (1% carboxymethylcellulosesodium salt, cat. no. C4888, 
Sigma-Aldrich with 0.1% Tween 80, cat. no. P1754, Sigma-Aldrich). Once tumors surpassed 
300 mm3 in size, mice were again stratified based on tumor volume to receive a single 
intraperitoneal administration of 33 mg/kg cabazitaxel or placebo control (NaCl). Overall 
we had four treatment groups with 9-12 mice each, cabazitaxel and enzalutamide mono-
treatment, the combination treatment and placebo control. Tumor volume was monitored 
every 3-4 days by calipers and mice were followed until tumors exceeded a volume of 
1500 mm3, or a maximum follow up of 60 days after cabazitaxel treatment. Blood samples 
for PSA analysis were obtained at first tumor measurement, when mice were stratified 
to receive treatment and at the end of the experiment. For VCaP-Enza-B we performed a 
pilot study to assess tumorigenicity, response to enzalutamide and cabazitaxel treatment. 
Sixteen mice were inoculated with 5*10⁶ VCaP-Enza-B cells mixed with 100 µl Matrigel (cat. 
no 356231, Corning, NY), tumor take was observed in all mice. Once tumors surpassed 150 
mm3, mice were stratified based on tumor volume to receive daily enzalutamide treatment 
(60 mg/kg) or vehicle control for a period of 14 days. Impact of enzalutamide treatment 
on tumor growth during treatment was assessed using the log-cell kill method.10 After 
completing treatment with enzalutamide or placebo control, we exposed nine mice to 
cabazitaxel for dose optimization. Four mice received an intravenous administration of 
33 mg/kg cabazitaxel, three mice received 16 mg/kg and two mice received 10 mg/kg. All 
mice were followed for at least two weeks to monitor tumor response. Subsequently we 
examined the enzalutamide with cabazitaxel treatment combination versus cabazitaxel 
alone. Twenty mice were inoculated with 3*10⁶ VCaP-Enza-B cells mixed with Matrigel, 
tumor take was observed in 19 out of 20 mice. Once tumors surpassed 150 mm3, mice 
were stratified to receive daily enzalutamide (60 mg/kg) treatment or vehicle control, 
then all mice received a single intravenous administration of cabazitaxel at tumor volume 
750 mm3 at 10 mg/kg. Histology of the VCaP-Enza-B tumors and expression of the AR 
and cell cycle marker Ki67 were subsequently investigated by immunohistochemistry as 
described previously.6 Details regarding humane endpoints, general maintenance of the 
mice and statistical analysis have been described elsewhere.6
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Animal Welfare
All animal experiments were approved by the Animal experiment committee under the 
Dutch experiments on Animal Act, with the reference number AVD101002017867. The 
current study is in compliance with the Arrive guidelines. Group size and experimental set-
up were based on pilot experiments. All operations (tumor inoculation, blood sampling) 
were conducted under adequate anesthesia to minimize animal discomfort as described 
previously.5 Subcutaneously growing tumors only cause mild discomfort. 
RNA-sequencing of enzalutamide treated PC346C-DCC-K tumors
Twenty-one, six week old, NMRI nu/nu male mice were subcutaneously inoculated with 
PC346C-DCC-K cells. The experimental set-up was similar as described above with the 
following adaptations; mice were stratified to a 2:1 ratio to receive daily enzalutamide 
treatment or placebo control for seven days and were subsequently sacrificed and tumor 
xenografts snap-frozen. Total RNA was isolated from tumor xenografts as described 
previously.6 Library Prep was performed using the NEBNext Ultra Directional RNA Kit for 
Illumina according to the protocol “NEBNext Ultra Directional RNA Library Prep Kit for 
Illumina” (NEB #E7420S/L). Briefly, mRNA was isolated from total RNA using the oligo-dT 
magnetic beads. After mRNA fragmentation, cDNA synthesis was performed and used 
for ligation with adapters and PCR amplification of the resulting product. The quality and 
yield after sample preparation was measured with the Fragment Analyser. One sample 
was re-sequenced due high frequency of multi-mapped reads implicating inadequate 
depletion of ribosomal RNA. Paired-end RNA-Seq data of enzalutamide PDX samples (N 
= 15) was analyzed using UCSC human genome build hg38 and GENCODE annotation 
release v26 (GRCh38.p10) and mouse genome build mm10 (reference strain C57BL/6J) 
with GENCODE annotation release M15 (GRCm38.p5) for downstream disambiguation 
of human/mouse data. FASTQC (v0.11.5)11 was applied on the paired-end FASTQ files for 
quality control, both before and after running trimmomatic (v0.36),12 which removed 
TrueSeq adapter sequences. STAR (v2.5.3a) was used as aligner, with 2-pass mapping 
for each sample separately. AstraZeneca’s disambiguation algorithm (Python variant, 
2013)13 for reads aligned to two species has been used to assess the best alignments and 
disambiguate the BAM files. Mapping quality plot was generated and checked based on 
sambamba Flagstat (v0.6.7)14 statistics. Count files, with the number of reads for each gene 
were created with subread FeatureCounts (v1.5.2)15 on the disambiguated BAM files. R 
(version 3.4.3) was used for further statistical analyses and data visualization. Differential 
expression analysis was performed with condition ‘enzalutamide treated’ (N = 10) versus 
‘untreated’ (N = 5) using the DESeq2 package (v1.18.1)16 and the Wald-test. P values were 
adjusted using the Benjamini-Hochberg procedure.17 Settings of different tools can be 
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seen in the supplementary data file. Gene set enrichment analysis (GSEA, v4.1.0) was 
performed using normalized gene expression values (count per million) of the individual 
tumor samples, with condition ‘enzalutamide treated’  versus ‘untreated’ and applied to 
the Molecular Signatures Database (MSigDB) hallmark gene set collection.18 
Live cell imaging of cabazitaxel induced microtubule stabilization and 
apoptosis in PC346C-DCC-K cells 
To study the impact of AR pathway inhibition on cellular response to cabazitaxel treatment, 
PC346C-DCC-K cells were engineered to overexpress enhanced yellow fluorescent protein 
(EYFP) labelled beta-tubulin (EYFP-β-Tubulin) and the human histone H2B gene fused to 
red fluorescent protein (H2B-RFP). The EYFP-β-Tubulin expression was used to monitor 
taxane target engagement and the histone marker for visualizing treatment induced 
perturbations of mitosis, proliferation and apoptosis. PC346C-DCC-K cells were first 
transduced to stably express H2B-RFP, selected based on RFP expression, transfected with 
EYFP-tubulin and again selected based on fluorescent expression of both markers. Large 
scale lentiviral production was performed by calcium phosphate transfection of Hek293T 
(RRID:CVCL_1926) cells with the LV-RFP construct expressing H2B-RFP, pMD2.G plasmid 
for the viral envelope and psPAX2 for packaging.19  Viral supernatant was collected 24 
and 48h after transfection and centrifuged at 3000g to remove cellular debris. The LV-RFP 
construct expressing H2B-RFP was kindly gifted by Elaine Fuchs (RRID:Addgene_26001, 
Addgene, Watertown, MA).20 Viral supernatant was added to the PC346C-DCC-K cells, 
incubated overnight and the medium was refreshed the following day. Cells were 
passaged three times before selection and transfection with the second marker to ensure 
the viral particles were washed away. For transfection with the expressing EYFP-α-Tubulin 
plasmid (kindly provided by Dr. Galjart, Erasmus MC) we used Lipofectamin 2000 (cat. no. 
11668030, Thermo Fisher Scientific, Waltham, Massachusetts, USA). Selection PC346C-
DCC-K cells was performed by fluorescent activated cell sorting (FACS) using a BD FACS 
Aria III (BD Biosciences, Franklin Lakes, New Jersey, USA) equipped with 4 lasers and a 
85 µm nozzle. mRFP1 fluorescence was detected using a 561 nm yellow-green laser and 
a 600 LP + 610/20 BP emission filters, similar to mCherry RFP. EYFP fluorescence was 
detected using a 488 nm blue laser and 502LP + 530/30 BP emission filters, similar to 
GFP. Dead cells were gated out by means of Hoechst 33258 fluorescence (Hoechst 33258, 
Sigma Aldrich). Doublets and multicellular clusters were gated out using forward and side 
scattering according to standard protocols: FSC-W/FSC-A gate, followed by SSC-W/SSC-A 
gate, verified on FSC-A vs FSC-H gate. Sorting purity, viability, and absence of doublets 
was verified after sorting, by re-analysis of sorted cells. Cell viability and response to 
taxane treatment was compared to the parental PC346C-DCC-K, using the MTT assays as 
described above. No significant impact of the expression of H2B-RFP and EYFP-β-Tubulin 
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on taxane sensitivity was found. For live cell imaging, 1*10⁴ PC346C-DCC-K cells co-
expressing H2B-RFP and EYFP-β-tubulin were plated with 100 µl PGM-DCC medium in a 
96-wells Cell Carrier Ultra plates suited for live cell imaging (cat. no. 6055302, PerkinElmer, 
Hamburg, Germany). Cells were incubated for 72 hours to ensure optimal attachment and 
cell spreading. One hour before imaging cells were pre-treated with 1 µM enzalutamide 
and/or 0.1 nM R1881. After imaging an initial pre-treatment time point (t-1), cells were 
exposed to 3 nM cabazitaxel and image acquisition was continued for 100 hours with an 
interval of 150 minutes. During intervals, the cells were stored in an integrated cell culture 
incubator to optimize cell viability. Sixteen images covering 103714 µm2 (containing 
minimally 1000 cells at the start of the experiment) were acquired using an Opera Phenix 
spinning-disk confocal high-content screening system (PerkinElmer), equipped with a 40x 
water immersion object and a 16 bit sCMOS 4 Megapixel camera. EYFP-β-tubulin and H2B-
RFP were sequentially excited with 488 nm and 561 nm solid state laser lines, detected at 
500-550 nm and 570-630 nm wavelength ranges, respectively. Both analyses, apoptosis 
induction and microtubule stabilization, were performed using custom image analysis 
protocols in the Harmony analysis software (version 4.9, Perkin Elmer). First, total area 
covered by cells was selected using the EYFP-β-tubulin signal. The level of microtubule 
stabilization was determined in the total area covered by EYFP-β-tubulin expressing cells, 
using the Haralick Contrast parameter.21,22 To quantify apoptosis, fragmented nuclei of 
cells expressing RFP-H2B were detected as spots and clustered by a maximum distance 
of 5 µm to be assigned to individual apoptotic cells and expressed as percentage to total 
nuclei.  
Role of the funding source 
This study was financially supported by an unrestricted grant by Sanofi, however Sanofi 
was not involved in the design and interpretation of this study. 
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Results
Enzalutamide improves cabazitaxel activity in a model of CRPC
The impact of enzalutamide on cabazitaxel activity was first evaluated in an in vitro 
setting. We used the AR expressing CRPC cell line PC346C-DCC-K, for which we previously 
reported an interaction between AR signaling and taxane resistance.6 PC346C-DCC-K 
harbors intrinsic taxane resistance, as the maximum response to cabazitaxel plateaued 
at <50% reduction in cell viability (Figure 1a). The addition of 1 µM enzalutamide to 
the cabazitaxel dose range consistently reduced cell viability by ~25% compared to 
cabazitaxel monotherapy (P<0.0001; IC50 0.32 nM cabazitaxel). In line with the in vitro 
results, cabazitaxel was found to be only temporarily effective in vivo with 11 out of 12 mice 
showing initial regression of PC346C-DCC-K tumors followed by rapid outgrowth (Figure 
1b, blue data points). The combination treatment of enzalutamide and cabazitaxel was able 
to induce a complete tumor regression in 4/12 mice and substantially delayed the onset 
of progression in the remaining mice (Figure 1b, orange data points). Of note, the addition 
of enzalutamide did not result in greater toxicity, as bodyweight loss following cabazitaxel 
administration was comparable in mice receiving the combination or mono-treatment 
(Supplementary figure 1a). Overall, combining enzalutamide with cabazitaxel significantly 
improved tumor response compared to cabazitaxel monotherapy, with median time to 
humane endpoint 77 days and 48 days respectively (P<0.0001, Supplementary figure 1b). 
Although the combination treatment greatly impacted tumor response, enzalutamide 
monotherapy was found to be ineffective (Figure 1c, supplementary figure 1b log-rank 
test P=0.17). However, enzalutamide treatment in PC346C-DCC-K tumor bearing mice did 
reduce PSA plasma levels, suggesting effective inhibition of the AR pathway (Figure 1d, 
P<0.001). 
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 Figure 1: Combined treatment efficacy of enzalutamide and cabazitaxel towards a model 
of AR positive castrate resistant prostate cancer. A) Efficacy of cabazitaxel mono-therapy or 
combined with enzalutamide, towards an AR positive CRPC cell line. Cell viability was assessed 
by exposing PC346C-DCC-K cells to a dose range of cabazitaxel (blue) alone or with the addition 
of 1 µM enzalutamide (orange) for 10 days. Shown is the median cell viability of three individual 
experiments normalized to vehicle controls, error bars display standard error of the mean (SEM) 
and non-linear regression analysis was used to compare and calculate IC50 values (cabazitaxel 
IC50 not reached, enzalutamide with cabazitaxel IC50 0.33 nM, P<0.0001). B-C) Antitumor efficacy 
of cabazitaxel, enzalutamide and the treatment combination in vivo. Shown are individual tumor 
growth curves of the PC346C-DCC-K model. On day 0 tumors surpassed a volume of 150 mm3 and 
mice were stratified based on tumor volume to receive either daily enzalutamide treatment or 
placebo control. Once tumors doubled in size, mice were again stratified to either receive a single 
dose of cabazitaxel treatment (b) or placebo control (c). Mice were followed until tumors surpassed 
1500 mm3 in size or a maximum follow-up of 60 days after cabazitaxel treatment. One mouse in the 
cabazitaxel mono-treatment group was excluded due to bodyweight loss and abnormal behavior 
which, was unrelated to treatment. D) Impact of enzalutamide treatment (n=12) on PSA plasma 
levels as compared to placebo controls (n=9). Plasma was sampled when mice were stratified to 
receive daily enzalutamide treatment or vehicle control (Sample 1) and when mice were stratified to 
receive cabazitaxel or placebo control (Sample 2). Relative PSA index was calculated by dividing PSA 
levels by tumor volumes at time of sampling. Matched samples are connected by a line, boxplots 
























































































Adding enzalutamide to cabazitaxel improves overall activity even in an 
enzalutamide resistant model
Given the impact of the treatment combination, even in anti-androgen resistant setting, 
we selected an enzalutamide resistant VCaP sub line for validation studies. VCaP-Enza-B 
maintains AR signaling activity under high dose enzalutamide treatment (Figure 2A, 
supplementary figure 2). In contrast to PC346C-DCC-K, VCaP-Enza-B displayed high taxane 
sensitivity, as 1 nM of cabazitaxel reduced cell viability by 90% (Figure 2B). Nevertheless, 
adding enzalutamide to cabazitaxel further reduced cell viability as we identified a 
significant IC50 shift from 0.24 nM for cabazitaxel to 0.11 nM for the combination 
(P<0.0001). For subsequent in vivo studies, we first confirmed enzalutamide resistance of 
VCaP-Enza-B and optimized cabazitaxel dosing (Supplementary figure 3A-C). Low dose 
cabazitaxel treatment was found to induce a partial tumor response, thus creating a 
therapeutic window to study the addition of enzalutamide. Combining enzalutamide with 
cabazitaxel treatment improved overall activity compared to cabazitaxel monotherapy 
with median time to humane endpoint 80 and 53 days respectively (P<0.001, Figure 
2C and supplementary figure 3D). Similar to PC346C-DCC-K, enzalutamide treatment 
reduced plasma PSA levels in VCaP-Enza-B tumor bearing mice while having no impact 
on tumor growth (Figure 2D). Overall, we conclude that combining enzalutamide and 
cabazitaxel treatment showed superior anti-tumor efficacy compared to cabazitaxel 
without targeting AR signaling.
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Figure 2: Combined treatment efficacy of enzalutamide and cabazitaxel towards an enzalutamide 
resistant prostate cancer model. A-B) Efficacy of enzalutamide, cabazitaxel and the combination 
with enzalutamide in vitro using an AR positive enzalutamide resistant cell line. Cell viability was 
assessed by exposing VCaP-Enza-B cells to a dose range of enzalutamide (A), cabazitaxel (turquoise, 
B) alone or with the addition of 1 µM enzalutamide (red, B) for 7 days. Shown is the median cell 
viability of three individual experiments normalized to vehicle controls, error bars display standard 
error of the mean (SEM) and non-linear regression analysis was used to compare and calculate IC50 
values (cabazitaxel IC50 0.24, enzalutamide with cabazitaxel IC50 0.11 nM, P<0.0001). Efficacy of 
enzalutamide was calculated using linear regression analysis (IC50 5.4 µM). C) Antitumor efficacy 
of cabazitaxel and the treatment combination in vivo. Shown are individual tumor growth curves of 
the VCaP-Enza-B model. On day 0 tumors surpassed a volume of 150 mm3 and mice were stratified 
based on tumor volume to receive either daily enzalutamide treatment or placebo control. Once 
tumors surpassed a volume of 750 mm3 mice were received a single dose of cabazitaxel treatment. 
Mice were followed until tumors surpassed 1500 mm3 in size or a maximum follow-up of 60 days 
after cabazitaxel treatment. D) Impact of enzalutamide treatment (n=10) on PSA plasma levels as 
compared to placebo controls (n=9). Plasma was sampled when mice were stratified to receive daily 
enzalutamide treatment or vehicle control (Sample 1) and when mice received cabazitaxel (Sample 
2). Relative PSA index was calculated by dividing PSA levels by tumor volumes at time of sampling. 
Matched samples are connected by a line, boxplots represent the median values with 25th and 75th 
percentile and hinges span the 1.5 interquartile range.






















































































Enzalutamide effectively suppresses AR signaling even in a treatment 
resistant model 
To confirm active inhibition of AR signaling by enzalutamide treatment and to identify 
potential compensatory growth mechanisms, we investigated differential gene 
expression in short-term enzalutamide treated PC346C-DCC-K tumors. Although tumor 
growth of PC346C-DCC-K was unaffected, enzalutamide treatment significantly altered 
the expression of over 1,900 genes (supplementary data file). Principle component 
analysis of gene expression data clearly separated tumors obtained from enzalutamide 
treated from placebo control mice (Figure 3A). Subsequent gene set enrichment 
analysis (GSEA) identified ‘Androgen response’ as the most significantly altered gene-set 
with a normalized enrichment score of -1.74 and a false discovery rate of 0.09 (Figure 
3B). Interestingly several metabolic pathways, including fatty acid metabolism, were 
significantly repressed by enzalutamide treatment (Figure 3C). GSEA did not identify any 
significantly upregulated gene-sets that could reflect compensatory growth mechanisms 
as a result of enzalutamide treatment (Supplementary figure 4). Overall, RNA-sequencing 
confirmed that enzalutamide treatment repressed AR signaling in PC346C-DCC-K tumors.
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Figure 3: Differential gene expression inferred by enzalutamide treatment in PC346C-DCC-K. 
A) Principle component analysis of mRNA expression in PC346C-DCC-K tumors obtained from 
enzalutamide treated (n=10) and placebo control mice (n=5). Mice were treated for seven days 
by daily administration of enzalutamide or vehicle control upon which tumors were isolated and 
used for RNA-sequencing. B-C) Gene set enrichment analysis (GSEA) of differential gene expression 
caused by enzalutamide treatment in PC36C-DCC-K tumors using the ‘hallmark collection’. B) 
Overview of significantly enriched gene-sets caused by enzalutamide treatment. Significantly 
enriched gene-sets were selected based on P value (<0.05) and false discovery rate (FDR <0.25). 
Y-axis displays the normalized enrichment scores for the individual gene-sets, negative values infer 
pathway inhibition. Gene-sets are ranked based on lowest FDR, thus highest confidence level. C) 
GSEA plot for the hallmark gene-set ‘Androgen signaling’.  
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Targeting AR signaling enhances cabazitaxel induces apoptosis
To further unravel the impact of either inhibiting or stimulating AR signaling on cabazitaxel 
activity we used live-cell imaging. PC346C-DCC-K cells were transfected to dually express 
fluorescently labelled H2B and β-tubulin, a histone marker used to track mitosis and to 
monitor taxane induced tubulin stabilization, respectively. After cabazitaxel exposure 
(3 nM) we observed rapid formation of tubulin bundles with high fluorescent intensity, 
indicative of taxane induced tubulin stabilization (Figure 4A, second column). As expected, 
tubulin stabilization induced abnormal and prolonged mitosis, which led to mitotic 
slippage and multinucleated cells (Figure 4A, third column). In androgen supplemented 
conditions (R1881), apoptosis was rarely observed during the treatment span of 100h. 
Within the first 48h, we did not observe a substantial impact of either castrate (minus 
R1881) or enzalutamide treated conditions on cabazitaxel activity. However, subsequent 
cell divisions more frequently resulted in apoptosis in androgen suppressed conditions. 
To validate these observations we used image-based quantification of proliferation, 
apoptosis and tubulin stabilization. Indeed, cabazitaxel treatment induced rapid tubulin 
stabilization as identified by Haralick contrast (Figure 4B). Proliferation was effectively 
suppressed by cabazitaxel treatment, although androgen stimulation induced a small 
but significant increase (Figure 4C, P<0·0001). The low percentage of fragmented nuclei 
as a consequence of apoptosis confirmed our observation of cabazitaxel resistance in 
androgen supplemented conditions (Figure 4D). Either castrate culture conditions or the 
addition of enzalutamide increased the percentage of cabazitaxel induced apoptotic cells 
by 1.5-2% (P<0·001). 
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Figure 4: Impact of AR pathway manipulation on cabazitaxel treatment efficacy as studied by 
live-cell imaging. a) Representative images of PC346C-DCC-K cells expressing EYFP-β-tubulin 
(green) and H2B-RFP (orange) treated with 3 nM cabazitaxel. The rows represent the different 
androgen conditions, in the top row culture media was supplemented with 0.1 nM of the synthetic 
androgen R1881, panels in the middle show cells in castrate culture conditions and lowest show 
enzalutamide treatment(1 µM ) in the presence of R1881. The first column depicts images obtained 
before addition of cabazitaxel while the second column shows images obtained during the first 
or second interval after taxane treatment. The arrows highlight tubulin structures as a result of 
cabazitaxel treatment. The third column shows cells treated with cabazitaxel for 24-48h, in which 
multinucleated cells are circled. The fourth column displays images obtained four days after initiating 
treatment and highlights fragmented cells, which point to treatment induced apoptosis. Scale bars 
represent 50 µm in size. B-D) Results of image based quantification of normalized Haralick contrast 
(B), nuclear count (C) and percentage fragmented cells (D). Shown are the results of four individual 
experiments performed in triplicate, data points represent median values with SEM displayed as 
a band. Haralick contrast measures pixel to pixel differences in fluorescent intensities and was 
applied to inspect tubulin structures. Normalization to Haralick contrast levels in pre-treatment 
images was performed. The slow reduction in Haralick contrast over time is most likely a result of 
monitor bleaching. Nuclear count was used to monitor proliferation and normalized to numbers in 
pre-treatment images. Fragmented cells were quantified and normalized to nuclear count for each 
individual time point to calculate the percentage apoptotic cells. 
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Discussion 
The present study explored whether cabazitaxel treatment efficacy could be enhanced 
by targeting AR signaling. We showed that adding enzalutamide to cabazitaxel inferred 
greater anti-tumor activity, compared to both single treatments. Importantly, the 
combination treatment was found to remain active in patient-derived xenograft models 
of enzalutamide resistant CRPC where AR signaling could still be effectively blocked by 
enzalutamide treatment. Moreover, targeting AR signaling increased the rate of cabazitaxel 
induced apoptosis. Overall, our study shows that cabazitaxel efficacy is directly affected 
by AR signaling which paves the way for promising combination treatments in CRPC.
Taxane chemotherapeutics exert their function by targeting the β-tubulin subunit of the 
tubulin polymer, which forms the microtubule network, and induces stabilization. During 
mitosis, taxane treatment interferes with chromatid separation and eventually leads to cell 
cycle stalling in the G2/M phase. Arrest in mitosis can directly induce cell death by mitotic 
catastrophe, although cancer cell lines have shown to display variable response to taxane 
treatment.23 Live-cell imaging revealed that in taxane resistant cells, cabazitaxel treatment 
effectively induces cell cycle stalling, mitotic slippage and multinucleation although this 
rarely triggers mitotic cell death. Adding enzalutamide did further suppress proliferation 
and increased the percentage of fragmented cells, but only after 48h of taxane treatment. 
Blocking the AR pathway therefore likely decreases cell viability after the first abnormal cell 
cycle. Of note, the impact of enzalutamide co-administration increased the percentage of 
apoptotic cells by only 1.5-2%. However, we expect that over time, the accumulation of 
apoptotic cells would significantly contribute to therapeutic efficacy. 
Sustained AR signaling plays a major role in CRPC, as exemplified by the frequency of 
genetic aberrations and splice-variant expression driving resistance to AR signaling 
targeted treatment.3,24 The current study, together with our previous reports, implicates 
a major role for AR signaling in taxane treatment efficacy.5,6  The underlying mechanisms 
resulting in greater cabazitaxel sensitivity in enzalutamide treated PCa cell remains 
to be clarified, although several metabolic pathways were significantly impacted by 
enzalutamide treatment. Potentially, multinucleated cells may become sensitive to 
enzalutamide induced suppression of metabolic activity and are more likely to trigger 
apoptosis. Clearly further investigation is warranted.
A preclinical study by Martin et al., also reported an added benefit of combining cabazitaxel 
with AR signaling targeted treatment in AR positive PCa models.25 The authors concluded 
that adding enzalutamide to cabazitaxel was effective in hormone sensitive PCa but not in 
CRPC cell lines. Moreover, the addition of enzalutamide to cabazitaxel did not significantly 
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decrease the tumor mass of 22Rv1 xenografts. However,  activity of the combination 
treatment was assessed using a different dosing schedule and based on a single tumor 
measurement obtained four days  after  completing the  cabazitaxel treatment. In our in 
vivo experiments, the greatest impact of the combination treatment was on long-term 
suppression of tumor-growth after cabazitaxel treatment. Martin et al. did identify an 
impact of the combination treatment on the frequency of proliferating and apoptotic 
cells upon inspection of the 22Rv1 tumors. Overall, we argue that a premature endpoint 
potentially compromised the assessment of the combination treatment. 
The addition of enzalutamide to cabazitaxel has been investigated in a phase I clinical 
trial performed at our institute.26 Enzalutamide is a known CYP3A4 inducer and could 
impact on cabazitaxel exposure through increased clearance. Indeed, concomitant 
enzalutamide treatment was found to reduce cabazitaxel plasma levels by 22%. We have 
previously shown that adequate taxane exposure is key for optimal anti-tumor activity.27 
However, in the clinical study two cycles of the combination treatment was still found 
to induce a >50% PSA reduction in 8/13 CRPC patients.26 This suggests that combining 
enzalutamide with cabazitaxel is an effective treatment, despite the moderately 
decreased systemic cabazitaxel exposure. Moreover, our current preclinical data suggest 
that patients who are no longer responsive to enzalutamide treatment, could benefit 
from combining enzalutamide with cabazitaxel. Several ongoing phase II/III clinical 
trials investigate the feasibility of combining AR signaling targeted agents with taxane 
chemotherapeutics for advanced PCa.28 With the treatment landscape of mPCa moving 
towards effective combination strategies, adding AR signaling targeted inhibitors to 
taxane chemotherapeutics provides a promising strategy for CRPC patients. 
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Supplementary figure 1: In vivo anti-tumor efficacy of the enzalutamide and cabazitaxel 
combination treatment towards the PC346C-DCC-K patient derived xenograft. A) Normalized 
bodyweights of tumor bearing mice receiving cabazitaxel (dark blue), enzalutamide (yellow) 
or combination treatment (orange) compared to placebo controls (light blue). Bodyweights of 
individual mice were normalized to weight on day 0, when mice were stratified to receive cabazitaxel 
treatment or placebo control. Displayed are the median normalized bodyweights (%) per treatment 
group with error bars showing standard error of the mean (SEM). Loss of bodyweight induced by 
cabazitaxel treatment did not surpass 20% which is used as a humane endpoint. B) Kaplan Meier 
curve displaying the cumulative survival for the four treatment groups placebo control (light blue), 
enzalutamide (yellow), cabazitaxel (dark blue) and the treatment combination (EnzaCaba, orange). 
Survival was calculated from the day mice were stratified to start enzalutamide treatment until 
tumors exceeded a volume of 1500 mm3. Mice were censored when tumors did not reach 1500 
mm3 in size during the maximum follow-up of 60 days after cabazitaxel treatment. One mouse in 
the EnzaCaba treatment group was found dead two weeks after cabazitaxel treatment. Results from 
the pair-wise comparison, using the log-rank test with Bonferroni correction are shown in the table.
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Supplementary figure 2: characterization of enzalutamide resistant VCaP cell lines. A) RNA 
expression of the androgen receptor (AR), AR-variant 7 (AR-V7) and the target genes FKBP5, KLK3 
and TMPRSS2 in VCaP and its enzalutamide resistant cell lines as assessed by qRT-PCR. The hinges 
of the boxplots represent the 25th and 75th percentile with median expression and the whiskers 
represent 1.5x the interquartile range (IQR). For each gene two technical replicates were included 
and expression was normalized to two household genes using the 2-ΔCt method. B) Protein 
expression of AR, AR-V7 and PSA in VCaP and its enzalutamide resistant cell lines as assessed by 
western blot. Protein lysate from the DU145 cell line was used as a negative control for AR, AR-V7 
and PSA expression while LnCaP was used as a positive control for AR and PSA expression. Actin was 
used as a loading control.
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Supplementary figure 3: In vivo characterization and treatment sensitivity of VCaP-Enza-B. A) 
Enzalutamide resistance of the VCaP-Enza-B tumor model. Shown are individual tumor growth 
curves of mice receiving either daily enzalutamide treatment or placebo control for two weeks. 
Impact of enzalutamide treatment was assessed using the log-cell kill calculation (0.087), VCaP-
Enza-B was confirmed as enzalutamide resistant (log-cell kill <0.7). B) Response of the VCaP-Enza-B 
tumor model to different cabazitaxel dosages. Subset of VCaP-Enza-B tumor bearing mice as 
displayed in A were subjected to either 10 mg/kg (N=2 light blue), 16 mg/kg (N=3, blue) or 33 mg/
kg (N=4, dark blue) cabazitaxel treatment. Timing of cabazitaxel administration is highlighted in 
yellow. C) Histological assessment and immunohistochemical staining of the androgen receptor 
and Ki67 in VCaP-Enza-B tumors.
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Supplementary figure 4: Gene set enrichment analysis of differential gene expression induced 
by enzalutamide treatment in PC346C-DCC-K tumors. Gene set enrichment analysis (GSEA) 
using the Hallmarks gene sets applied to differential gene expression induced by enzalutamide 
treatment in PC346C-DCC-K tumors. Shown is an overview of normalized enrichment scores (Y-axis) 
of the individual gene sets and the matching false discovery rate (FDR). Gene sets that meet the 
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Circulating tumor cell (CTC) derived organoids have the potential to provide a powerful 
tool for personalized cancer therapy, but are restrained by low CTC numbers provided 
by blood samples. Here, we used diagnostic leukapheresis (DLA) to enrich CTCs from 
metastatic prostate cancer (mPCa) patients and explored whether organoids provide a 
platform for ex vivo treatment modelling.
Methods
We prospectively screened 102 mPCa patients and performed DLA in 40 patients with ≥5 
CTCs/7.5 mL blood. We enriched CTCs from DLA using white blood cell (WBC) depletion 
alone or combined with EpCAM selection. The enriched CTC samples were cultured in 3D 
to obtain organoids and used for downstream analyses. 
Results
The DLA procedure resulted in a median yield of 5312 CTCs as compared to 22 CTCs in 7.5 
mL of blood. Using WBC depletion, we recovered 46% of the CTCs, which reduced to 12% 
with subsequent EpCAM selection. From the isolated and enriched CTC samples, organoid 
expansion succeeded in 35%. Successful organoid cultures contained significantly higher 
CTC numbers at initiation. Moreover, we performed treatment modelling in one organoid 
cell line and identified substantial tumor heterogeneity in CTCs using single cell DNA 
sequencing. 
Conclusions
DLA is an efficient method to enrich CTCs, although the modest success rate of culturing 
CTCs precludes large scale clinical application. Our data do suggest that DLA and 
subsequent processing provides a rich source of viable tumor cells. Therefore, DLA offers 
a promising alternative to biopsy procedures to obtain sufficient number of tumor cells to 
study sequential samples in mPCa patients.
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Introduction 
Translational studies on advanced prostate cancer (PCa) have often been limited to static 
sources, such as resection of the primary tumor or biopsies.1-4 However, cancer is an ever 
moving target, as dynamic evolution drives spatial and temporal heterogeneity allowing 
tumors to adapt and escape therapeutic interventions. We therefore require new methods 
that provide real-time insights into evolving cancer biology for treatment tailoring. 
Circulating tumor cells (CTCs) could serve as a dynamic tumor source which captures the 
genetic and phenotypic heterogeneity of cancer and can be obtained at multiple time-
points during the disease course to assess clinical progression.5 Additionally, CTCs can 
be obtained from peripheral blood in a relatively non-invasive manner, thus providing 
an easily accessible source of metastatic cells as an alternative to tumor biopsies. This is 
particularly beneficial for patients with primarily bone metastasis such as in metastatic 
PCa (mPCa). In mPCa, CTC numbers have already been shown to harbor significant 
prognostic and predictive value.6-10 The possibility to obtain viable CTCs also provides the 
opportunity to propagate CTCs ex vivo. The development of cancer organoids has allowed 
us to better capture the tumor-specific characteristics than standard 2D culture methods.11 
Together, this provides the opportunity to use CTC derived organoids as a representative 
model of the current disease status and use for drug discovery and sensitivity-screening.12 
PCa CTCs can be cultured as organoids, although the reports thus far suggest a very low 
efficiency rate for success.13,14 Previous reports suggest that one important obstacle is the 
high number of CTCs needed to initiate organoid propagation.13,15 Since the median CTC 
count in mPCa patients is 2-20 CTCs per 7.5 mL of blood10, ex vivo expansion of CTCs is 
unlikely to be successful in most patients. Diagnostic leukapheresis (DLA) is a standardized 
procedure to enrich for mononuclear cells by continuous centrifugation of blood. Since 
CTCs have a similar density to mononuclear cells, they are enriched as well.16 Importantly, 
DLA is a minimally-invasive and generally safe procedure, that is well tolerated by 
patients.17 Within this prospective study we set out to isolate CTCs from mPCa patients 
by DLA. We hypothesized that the increased number of CTCs obtained by DLA, will allow 
us to culture CTC derived organoids and potentially provide a platform for individualized 
disease modelling. Using optimized methods we validated DLA as a feasible and safe 
method to enrich for CTCs in mPCa patients. CTCs could be propagated as short-term 
organoid cultures in 35% of the samples, from which we could obtain one stable organoid 
cell line. These short-term organoid cultures expressed the classical markers of PCa and 
maintained genomic variants previously identified in metastatic samples. Overall, our 
study provides an important step forward in implementing CTCs in individualized disease 
modelling, nevertheless identifies several challenges that require further optimization.
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Material and methods
Patients with mPCa were included and selected based on the presence of ≥5 per 7.5 mL of 
blood. The study was conducted in accordance with the Declaration of Helsinki and was 
approved by the medical ethical committee of the Erasmus Medical Center Rotterdam 
(EMC16-449), full exclusion and inclusion criteria are described in the supplementary 
material and methods. DLA was performed using the standard settings, only the plasma 
pump rate was adjusted. CTCs from DLA were enriched by negative depletion of white 
blood cells using RosetteSep(tm) CTC Human CD45 Depletion Cocktail (STEMCELL 
Technologies, Vancouver, British Colombia, Canada), with or without subsequent manual 
positive immunomagnetic enrichment using CellSearch EpCAM ferrofluids. The enriched 
DLA samples were cultured under optimized conditions to obtain PCa organoids.
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Patient and tumor characteristics N = 37*
Age, years (median, range) 70 (49-83)




Hormone status at time of inclusion
HSPC 12
CRPC 25











Type of prior therapy
Local therapy (i.e. radical prostatectomy or RT on prostate) 16
ADT (i.e. chemical or surgical) 25
Chemotherapy 17




Total duration of DLA (minutes; median, range) 104 (25-925)
Total processed blood volume (mL; median, range) 5112 (1153-10001)
Volume of collected DLA product (mL; median, range) 96 (18-178)
Missing 3
Table 1: Patient characteristics. Baseline characteristics are shown for patients who were eligible 
for the diagnostic leukapheresis (DLA) procedure. Prior systemic treatments are only applicable to 
castration-resistant prostate cancer (CRPC) patients as concomitant androgen deprivation therapy 
(ADT) was an exclusion criteria for hormone-sensitive prostate cancer (HSPC) patients. In addition 
we show the duration, processed blood volume and collected volume of the DLA procedure. *Four 
patients underwent DLA twice. 
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Results 
Patient characteristics and CTC screening
We screened 102 mPCa patients for eligibility and selected 45 patients who had ≥5 CTC in 
7.5 mL of peripheral blood (PB) for CTC collection by DLA (Figure 1A). Metastatic castration 
resistant PCa (mCRPC) patients screened for study participation tended to have a higher 
CTC burden compared to the metastatic hormone sensitive PCa (mHSPC) patients 
(median of 5 CTC/7.5 mL vs 1 resp. P=0.07, supplementary figure 1A). Moreover, 50% of 
the mCRPC patients had 5 or more CTCs while 39% of the mHSPC patients were included. 
The overall median CTC count of the included patient population was 22 CTCs per 7.5 mL 
PB prior to DLA, with 10 CTCs/7.5 mL and 26 CTCs/7.5 mL for mHSPC and mCRPC patients 
resp. (Figure 1B). The CTC burden was monitored in 24 patients and was found to remain 
stable in between screening, prior to the DLA and after completion of the DLA procedure 
(P=0.37, supplementary figure 1B). 
Diagnostic leukapheresis
After initial screening, a total of 40 patients successfully underwent DLA, as four patients 
withdrew and the DLA procedure was terminated in one patient because of an adverse 
event (grade 3 vasovagal reaction directly after start of the procedure). No other grade ≥3 
adverse events were observed. The baseline characteristics of the patient population and 
DLA procedure are described in Table 1. Four patients were included twice at separate 
time points during their treatment course, resulting in serial samples for subjects 9, 11, 24 
and 22 (annotated as e.g. 9-I/II). We examined the impact of DLA density settings on CTC 
enrichment in four patients, by performing the DLA procedure in two fractions of both 
5L blood at 2% and 5% hematocrit respectively. As there was a trend towards higher CTC 
yield when DLA was performed at 5% hematocrit (Supplementary figure 1C, P=0.125), we 
continued the DLA procedure using high DLA density settings and processed 5L of total 
blood volume, which limited the procedure time to approximately 2 hours. The median 
CTC concentration of the DLA product was 64/mL compared to 2.5/mL in PB samples pre-
DLA (P<0.001), with an estimated median yield of 5312 CTCs in 96 mL of DLA product 
(Figure 1C). Using these DLA settings, we were able to retrieve a median of 36% of the 
estimated CTCs available given the processed blood volume and the CTC count in PB 
(Supplementary figure 1D).
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DLA performed
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Figure 1: Overview of patient inclusion, diagnostic leukapheresis procedure and subsequent 
circulating tumor cell enrichment methods. A) Patients were eligible for diagnostic leukapheresis 
(DLA) if they had adequate venous access and ≥5 circulating tumor cells (CTCs). Two patients 
refrained from participation because of urge-incontinence and because of pain. Five patients were 
not screened for the presence of CTCs in peripheral blood due to inadequate venous access. After 
screening and inclusion four patients refrained from DLA because of progressive disease. B) CTC 
count in metastatic castration resistant (mCRPC, n=31) and hormone sensitive prostate cancer 
(mHSPC, n= 9) patients who succesfully underwent DLA. CTC burden was determined in 7.5 mL 
peripheral blood (PB) sampled before the start of DLA. Statistical comparison was performed using 
an unpaired two-sided Wilcoxon rank test P=0.07. C) Absolute CTC count in PB and DLA product. 
The X-axis shows CTC count per mL PB, per mL DLA product and extrapolated to total DLA volume. 
Each dot represents an individual subject (n=40) and for all subjects we show the results of the 5% 
RBC density setting in 5L processed blood volume. Samples from the same subject are connected 
by a (dashed) line. Y-axis is a logarithmic scale. Statistical comparison of CTC yield per mL DLA versus 
PB was performed by a paired two-sided Wilcoxon rank test P<0.0001. 
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CTC enrichment from DLA material
We compared two methods to enrich and isolate CTCs from the DLA product: depletion 
of WBCs using the RosetteSepTM method, with or without subsequent positive selection 
using EpCAM directed antibodies. For the RosetteSep(tm) method to function, WBCs 
are cross-linked with RBCs leading to erythrocyte rosetting of WBC allowing for gradient 
separation. Since the DLA product contains a high WBC and relative low RBC concentration, 
we needed to add RBCs to achieve an optimal WBC:RBC ratio for depletion of WBCs. Using 
the autologous RBCs from 40 mL of PB, we were able to effectively process a median of 
25.5 mL out of the 96 mL DLA obtained. We compared the impact of WBC depletion alone 
and subsequent EpCAM enrichment using twelve paired samples (Supplementary figure 
2). WBC depletion alone was found to reduce the WBC concentration from 93.6*10⁶/mL to 
0.12*10⁶/mL, resulting in a WBC depletion factor of 3.1 log10-fold. With subsequent EpCAM 
enrichment of CTCs, we further reduced the WBC concentration to 4.1 log10-fold. However, 
this was at expense of a substantial CTCs loss, as the median CTC recovery reduced from 
54% with WBC depletion alone to 11.5% with additional EpCAM selection (P<0.001). We 
therefore chose to use WBC depletion alone for the majority of the remaining samples 
and only applied additional EpCAM selection if WBC depletion insufficiently enriched the 
sample. In the overall population, we reduced the WBC concentration by 3.21 log10-fold 


































Figure 2: Efficiency of CTC enrichment and isolation techniques for diagnostic leukapheresis. 
A-B) Two CTC enrichment methods were compared (depicted on the X-axis): (1) white blood cell 
(WBC) depletion (n=40) and (2) WBC depletion followed by EpCAM enrichment (n=15). The boxplot 
depicts the median, upper and lower quartiles, whiskers indicate 1.5 times the interquartile range 
(IQR). Individual data points are shown. A) WBC depletion factor after CTC enrichment. To calculate 
the WBC depletion factor, the number of WBCs before enrichment was divided by the number of 
WBCs after enrichment. WBC concentration was measured by a hematology analyzer. Y-axis is a 
logarithmic scale. B) Relative CTC recovery (%) after CTC enrichment. To calculate CTC recovery, 
the absolute CTC count after the enrichment was divided by the absolute CTC count before the 
enrichment. Absolute CTC counts were extrapolated from 1 mL samples. 
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CTC derived organoids
After 18 DLA samples we performed an interim analysis to assess the success rate 
of organoid cultures from isolated and enriched CTC samples. In nine out of eighteen 
samples we obtained organoid samples of which seven could be maintained for at least 
six weeks and thus we continued with the second stage of our prospective study. In total, 
we established CTC derived organoids in 14 out of 40 DLA samples (35% success rate, 
Supplementary figure 3). At this point we terminated recruitment as the primary endpoint 
of 50% success rate was no longer a feasible goal. Both the absolute CTC yield after 
enrichment and the tumor cell percentage in culture was found to be higher in samples 
that resulted in organoid propagation ex vivo (P<0.001 and P<0.01 resp, Figure 3A and 
B). Moreover, only one out of nine mHSPC samples, with the highest CTC yield within the 
population (subject 38; 64,155), could be propagated as organoid. The majority of the 
organoid cultures could be maintained for six to eight weeks until proliferation stalled, 
thus providing limited number of organoids for downstream applications (Figure 3C). Two 
organoid cultures (EMC-PCa-25 and EMC-PCa-41) could be expanded and maintained for 
over six months, the latter yielding a stable cell line. Validation of the PCa origin of the 
organoids was shown by quantitative real-time PCR (qRT-PCR) analysis of prostate (cancer) 
specific transcripts (Table 2, Supplementary figure 4). The vast majority of the isolated 
samples were positive for AR and/or KLK3 (PSA) while expression of AR-V7 was identified 
in only one sample. Three out of 14 organoid cultures (Subject 16, 41 and 93) expressed 
the TMPRSS2-ERG fusion transcript. We performed additional validation of PCa origin 
using patient specific somatic SNVs previously identified in metastatic biopsies (Table 2, 
Supplementary table 2 and 3)4. We validated PCa origin in the matched organoid cultures 
from subject 9-I/II, 79 and 24-I/II by detection of the TP53 and PTEN SNVs resp. Subject 
79 was a patient with neuro-endocrine PCa (NEPC), of whom the CTC derived organoids 










































Stable organoid cell line
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Figure 3: Overview of successful CTC derived organoid cultures. A-B) Results of CTC enrichment 
and isolation of samples that generated organoids (n=14) and those that did not (n=44). From eleven 
DLA products we cultured two samples, as white blood cell (WBC) depletion alone and subsequent 
EpCAM enrichment was performed. A) Estimated CTC yield after CTC enrichment and isolation as 
determined by CTC count from 1 mL sample and extrapolated to the entire product after processing. 
Y-axis is a logarithmic scale. Statistical comparison was performed by a paired two-sided Wilcoxon 
rank test, P<0.001 and P<0.01 resp. B) Tumor cell percentage in sample after CTC enrichment and 
isolation. Percentage of tumor cells was calculated by dividing CTC count by WBC count in sample 
after enrichment and isolation. Y-axis is a logarithmic scale. C) Swimmersplot of all patient samples 
used to generated CTC derived organoids (marked by ticks), for confirmed organoid samples the time 
in culture is shown. Most organoid cultures could be maintained as short-term cultures and were 
subsequently isolated for genetic and/or transcriptional analysis. Organoid sampling is marked by 
a star and passaging of organoids is marked by arrow heads. Light blue bars represent CTC samples 
from metastatic hormone sensitive prostate cancer (mHSPC) patients while dark grey is used for 
metastatic castrate resistant prostate cancer (mCRPC). Subject 41 was deemed a stable organoid cell 
line (EMC-PCa-41) after 10 passages. X-axis depicts the time in weeks since initiating organoid culture. 
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Table 2: Validation of prostate (cancer) transcripts and patient specific somatic variants in 
CTC derived organoids. Overview of genomic and transcriptomic characteristics of the isolated 
organoids. Expression of prostate (cancer) transcripts in the organoid samples was acquired by qRT-
PCR. Positive expression was determined by a ΔΔCq above -8.5 (normalized to EPCAM/KRT19 and 
VCaP RNA used as calibrator). Patient specific somatic single nucleotide variants (SNVs) were selected 
using WGS data from metastatic biopsies (CPCT-02 study) and validated using dPCR. Shown are the 
SNVs and variant allele frequency as defined by dPCR in the organoid samples. NT, not tested.
Subject ID Expression prostate (cancer) transcripts Somatic variant 
(variant allele frequency)
9-I AR and AR-V9 TP53 c.407A>T (99.7%)
9-II NT TP53 c.407A>T (83.9-99.9%)
16 AR, KLK3 and TMPRSS2-ERG NT
21 AR and KLK3 NT
24-I PSA PIK3CA c.3140A>G (1.9%)
24-II AR and KLK3 PIK3CA c.3140A>G (45%)
25 AR, KLK3 and AR-V9 PLCG2 c.655G>A (27.5%)
38 AR and KLK3 NT
41 AR, KLK3 and TMPRSS2-ERG NT
79 - TP53 c.733G>A (97%)
91 AR and KLK3 NT
93 AR, KLK3 and TMPRSS2-ERG NT
94 AR and KLK3 NT
97 AR and KLK3 NT
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Characterization of CTC derived organoid cell line 
From the organoid culture samples we were able to generate one stable organoid cell 
line, which enabled us to perform in-depth genomic and phenotypical characterization. 
WGS of EMC-PCa-41 revealed a triploid genome with an estimated tumor cell purity 
of 99%, an overall tumor mutational burden of 2.13 somatic mutations per mega base 
pairs and no predominant mutational signature (Figure 4A). We identified multiple 
CNAs including a focal amplification on chromosome Xq, encompassing the AR locus 
and a focal deep deletion on 10q causing loss of PTEN. Furthermore, EMC-PCa-41 was 
characterized by multiple inter- and intra-chromosomal rearrangements, including the 
interstitial deletion leading to the TMPRSS2-ERG fusion as was identified by qRT-PCR (Table 
2, Supplementary figure 4). Moreover, ERG expression in the organoids was validated by 
immunohistochemistry (Figure 3B). Overall, EMC-PCa-41 harbors genomic features which 
are frequently identified in mCRPC tumors, such as alteractions encompassing the AR, PTEN 
and ERG gene.4 Next, we determined the sensitivity of EMC-PCa-41 to commonly used 
treatments for mCRPC; enzalutamide and taxane chemotherapeutics (Figure 4C and D). 
Both androgen depleted culture conditions (-R1881) and enzalutamide treatment could 
only partially inhibit cell proliferation of EMC-PCa-41, suggesting resistance. Interestingly, 
subject 41 started with enzalutamide after the DLA procedure and switched treatment 
after only two months due to rising PSA levels (Supplementary figure 5).
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Figure 4: Genetic and phenotypic characterization of the CTC derived stable organoid cell line, 
EMC-PCa-41. A) CIRCOS plot representing the whole genome characterization of EMC-PCa-41 as 
obtained by whole genome sequencing. The first outer track depicts the genomic ideogram. The 
second track displays the copy number profile with amplifications marked in light-green, deep 
amplification in dark-green, deletions in blue and deep deletions in dark-blue. The third track depicts 
the lower-allele frequency (LAF) values of individual copy-number segments (LAF values =0.33 in pink 
and LAF values >0.33 in black). The fourth track displays the number of mutations per 5 megabase 
pairs (Mb), with regions of mutational frequency above 20 Mb marked in blue. The fifth track highlight 
regions marked by regional hypermutation (kataegis). Inner circle displays structural variants, with 
deletions in black, translocations in dark blue, insertions in yellow, inversions in light-blue and 
tandem duplication in red. B) Representative overview and detailed images of immunohistochemical 
staining on EMC-PCa-41 organoids of AR, PSA, cytokeratin 8/18 (CK8/18) and ERG, and counterstained 
with hematoxylin. Top row depicts negative control in which the primary antibody was omitted. 
Scale bar represents 10 µm in size in the detailed images and 100 µm in the overviews. C) Drug 
sensitivity of the organoid cell line EMC-PCa-41 towards the anti-androgen treatment enzalutamide 
and taxane chemotherapeutics, as compared to the established PCa organoid cell lines. Data shown 
is the average of 3 individual cell viability experiments with three technical replicates, scale bars 
represent SEM. Hormone sensitivity of EMC-PCa-41 was determined by cell viability in androgen 
depleted conditions (-R1881) and compared to the AR positive cell organoid cell line MSK-PCa-2. 
Chemosensitivity was compared to the AR negative cell line MSK-PCa-1.
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CTC and organoid heterogeneity by single cell copy number alterations 
To investigate the heterogeneity within CTCs and early-stage organoid cultures, we 
performed low-pass WGS on multiple single cells obtained from the two long-term mCRPC 
organoid samples with matched CTCs and WBCs that served as normal controls (subject 
25 and 41). The genomic profiles revealed several single cells without any distinct CNA 
that clustered together with WBC controls. Additional validation excluded these single 
cells, as they lacked tumor-specific SNVs and were likely non-malignant (supplementary 
figure 6). We then performed a t-SNE analysis to identify clusters of tumor cells bearing 
similar copy-number profiles to assess heterogeneity and extract consensus copy number 
profiles. The CTCs and organoid cells isolated from subject 25 separated into five distinct 
clusters (Figure 5A). The organoid cells isolated from early cultures clustered separately 
(cluster 1) from the CTCs and displayed unique focal amplifications on chromosome 11p, 
14 and 15 (supplementary figure 7). Tumor cells obtained from subject 41 clustered into 
three distinct groups (Figure 5B) and showed distinct heterogeneity and ploidy between 
clusters. Moreover, the consensus plot from cluster 1 revealed a baseline copy number 
of 6 with focal amplifications on chromosome 4, 13 and 20. Cluster 3, encompassing 8 
of 18 CTCs, harbored a triploid genome and closely resembled the focal amplifications 









































Figure 5: Clustering of individual circulating tumor cells and organoid cells based on low-pass 
whole genome sequencing data. t-SNE plot (k-nearest neighbor algorithm; Louvain method) 
of tumor cells, clustering by absolute copy-number values (0.01 Mb). Copy-number values were 
obtained by low-pass whole genome sequencing of single tumor cells after whole genome 
amplification, white blood cells were taken along as negative controls (not displayed in t-SNE). 
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Discussion
This study confirms that DLA is a safe and efficient method to harvest large amounts 
of CTCs from mPCa patients. Furthermore, we have optimized WBC depletion methods 
to efficiently recover CTCs and remove WBCs from DLA samples. From the isolated and 
enriched CTC fractions we were able to establish organoid cultures in 35% of the samples 
which were mostly of short-term nature, although one sample led to a stable organoid 
line. Our study shows that DLA is a promising method to obtain viable tumor cells from 
mPCa patients for subsequent downstream analyses such as single cell sequencing. 
Unfortunately, the modest success rate to expand organoid cultures precluded us from 
using CTC derived organoid cultures as a platform to select personalized treatment 
options for now.
The use of living cells, directly obtained from patients as “real-life” drug screening models, 
is an appealing prospect in our quest to improve personalized cancer treatment. Indeed, 
phenotyping living tumor cells has the advantage to directly measure the response to 
treatment compared to “phenotyping after fixation” based stratification.18 Previous reports 
on CTC cultures indicated that one of the main factor for success is the number of cells to 
initiate expansion.13,15 Indeed, we found that samples that were successfully propagated 
as organoids contained significantly higher number and percentage of CTCs after 
enrichment and isolation. While DLA allows us to obtain vast numbers of CTCs, processing 
of the DLA material provides new challenges due to the excess of WBCs present in the 
sample. The currently available methods for WBC depletion or CTC enrichment require 
an excess of magnetic beads or RBCs to achieve the appropriate ratio to capture all cells 
by antibodies. This limited the DLA volume that can be (cost)effectively processed. In 
our study, we were limited to one-fourth of the DLA sample from 5L blood and thus the 
number of CTCs obtained for culture. Further optimization of DLA sample processing 
could therefore tremendously impact the amount of viable tumor cells obtained and 
benefit downstream applications.
In our study we obtained DLA samples from 40% of the screened patients and were able 
to generate organoids in 35% of the obtained DLA samples including two long-term 
cultures. This is a substantial improvement compared to previous reports that used CTCs 
for ex vivo organoid cultures.19 The paper of Gao et al. described the formation of one 
(long-term) organoid culture out of 17 patient samples (success-rate of 6%).13 Noteworthy, 
patients were preselected based on >100 CTCs per 10 mL of PB, although the number 
of patients screened were not reported. Lambros et al. described the formation of one 
neuro-endocrine organoid culture out of 14 patient samples (success-rate of 7%) which 
was used for genetic profiling.14 Whether these organoids could be maintained as long- or 
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short-term cultures is unclear. Unfortunately, most of the organoids obtained in our study 
could be maintained as short-term cultures with limited proliferative capacity, implicating 
that the current culture techniques do not provide an optimal environment for sustained 
viability. We were able to maintain two samples for ≥6 passages (subject 25 and 41), 
eventually leading to one stable organoid line (EMC-PCa-41). Obtaining preclinical models 
of PCa has been notoriously difficult, presumably due to the low proliferative capacity of 
PCa as well as overgrowth of benign epithelial and stromal cells. Therefore, establishing 
PCa cell lines from liquid biopsy samples provides several advantages, including lack of 
normal epithelial cells and the possibility to obtain metastatic samples from patients with 
bone only disease in a minimally-invasive manner. The CTC derived organoid cell line EMC-
PCa-41 provides an unique novel model for mCRPC with enzalutamide resistance similarly 
to the patient. Moreover, EMC-PCa-41 harbors genomic alterations similar to a large subset 
of mCRPC patients as well as the TMPRSS2-ERG gene fusion, which is underrepresented in 
the currently available models of PCa.4,20 
Treatment modalities for mPCa have profoundly changed and expanded during the 
last decade. Understanding how PCa cells adapt to the selective pressure of treatment 
is becoming increasingly important to further improve treatment outcome. Therefore, 
we need patient derived materials that reflect the current status of the patient’s cancer, 
including the spatial and temporal tumor heterogeneity. Here we show that DLA enables 
in-depth studies into intra-tumor heterogeneity in mPCa by performing single cell whole 
genome DNA sequencing on CTCs. The single cell analysis distinguished clusters of cells 
with unique copy number alteration which is in line with a previous study.14 Within our 
study we were also able to obtain matched samples in four patients, which shows that 
longitudinal CTC sampling by DLA is feasible, providing a platform to study clonal evolution 
and adaptation to treatment. Overall, our study provides an important step forward in 
implementing CTCs in individualized disease modelling, nevertheless identifies several 
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Supplementary figure 1: Circulating tumor cell burden in metastatic prostate cancer patients 
and optimization of diagnostic leukapheresis. A) Circulating tumor cell (CTC) count at screening 
of all metastatic prostate cancer patients (mPCa) included in this study (n=98). The boxplots depict 
the upper and lower quartiles, with the median shown as a solid line; whiskers indicate 1.5 times 
the IQR. Y-axis is a pseudo log scale. CTC count per 7.5 mL peripheral blood is shown for mPCa 
patients with hormone sensitive (n=28) and castrate resistant (n=67) disease and compared using 
an unpaired two-sided Wilcoxon sign rank test (P=0.07). B) CTC count per 7.5 mL peripheral blood 
(PB) as obtained during different stages of study participation. For 24 patients we assessed the 
CTC burden in samples acquired at screening, just prior to diagnostic leukapheresis (pre-DLA) 
and post-DLA. Y-axis is a log-scale, matched samples are connected with a line. CTC burden in the 
different samples was compared by a Friedman test, no statistical significant impact was observed 
(P=0.37).  C) Estimated CTC yield in the DLA product obtained at different densities. X-axis displays 
the two tested density conditions: 2% red blood cells (RBC) and >5% RBC. Each dot represents an 
individual subject (n=4), and samples from the same subject are connected. Y-axis is a logarithmic 
scale. Statistical comparison was performed by a paired two-sided Wilcoxon rank test (P=0.125). D) 
Relative CTC recovery (%) in DLA product processed at different densities. The X-axis displays the 
two tested density conditions: 2% and >5% RBC (n=7 and n=46 fractions resp.). In six patients two 
DLA fractions were collected. The boxplots depict the upper and lower quartiles, with the median 
shown as a solid line; whiskers indicate 1.5 times the IQR.
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Supplementary figure 2: Comparison of white blood cell depletion with or without EpCAM 
enrichment for the efficacy to enrich for circulating tumor cells. A-B) Two CTC enrichment 
methods were compared in twelve paired samples (depicted on the X-axis): (1) white blood cell 
(WBC) depletion and (2) WBC depletion followed by EpCAM enrichment. The boxplots depict the 
upper and lower quartiles, with the median shown as a solid line; whiskers indicate 1.5 times the 
IQR. Paired samples are connected with a line. Statistical comparison was performed by a paired 
two-sided Wilcoxon rank test, P<0.001 for both datasets. A) Displays the WBC depletion factor after 
CTC enrichment. To calculate the WBC depletion factor, the number of WBCs before enrichment 
was divided by the number of WBCs after enrichment. Y-axis is a logarithmic scale. B) Displays the 
relative CTC recovery (%) after CTC enrichment. To calculate relative CTC recovery, the estimate CTC 
count after the enrichment was divided by the estimate CTC count before the enrichment. Estimate 
CTC counts were extrapolated from 1 mL samples. 
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Supplementary figure 3: Overview of successful CTC derived organoid cultures.
Overview of all successful circulating tumor cells (CTC) derived organoid cultures obtained (n=14), 
and organoid expansion observed over time. Timespan (in days) of organoid cultures are indicated 
in the top left corners, scale bars depicted are 50 µm in size with the exception of the day 5 image 
of subject 9 (100 µm). 
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Supplementary figure 4: Results of qPCR validation of prostate (cancer) associated genes of 
circulating tumor cell derived organoids. Heatmap of androgen receptor full length (AR fl), AR splice 
variant 7 (AR-V7), KLK3 (PSA) and TMPRSS2-ERG expression as determined by qPCR in circulating 
tumor cell (CTC) derived organoid cultures. Expression is depicted by ΔΔCq which is defined by 
target Ct values normalized to EPCAM/KRT19 expression and VCaP RNA used as calibrator. If 
several organoid samples were obtained, median expression per culture media (PGM or APCOM) 
was calculated and depicted in the heatmap. Organoids were deemed positive for expression of 
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Supplementary figure 5: Clinical overview of subject 41. Clinical overview of subject 41, including 
PSA levels during the disease course (top part). Initially, a Gleason (GL) 6 adenocarcinoma of the 
prostate was diagnosed by systematic biopsies at an initial PSA of 8.6 µg/L (while the patient was 
using dutasteride). MRI showed a PIRADS 5 lesion which was target biopsied and revealed a Gleason 
7 adenocarcinoma of the prostate. After robot-assisted laparoscopic prostatectomy (RALP) with 
pelvic lymph node dissection (PLND), PSA remained detectable at 0.2 µg/L. Upon PSA progression 
metastases in lymph node (Ln) and bone (Bn) were detected and androgen deprivation therapy 
(ADT) was started. Before start of enzalutamide, the patient underwent diagnostic leukapheresis 
(DLA). The patient received four cycles of docetaxel which was discontinued because of an ischemic 





Subject 41 TP53 NKX3-1 MYO10 CLDN12 Excluded
L5876_C_6301 wt wt wt mut
L5877_C_6302 mut mut mut mut
L5879_C_6304 mut mut mut
L5948_C_6332 mut mut
L5944_C_6324 mut mut mut mut
L5961_C_6310 mut mut mut
L5878_C_6303 mut mut mut
L5949_C_6333 mut mut mut
L5962_C_6314 mut mut mut
L5964_C_6317 mut mut mut
L5965_C_6319 wt wt wt wt Yes
L5955_o1721_5 mut mut mut
L5874_C_6299 mut mut mut mut
L5967_C_6323 mut mut wt
L5880_C_6305 mut mut mut
L5945_C_6325 mut mut
L5946_C_6326 mut mut mut
L5881_C_6306 mut mut mut mut
L5875_C_6300 mut mut mut
L5947_C_6328 mut mut
L5956_181819_4 wt wt wt Yes
L5950_W_1423 wt wt wt wt
L5951_W_1424 wt wt wt wt
L5959_181819_1 wt wt wt wt Yes
L5958_181819_9 wt wt wt Yes
L5952_o1721_2 wt wt wt Yes
L5954_o1721_4 wt wt wt Yes
L5960_181819_18 wt Yes
L5953_o1721_3 wt wt Yes
L5957_181819_5 wt wt wt Yes

































Supplementary figure 6: Initial clustering of copy number alterations in circulating tumor cells 
and early organoids from two metastatic castration resistant prostate cancer samples and 
subsequent validation. Unsupervised hierarchical clustering with dendogram (Euclidean distance; 
ward method) using log2 ratio of normalized counts per 0.25 megabase, depicting CNA of individual 
circulating tumor cells (CTCs, aqua), organoid cells (beige) and white blood cells (WBCs, yellow) 
for subject 25 (top panel) and 41 (bottom panel). CNA segments for each individual cell (column) 
are shown from left to right and ordered on chromosome (indicated below). The color gradient 
represents copy number deletions in dark blue (-2 to 0) and amplification in dark red (0 to 2).The 
tables alongside the hierarchical clustering represent the results from the validation experiments. 
Sanger sequencing was performed to identify somatic variants in whole genome amplified DNA 
from the CTCs, organoids and WBCs from subject 25 and 41. Empty wells represent missing data, 
shown are the organoid and CTC samples excluded based on validation.
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Supplementary figure 7: Copy number heterogeneity in circulating tumor cells and organoids. 
A-B) Consensus profiles per t-SNE cluster, depicting median absolute copy numbers in A) subject 
25 and (n=24) B) subject 41 (n=19). The Y-axis displays the absolute copy number ranging from 0 to 
(≥) 8 copies. X-axis displays the genomic position of the copy-number segments, ticks indicate 50 
megabase (Mb). The color gradient represents absolute copy number, with deletions in blue (0 to 
<2) and amplification in red (>2 to (≥)8).
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Supplementary material and methods
Study design
This prospective study was conducted in accordance with the Declaration of Helsinki and 
was approved by the medical ethical committee of the Erasmus Medical Center Rotterdam 
(EMC16-449). The study was performed using a Simon’s two-stage design1, with an interim 
analysis after 18 DLAs were performed. Continuation to the second stage could only 
continue if seven out of 18 samples yielded successful organoid cultures meaning that 
organoids could be propagated for six weeks or longer and PCa origin could be validated. 
The study protocol, including sample size calculations, has been added as supplemental 
information.
Patients 
From November 2016 till July 2020, patients with mPCa were prospectively included 
(NL6019; https://www.trialregister.nl/trial/6019). All patients provided written informed 
consent before any study procedure took place. Patients ≥18 years in age were eligible 
if they had histologically or cytologically confirmed PCa, with measurable metastatic 
lesion(s) (according to PCWG2 and/or RECIST 1.1 criteria)2,3 and intended to start a new 
line of systemic treatment. Patients should have at least two adequate peripheral veins as 
access point for DLA. Additionally, patients should be in good physical condition (WHO 
performance status ≤ 2), have an adequate hematology, coagulation status and liver/renal 
function as assessed by routine laboratory tests (see study protocol for details). Exclusion 
criteria were, CTC count of <5 per 7.5 mL of blood at screening, known hypersensitivity to 
anticoagulant used during DLA, hemorrhage disease or coagulation disorders and chronic 
viral infections. We excluded hormone sensitive PCa patients currently undergoing ADT, 
to prevent possible interference of ADT on the number of CTCs and CTC characteristics. 
After completing the DLA procedure hormone sensitive patients started with ADT. 
Patients were allowed to enter the study multiple times during their treatment course. 
All patients provided written informed consent before any study procedure. The study 
procedures included a blood draw at baseline to screen for eligibility criteria, a blood draw 
before start of the DLA procedure and the DLA procedure itself. Clinical data on disease 
characteristics, previous therapies and response on the subsequent systemic therapy 
were collected in an electronic case report form (ALEA Clinical). 
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Primary and secondary endpoints 
The primary endpoint of this study was the rate of successfully cultured organoids from 
CTCs obtained by DLA with successfully being defined as i) propagation for at least 6 
weeks in culture and ii) proven PCa characteristics. PCa characteristics include epithelial 
origin CK8/18, lack of p63 (not basal cells), and (combined) expression of TMPRSS2-ERG 
fusion, AR (splice variants) expression, PTEN loss, MYC amplification (together indicative 
of PCa) or the detection of patient-specific somatic variants (known from previously 
characterized tumor material).
Study procedures
The study procedures included a blood draw at baseline to screen for eligibility criteria, 
including CTC count, a blood draw before start of the DLA procedure and the DLA 
procedure itself. All study procedures were performed before start of a new line of 
treatment. 
Circulating tumor cell enumeration using CellSearch 
For CTC enumeration, 7.5 mL of blood; 1 mL of DLA product diluted in 6.5 mL of PBS (Thermo 
Fisher Scientific, Waltham, MA); or a proportion of the enriched fraction was collected in 
a CellSave Preservative tube (Menarini Sillicon Biosystems, Castel Maggiore, BO, Italy). All 
samples were processed within 96 hours and CTC enumeration was performed using the 
Circulating Epithelial Cell Kit on the CellSearch® system (Menarini Sillicon Biosystems) 
by certified personnel. Briefly, samples were subjected to immunomagnetic capture 
using ferrofluids coupled to anti-EpCAM antibodies and enriched cells were stained with 
antibodies specific for cytokeratin (CK) 8, 18, and 19, CD45 and nucleic acid dye (DAPI). 
Images were captured using the CellTracks Analyzer II (Menarini Silicon Biosystems) 
and manually examined to determine the presence of CTCs. Cells were defined as CTCs 
when positive for CK and DAPI and negative for CD45 according to the manufacturer’s 
instructions. CellSearch cartridges were stored in the dark at 4°C before further analyses.
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Diagnostic leukapheresis 
DLA was performed at the department of Hematology at the Erasmus Medical Center using 
the Spectra Optia Cell Separator machine (Terumo BCT, Lakewood, CO). Only peripheral 
venous access was used to process a maximum volume of 10 L of circulating blood. Citrate 
dextrose solution A was used as anticoagulant. For CTC isolation the standard settings for 
white blood cell (WBC) isolation were applied, only the plasma pump rate was increased 
to collect a slightly higher cell density with an approximate hematocrit of 5% instead of 
2%. In addition, extra blood was drawn for the collection of red blood cells (40 ml in EDTA 
tubes), CTC count of peripheral blood (20 ml in CellSave tubes) and routine hematological 
tests. Fresh DLA product was immediately processed for CTC enrichment. Excess DLA 
product was stored in liquid nitrogen at 2 mL aliquots containing 50% autologous plasma 
and 10% DMSO (Sigma-Aldrich, Saint Louis, MO) for biobank purposes. All grade ≥3 
(serious) adverse events during and within 48 hours after DLA were registered.
Circulating tumor cell enrichment 
CTCs from DLA were enriched by negative depletion of WBC using RosetteSepTM CTC 
Human CD45 Depletion Cocktail (STEMCELL Technologies, Vancouver, BC, Canada) with 
the following modifications. WBC concentration of the DLA product was measured using 
a hematology analyzer (Beckman Coulter, Brea, CA) and diluted with phosphate buffered 
saline (PBS) to a final concentration of 50x10⁶ WBC/mL. Red blood cells (RBCs) were collected 
in K2EDTA vacutainer® tubes (BD, Franklin Lakes, NJ) before start of the DLA procedure 
and concentrated by centrifugation at 800g for 8 minutes. These autologous RBCs were 
added to the DLA product to achieve a 1:50 WBC:RBC ratio before incubation with the 
RosetteSepTM Cocktail to induce crosslinking of RBCs with WBCs. RBC/WBC rosettes were 
depleted using SepmateTM-50 tubes and LymphoprepTM as density gradient medium (both 
STEMCELL Technologies), by centrifugation at 1200g for 12 minutes at room temperature 
with the brake off. Enriched CTCs were washed using PBS. For 15 DLA samples additional 
manual positive immunomagnetic enrichment was performed. Ten mL of CD45 depleted 
fraction was incubated with 150 µL CellSearch EpCAM ferrofluids and 150 µL capture 
enhancement reagent for 10 min, at room temperature on a roller mixer. To separate the 
magnetic labeled CTCs, the tube was placed next to a MagCellect magnet (R&D systems, 
Minneapolis, MN) and the supernatant aspirated. A second magnetic separation was 
performed for optimized enrichment. Finally, the enriched CTCs were collected in culture 
medium and used for organoid culture. 
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Organoid culture from circulating tumor cells
The enriched CTC suspension was collected by centrifugation at 1200g for 8 minutes. 
The cell pellet was cooled on ice and mixed with Matrigel (MG; Corning, cat. no. 356231, 
Corning, New York). The cell suspension-MG mix was dispensed in a pre-warmed 24-wells 
plate (Corning, cat. no. 3527), in 30-40 µl droplets. Subsequently, the plate was placed 
upside-down at 37°C and incubated for 15 minutes to let the MG solidify. Next, 500 µl of 
medium was added; CTCs were cultured in prostate growth medium (PGM) and adjusted 
prostate cancer organoid medium (APCOM) in parallel (overview in supplementary table 
1).4 APCOM was based on the previously published organoid culture media described by 
Gao et al. and Beshiri et al.5,6 Weekly images were obtained to monitor organoid growth 
using the Zeiss Axiovert 25 equipped with 10x and 20x Plan-Neofluar objectives, a AxioCam 
ICc1 camera and AxioVision imaging software (version 4.8.2.0, Oberkochen, Germany) and 
Nikon Eclipse TS2 equipped with 4x, 10x CFI Achro brightfield objectives and a 20x Fluor 
ELWD objective, a DS-Fi3 camera and NIS-Elements imaging software (Minato, Tokyo, 
Japan). Cell culture media was either replaced or supplemented every 3-4 days. 
DNA/RNA isolation and PCR analyses of CTC derived organoids 
For DNA and RNA isolation, organoids were collected, lysed with RLT buffer (Qiagen, cat. 
no. 79216, Hilden, NRW, Germany) and stored at -80°C until further processing. DNA and 
RNA isolation using the QIAcube system (Qiagen, cat. no. 9001293) in combination with 
the AllPrep DNA/RNA Micro Kit (Qiagen, cat. no. 80284,) was performed as described 
previously.7 cDNA was generated from RNA using the RevertAid H Minus First Strand 
cDNA Synthesis Kit according to the manufacturer’s protocol (Thermo Fisher Scientific, 
cat. no. K1632). Subsequently, cDNA (0.1 to 1 ng/µL) was pre-amplified for patient-specific 
targets and/or a multiplex prostate gene expression panel 7 with a Taqman assay covering 
wildtype and mutant molecules during 15 cycles using TaqMan PreAmp Master Mix 
(Thermo Fisher Scientific) as recommended by the manufacturer. Prior to downstream 
processing, the pre-amplified product was diluted 15-fold in LoTE buffer (3 mM Tris-
HCl/0.2 mM EDTA, pH 8.0). Gene expression levels were measured in real-time in the 
pre-amplified samples by qRT-PCR and subsequently analyzed as described previously.7 
For validation of single nucleotide variants (SNVs) in organoids (Supplementary table 
2), digital PCR (dPCR) reactions were performed with either the QuantStudio 3D Digital 
PCR System (Thermo Fisher Scientific) or the NaicaTM Crystal Digital PCR System (Stilla 
Technologies, Villejuif,  France) according to the manufacturer’s protocol. For the former, 
each pre-amplified cDNA sample or DNA sample was partitioned into 20,000 wells of a 
QuantStudio 3D Digital PCR v2 Chip and run on a ProFlex 2x Flat PCR System (Thermo 
Fisher Scientific). The target-specific optimized PCR program was: 10 min at 96°C, followed 
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by 40 cycles of 30 sec incubation at 98°C and 2 min at 55°C and a final pause for up to 16 
hours at 10°C. Chips were read in a QuantStudio 3D Digital PCR Instrument and analyzed 
with the web-based Quantstudio 3D dPCR Analysis Software version 3.01 (Thermo Fisher 
Scientific). For the latter, each pre-amplified cDNA sample or DNA sample was partitioned 
into 30,000 crystal droplets and amplified by the following program: 45 cycles of 30 sec at 
95°C and 15 sec at 58°C. Chips were read in a Naica Prism3 instrument and analyzed with 
the Crystal Miner software (Stilla Technologies). For both, at least one positive and one 
negative control sample was included in every run.
Single cell isolation
Single cells were isolated and after whole genome amplification (WGA) sequencing was 
performed as described in the supplementary material and methods. CellSearch enriched 
CTCs were sorted by flow cytometry using MoFlo XDP sorter (Beckman Coulter, Germany) 
and Single cell isolation of organoids was performed using the VyCAP Puncher System 
(VyCAP, Enschede, The Netherlands) as previously described.8,9      
Passaging and isolating organoids for phenotyping
For passaging and isolation of early stage organoids, MG droplets were mechanically 
disrupted and dispensed in a pre-cooled 96-wells plate (Corning, cat. no. 3595). TryplE 
(Thermo Fisher Scientific, cat. no. 12605010) was added to the wells and incubated at 37°C 
and organoids were resuspended regularly until the organoids were fractioned. Organoids 
were collected in cold medium (AdMEM/F12+++), centrifuged at 1200g for 5 min at 4°C 
and plated as described previously. For cell viability assays, enzymatic disruption was 
prolonged to acquire mostly single cells and plated at a density of 2500 cells per well in 8 
µl of MG in a 96-wells plate. To allow for organoid formation, cells were incubated for seven 
days with 100 µl media. We used APCOM without Y-27632 and R1881, as this would interfere 
with treatment induced cell-death and anti-androgen response. Subsequently medium 
was replaced to contain the appropriate drug/androgen concentration and incubated for 
another seven days (Enzalutamide Axon Medchem, Groningen, the Netherlands, cat. no 
1613; R1881 details in Supplementary table 1 and Taxanes were provided by Sanofi, Paris, 
France). Cell viability was measured using the CellTiter-Glo® 3D (Promega, cat. no. G9681, 
Madison, WI), and normalized to untreated controls. MSK-PCa1 and MSK-PCa2 were 
maintained in the organoid culture media described by Gao et al.5 and cell viability assays 
were performed as described above. For cryopreservation, isolated organoids were mixed 
with 1 mL cooled RecoveryTM Cell Culture Freezing Medium (Thermo Fisher Scientific, cat. 
no. 12648010), stored in a Styrofoam container (Westburg CoolCell LX, cat. no. BCS-405, 
Leusden,  The Netherlands) overnight at -80°C and subsequently transferred to liquid 
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nitrogen storage. For immunohistochemistry, organoids in MG were formalin fixed for 
four hours, and subsequently embedded in 4% agarose and paraffin. Four µm section 
were stained for the expression of the androgen receptor (AR; 1:200, SP107, Cell Marque, 
Rocklin, CA), prostate specific antigen (PSA ;1:500, N1517, Dako, Santa Clara, CA ), CK8/18 
(1:150, Ma5-14088, Thermo Fisher Scientific) and ERG (1:100, EPR3864, Abcam, Cambridge, 
UK) and visualized with DAB/H2O2 (EnVision kit, Dako). Images were obtained using the 
Olympus BX41 microscope equipped with 2x, 10x, 20x and 40x UPlanFL N objectives, a 
ColorView III camera and CellB imaging software (version 3.4, Olympus Shinjuku, Tokyo, 
Japan). 
Whole genome sequencing and variant calling of EMC-PCa-41
From six patients, whole genome sequencing (WGS) data from metastatic tissue was 
present as part of the CPCT-02 study (NCT01855477) and used to identify somatic SNVs 
for validation studies (Supplementary table 3).10 EMC-PCa-41 organoids were collected 
for WGS (passage no 5) in a similar fashion as passaging, washed with cold PBS and dry 
cell pellets were stored at -80°C. WBCs isolated from DLA were used as matched normal 
cells for sequencing. DNA isolation and WGS was performed by the Hartwig Medical 
foundation as previously described.10 In short, Illumina technology was used for WGS 
of DNA libraries on the HiSeq X Ten system using paired-end (2x150bp) sequencing 
(Illumina, San Diego, CA) to a minimum sequencing depth of 30x and 60x for the matched 
normal and tumor sample respectively. The human reference genome (GRCh37) was used 
for alignment and post-processing and subsequent somatic analysis for variants (SNVs, 
small insertion/deletions and multi-nucleotide variants), copy number alterations (CNA), 
structural variants was performed as previously described.10,11
Single cell isolation, whole genome amplification and sequencing of CTCs 
and single cells from organoids
For single cell isolation we used fresh DLA product diluted in CellSearch dilution buffer, 
collected in a CellSave tube and processed within 96 hours, or stored DLA product which 
was thawed before processing. Samples were processed on the CellSearch system as 
described above. CellSearch cartridges were stored in the dark at 4°C before further 
analyses. Isolation of single CTCs, defined as DAPIpos/CKpos/CD45neg cells, and single 
white blood cells WBCs, defined as DAPIpos/CKneg/CD45pos, was performed by flow 
cytometry using MoFlo XDP sorter (Beckman Coulter, Germany) as previously described.8 
Single cells were sorted into individual empty PCR tubes and stored at -20 °C until analysis. 
Single cell isolation of organoids was performed using the VyCAP Puncher System (VyCAP, 
Enschede, The Netherlands), combining a silicon chip with microwells, fluorescence 
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imaging, and a punching method to isolate and transfer the single cells to standard 
reaction tubes as previously described.9 Subsequent whole genome amplification (WGA) 
for all picked/sorted single cells was performed using adapter-linker PCR as previously 
described,12,13 and commercialized as Ampli1TM WGA Kit by Menarini Sillicon Biosystems. 
Ampli1TM LowPass kit for Illumina (Menarini Silicon Biosystems, Bologna, Italy) was 
used for preparing low-pass WGS libraries at Menarini Silicon Biosystem facilities. For 
high-throughput processing, the manufacturer procedure was implemented in a fully 
automated workflow on a STARlet Liquid Handling Robot (Hamilton, Reno, NV, USA). 
Resulting libraries were sequenced on HiSeq instrument (Illumina, Hayward, CA, USA) 
and the obtained FASTQ files were aligned to the human reference genome (GRCH37) 
sequence using Burrows-Wheeler Aligner version 0.7.12 (BWA).14 Quality control (QC) 
included read count distribution and derivative log ratio spread as described previously,15 
two CTCs from subject 41 failed to pass QC. CNA in the data were identified using Control-
FREEC software (version 11.0) and ploidy level was analyzed using the MSBiosuite pipeline 
based on best fitting of profiles to underlying copy number levels.16 
Validation of single cell sequencing 
Validation of single cell sequencing was performed by Sanger sequencing of known 
SNVs from subject 25 and 41, identified in WGS of the patient’s tumor or patient derived 
organoid cell line resp. In short, a nested PCR strategy was used to amplify genomic 
regions with known SNVs from the single cell WGA product (supplementary table 4). PCRs 
were performed using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific, 
cat. no. F530) and the final product was purified (QIAquick PCR purification kit, Qiagen, 
cat. no. 28104). The amplicons were Sanger sequenced (Macrogen Europe, Amsterdam, 
The Netherlands) and results were analyzed using pairwise alignment with the reference 
gene (BLAST, NCBI). CTCs and organoids samples that did not harbor any tumor specific 
SNVs were excluded, WBC served as negative controls.
Bioinformatics analysis of single cell copy number alterations
For the clustering of the complete dataset (Supplementary figure 6) we used the median 
ratio obtained by the Control-FREEC software, normalized each profile on fixed bins length 
(weighted mean on 0.25 Megabase (Mb) bins) and calculate the log2 values. Subsequently, 
after setting the minimum value to -2 and maximum value to 2, hierarchical clustering of 
profiles was performed, using “Euclidean” distance metric and “ward” clustering method. 
For clustering the validated tumor cell profiles, absolute copy-numbers were binned 
into 0.01 Mb bins which were subsequently annotated by the mean copy-number of 
overlapping copy-number segments and rounded to the nearest integer. These bins (0.01 
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Mb) were used as input for t-SNE (θ = 0.5 with a perplexity of 2) using the Rtsne package 
(v0.15).17 Subsequent clustering of the t-SNE results, outputted as two dimensions, was 
performed using the k-nearest neighbor algorithm (k = 15) and the Louvain method for 
community detection, as implemented by the igraph package (v1.2.5) from the statistical 
platform R (v3.6.1).18,19 Per cluster, a consensus copy-number profile was generated by 
adopting the median copy-number value per bin (0.01 Mb) over all samples captured 
within the respective cluster. Within the consensus copy-number profiles, the maximum 
absolute copy-number was capped to 8. 
Statistical analysis
Sample size calculation for the patient inclusion is described in the attached clinical 
protocol. For comparison of CTC count in PB samples obtained at screening versus before 
the DLA procedure, CTC yield in low versus high density fraction enrichment by DLA, 
CTC yield and WBC depletion after WBC depletion with or without EpCAM enrichment 
we used a paired, two-sided Wilcoxon-rank test due to the non-normality of the data. 
Data visualization and statistical testing were performed using the statistical platform R 
(version 3.6.1)19 or Graphpad Prism (version 5.01, GraphPad Software, San Diego, CA ), we 
considered statistical significance with P<0.05. 
Code availability
For the tools and scripts used for analyzing the organoid cell line WGS data, we refer to the 
previous report of L. van Dessel and J. van Riet et al., other tools and scripts will be made 
available upon request.11 
Data availability 
The CTC derived organoid cell line EMC-PCa-41 will be made available to academic 
institutions under the Erasmus MC Biological Uniform Material Transfer Agreement. The 
WGS data from metastatic biopsies were part of the CPCT-02 study, which has been 
made available by the Hartwig Medical Foundation. Both WGS and clinical data are freely 
available for academic use from the Hartwig Medical Foundation through standardized 
procedures and request forms can be found at 
https://www.hartwigmedicalfoundation.nl. The WGS data from the organoid cell line as 
analyzed in this manuscript will be made available at publication.
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Part I Impact of androgens and AR signaling on taxane treatment 
efficacy
The therapeutic landscape of metastatic prostate cancer (mPCa) has been transformed 
in the past two decades. Until 2004 androgen deprivation therapy (ADT) was the only 
effective treatment for patients with mPCa. Since then, taxane chemotherapeutics, 
androgen receptor signaling targeted inhibitors and combination strategies have been 
introduced. This has substantially improved the outlook of mPCa patients, as illustrated 
by a recent report by the Dutch Cancer registry (IKNL). The median overall survival after 
diagnosis of metastatic disease, increased from 26.5 to 37.2 months between 2004-2008 
and 2014-2018, respectively.1 The landmark CHAARTED and STAMPEDE studies have paved 
the way for combination treatments in hormone sensitive PCa (HSPC) patients when they 
showed that adding docetaxel to ADT induces a strong survival benefit.2,3 These findings 
have been implemented into the daily clinical practice of mPCa, although an underlying 
mechanisms for greater efficacy of the combination treatment remains unresolved. 
Preclinical research into clinical findings has previously been able to reveal drivers of PCa 
which subsequently provided opportunity for targeted approaches. The greater impact of 
docetaxel in a setting where ADT effectively suppresses androgen receptor (AR) signaling 
led us to hypothesize that the AR pathway and AR signaling directly interacts with taxane 
anti-tumor activity. In part I of this thesis we showed that AR signaling and AR targeted 
agents determine taxane treatment efficacy.
Testosterone interferes with taxane tumor accumulation
Using an AR positive model of castration resistant PCa (CRPC) we showed that testosterone 
interferes with cabazitaxel and docetaxel activity (Chapter II and III). Under castrate 
conditions, both docetaxel and cabazitaxel treatment induced long-term regression in 
the PC346C-DCC-K tumor model. In contrast, the activity of the taxane chemotherapeutics 
was negated in the presence of testosterone. To dissect the underlying mechanisms, 
we first examined taxane pharmacokinetics and tumor accumulation, which are key 
steps in achieving optimal treatment exposure (Figure 1, top panels). Testosterone 
supplementation did not impact taxane plasma levels but strongly reduced tumor 
accumulation levels (Chapter II). The impact of impaired taxane tumor accumulation on 
activity has been exemplified by a previous publication from our lab.4 Here, we showed 
that docetaxel resistant xenografts had strongly diminished taxane tumor accumulation 
in comparison to their docetaxel-sensitive counterparts. Subsequent transcriptomics 
analyses identified numerous differentially expressed genes in the docetaxel resistant 
xenograft, including loss of SLCO1B3.5
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Figure 1: A representation of taxane pharmacodynamics. After administration of the 
chemotherapeutic (top left), taxanes accumulate into the tumor tissue and cells (top right). Taxanes 
bind to the beta subunit of tubulins, which leads to stabilization of microtubule filaments (bottom 
left). Microtubule stabilization impedes accurate chromosome segregation in mitosis leading to 
cell cycle stalling (bottom right). This may directly result in apoptosis or (cancer) cells can slip out 
of mitosis without completing cell division. Our results suggest that these cells could die during 
secondary mitosis which can be enhanced by AR directed treatment. Figure made using Biorender.
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This transporter is of high interest as substrates for OATP1B3 (encoded by SLCO1B3) uptake 
include taxane chemotherapeutics and testosterone. We therefore hypothesized that 
testosterone might interfere with docetaxel uptake by OATP1B3 leading to impaired tumor 
accumulation. Using drug-uptake assays we demonstrated that testosterone competes 
with docetaxel for OATP1B3 mediated uptake, which reduced docetaxel accumulation 
(Chapter III). We thereby provided a possible mechanism of impaired docetaxel tumor 
accumulation in the presence of testosterone. 
Given the combined use of docetaxel with ADT, even in CRPC patients, the impact 
of testosterone on OATP1B3 mediated docetaxel uptake might be limited due to 
low levels of circulating testosterone. In castration resistant disease, AR signaling is 
frequently reinstated to promote proliferation This can be achieved by AR alterations 
and alternative androgen production through upregulation of adrenal enzymes such as 
17β-HSD.6 As a result, testosterone levels are elevated in metastatic tissue samples and 
sufficient to promote AR signaling.6,7 This suggests that testosterone could interfere with 
docetaxel tumor accumulation in CRPC. This mechanism could then be counteracted by 
abiraterone, which inhibits the CYP17A enzyme and further suppresses androgen levels.6,8 
Interestingly, abiraterone has also been described as substrate for OATP1B3 uptake and 
potentially competes with docetaxel uptake.8 Taken together, these observations suggest 
that uptake competition mechanisms play a role in treatment efficacy and could disturb 
taxane tumor accumulation, although clinical validation is warranted. 
Taxane target engagement as biomarker for treatment efficacy
The impact of testosterone levels on taxane exposure and tumor accumulation likely 
impairs taxane target engagement (Figure 1, bottom left panel). Taxanes function by 
blocking tubulin depolymerization, which leads to stabilization of microtubule filaments. 
Target engagement can be assessed by immunoblotting of acetylated-α-tubulin, a post-
translation modification following microtubule stabilization. We found that acetylated-
α-tubulin levels were somewhat reduced in tumor samples obtained from docetaxel 
treated and testosterone supplemented mice, which correlated with impaired docetaxel 
accumulation (Chapter III). To accurately assess the relationship between taxane tumor 
accumulation, target engagement and activity we require more sensitive assays. One 
such detection method is CETSA (cellular thermal shift assay). CETSA examines taxane 
target binding with high specificity and sensitivity in vitro, as well as in tissue samples.9 
We applied CETSA to PCa docetaxel resistant xenograft models with underlying impaired 
drug accumulation and identified decreased target binding as compared to docetaxel-
naïve counterparts (Chapter IV). The clinical feasibility of CETSA was explored using fine 
needle aspirations obtained from breast cancer patients, where it revealed high inter-
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patient heterogeneity in paclitaxel target engagement. 
The application of CETSA on clinical samples offers an opportunity to investigate the 
relationship between taxane pharmacokinetics, tumor accumulation, target engagement 
and treatment outcome in cancer patients. Although variation in taxane pharmacokinetics 
have been well-described, little is known about the factors that define tumor accumulation 
and microtubule stabilization.10 CETSA may provide insight into the limited efficacy of 
docetaxel rechallenge in mCRPC patients that previously received chemohormonal 
treatment for HSPC. A retrospective analysis of the GETUG-AFU 15 trial showed that 
docetaxel treatment induced a PSA response in 14% of the CRPC patient who progressed 
on chemohormonal treatment as compared to 45% of the patients who received ADT 
alone.11 Investigating taxane tubulin binding may help identify whether docetaxel 
rechallenges fails because of reduced tumor accumulation and/or target engagement. 
A subsequent effective treatment for these patients could be to switch to cabazitaxel. 
Preclinical cell line studies have shown that cabazitaxel more effectively accumulates into 
tumor cells and stabilizes microtubules compared to docetaxel, which could explain the 
treatment efficacy of cabazitaxel in docetaxel refractory patients.12 Concluding, CETSA 
provides a method to accurately quantify taxane target binding and offers further insight 
into treatment dynamics and outcome in cancer patients. 
AR signaling determines taxane treatment efficacy
In addition to impaired taxane tumor accumulation, testosterone may deminish taxane 
activity through the AR pathway. Supplementing mice with testosterone strongly 
promoted androgen signaling in the AR positive PC346C-DCC-K xenograft model, as 
shown by increased PSA release and transcriptional activity (Chapter III). Using two in vitro 
AR positive CRPC models, we confirmed that AR stimulation increased viability in docetaxel 
exposed cells. Subsequently, we re-supplemented castrate mice with testosterone after 
docetaxel induced long-term tumor regression, leading to rapid outgrowth of the vast 
majority of these small and dormant tumors. We concluded that AR signaling impairs 
taxane activity, therefore continued blockade of androgen signaling is vital to sustained 
taxane treatment efficacy. 
Based on the results described in Chapter II and III, we hypothesized that taxane anti-tumor 
activity can be improved by an AR signaling targeted agent. We therefore investigated 
the combined anti-tumor efficacy of enzalutamide with cabazitaxel as compared to both 
mono-treatments (Chapter V). The AR positive CRPC model PC346C-DCC-K is responsive 
to cabazitaxel treatment, although rapid tumor progression was invariably observed in 
non-castrate mice. Enzalutamide as a mono-treatment did not inhibit or delay tumor 
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growth, although a clear reduction in PSA plasma levels implied adequate AR inhibition 
by enzalutamide. Combining enzalutamide with cabazitaxel inferred greater anti-tumor 
activity than cabazitaxel alone. The efficacy of this combination was validated in a second 
enzalutamide resistant VCaP xenograft model. To dissect the underlying mechanism 
of enhanced cabazitaxel activity, we examined differential gene expression inferred 
by enzalutamide in PC346C-DCC-K tumors. Transcriptomic analysis confirmed that AR 
signaling was suppressed in enzalutamide treated tumors despite sustained proliferation. 
Unfortunately, no significant compensatory mechanism was identified that could sustain 
proliferation in the presence of AR pathway suppression. Blocking AR signaling lead to 
downregulation of metabolic enzymes that could compromise the overall fitness of cancer 
cells. Hypothetically, taxane induced mitotic disruptions and subsequent multinucleation 
combined with disruption of energy homeostasis could enhance anti-tumor efficacy 
(Figure 1, bottom right). Live cell imaging analysis confirmed that cabazitaxel treatment 
resulted in abnormal mitosis and improper segregation of the genetic material, which 
initially did not trigger apoptosis. The addition of enzalutamide, did enhance the activation 
of apoptosis in cells that survived the primary abnormal cell division. Overall, targeting AR 
signaling was shown to increase cabazitaxel efficacy even in models where enzalutamide 
treatment could not effectively block proliferation.
PSA plasma levels are widely used as a biomarker in PCa, especially in patients with 
metastatic disease where PSA dynamics inform on tumor burden and treatment response.13 
In patients receiving AR signaling directed treatment, PSA response can be a direct effect 
of repressed AR transcriptional activity. Indeed, PSA decline strongly correlates with 
progression free survival in enzalutamide treated patients.14 In almost 90% of the CRPC 
patients, first-line enzalutamide treatment induced at least a 30% decline in PSA levels. 
This suggests that at least some level of AR signaling suppression is achieved in the vast 
majority of patients and could potentiate cabazitaxel efficacy. Interestingly, in 10-30% 
of enzalutamide treated patients PSA dynamics did not predict radiographic response, 
as disease progression was observed within 6 to 12 months.14,15 These observations hint 
that the AR pathway is still effectively suppressed in a subset of patients that develop 
enzalutamide resistance. A similar phenomenon was observed in the enzalutamide 
resistant xenograft models where PSA levels declined after treatment initiation (Chapter 
V). 
The potential greater efficacy of combining taxanes with AR signaling directed 
treatments for advanced PCa is currently investigated in several phase II/III clinical trials.16 
Previously, docetaxel-based combinations with anti-angiogenic, immunotherapy and 
microenvironment targeted agents have been evaluated in clinical trials.16 Unfortunately, 
the addition of these novel compounds failed to show a significant survival benefit for CRPC 
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patients in large phase III clinical studies. The underlying reason for the negative outcome 
has been ascribed to overall lack of efficacy, increased toxicity leading to treatment 
discontinuation and absence of biomarkers to select the right patient population.17-19 For 
example, the use of a dual inhibitor of SRC family kinases and the pro-apoptotic protein 
ABL appeared a promising strategy for PCa. Preclinical studies showed encouraging 
results but failed to provide a mechanistic interaction for combining with docetaxel.20,21 
This might have contributed to the negative outcome of the large multi-center phase III 
clinical study.17 Future clinical trials should focus on combination strategies that are based 
on a mechanistic interaction to enhance taxane activity or vice versa. To support this, we 
should focus on dissecting the mechanism of action that taxanes invoke in patients. The 
impact of taxane chemotherapeutics on tubulin dynamics, cell cycle progression and 
mitotic cell death has been extensively described in cultured cells, but validation using 
patient tumor tissue is rare. A breast cancer study suggested that the therapeutic efficacy of 
taxane is independent of cell cycle stalling and subsequent mitotic catastrophe. The intra-
tumor paclitaxel concentrations reached in breast cancer patients did not induce mitotic 
arrest in cultured cells, although viability was effectively compromised through long-term 
exposure.22 Gaining mechanistic insight into taxane efficacy in a clinically relevant setting 
could provide a framework to select treatment combinations. Our results showed that 
androgens and AR signaling determine the outcome of taxane treatment, which provided 
a substantial basis for combining a taxane with AR signaling directed agent. The improved 
anti-tumor efficacy of adding enzalutamide to cabazitaxel confirmed that AR signaling 
impacts taxane activity both in vitro and in vivo. Our results also suggest that targeting AR 
signaling could enhance cabazitaxel efficacy in enzalutamide refractory patients. Overall, 
Part I of this thesis provides mechanistic insight and subsequent validation for targeting 
AR signaling in taxane treated patients that fits within the current treatment landscape of 
CRPC.
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Part II Optimizing personalized cancer treatment using CTC derived 
organoids
With the addition of ADT based combination treatments for HSPC and potential expansion 
of the CRPC treatment repertoire, defining the optimal treatment for the individual 
patient at the right moment has become increasingly complex. Predictive and prognostic 
biomarkers can be used to guide treatment selection and asses response in the individual 
patient. The use of liquid biopsies, such circulating tumor cells (CTC) and circulating 
tumor DNA (ctDNA) represent opportunities in the biomarker field.23 In addition to the 
prognostic value of CTC numbers to indicate tumor burden, presence of the AR splice 
variant 7 (AR-V7) in CTCs has shown to correlate with response to AR signaling targeted 
treatments. A prospective clinical trial in high-risk CRPC patients treated with abiraterone 
or enzalutamide confirmed that AR-V7 status at baseline was a strong predictor of poor 
response.24 At disease progression the percentage of AR-V7 positive patients had increased, 
suggestive of selection or adaptation of resistant tumor cells, although the majority of the 
patients remained negative. Moreover, other treatment resistance mechanisms contribute 
to disease progression in patients receiving AR signaling directed treatments, which are 
currently not evaluated. In addition there are currently no predictive biomarkers for 
response to taxane treatment ready for daily clinical practice. An interesting alternative to 
biomarker based treatment selection that incorporates both genotypic and phenotypic 
tumor characteristics is the use of patient derived tumor cells for ex vivo expansion and 
treatment screening. In addition, the cultivation of tumor cells as organoids provides a 
model that more accurately represents the complexity of cancer. Organoids maintain a 
3D organization which reflects the tumor morphology more closely and stem cell factors 
promote phenotypical heterogeneity, which offers an improved models from classical 2D 
cell lines.25 This concept has been applied to other cancer types, such as gastro-intestinal 
where patient-derived organoids reflected the response to chemotherapy.26 For PCa this 
has been more challenging due to the low-proliferative capacity, contamination of normal 
cells and limited availability of tissue samples from metastatic patients.  
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Alternatively, CTCs can be expanded as patient-derived organoids as sampling provides 
a less invasive alternative for metastatic patients.27,28 The major limitation of using CTCs 
for ex vivo expansion lies in the number of tumor cells obtained from a single sample, 
as the median CTC count in metastatic cancer patients typically ranges between 0-20 
cells per 7.5 mL of peripheral blood (PB). Studies thus far have suggested that successful 
ex vivo organoid expansion is limited to samples containing several hundred CTCs.27,28 
Diagnostic leukapheresis (DLA) may be used as a method to enrich mononuclear cells 
from the peripheral blood stream, which include CTCs in metastatic cancer patients.29 A 
platform that incorporates CTC sampling and ex vivo organoid expansion could provide 
treatment screening that reflects the current disease state of the patient. We performed a 
prospective clinical study (CIRCLE) to assess the feasibility of DLA to enrich CTCs, provide 
biomaterial for organoid culture and perform subsequent treatment screening in mPCa 
(Chapter VI). 
In the CIRCLE study 102 mPCa patients were screened for study participation. After 
selecting patients with ≥5 CTC per 7.5 mL peripheral blood and fit to undergo the DLA 
procedure, we obtained enriched CTC samples from 40 patients. DLA was generally safe, 
and provided a 240-fold enrichment of CTCs compared to PB samples. We obtained pre- 
and post-treatment samples from four patients, which opens up the possibility to study 
cancer evolution and adaptation to treatment. As DLA enriches for mononuclear cells, 
stringent methods are needed to effectively deplete white blood cells while retaining the 
majority of the viable CTCs. Using an antibody cocktail based method, we depleted the 
white blood cell concentration by 3.1 log10-fold while maintaining 46% of the CTCs. This 
is an improvement in comparison to a previous report, where a similar method yielded a 
CTC enrichment efficacy of 37%.30 Unfortunately, this method limited the DLA volume that 
can be cost-effectively processed to about one fourth of the original product, reducing 
the yield for subsequent organoid cultures. From the isolated and enriched CTC samples 
we were able to obtain organoids in 35% of the cultured samples, including one stable 
organoid line, EMC-PCa-41. Samples that could be propagated as organoids contained 
significantly higher number of CTCs, implicating that maximizing the number of viable 
cells obtained contributes to success. Most organoid samples could be maintained for 
6-8 weeks before proliferation ceased which provided insufficient biomaterial to perform 
treatment screening. 
VII
197Summary and General Discussion 
Organoids as disease models for cancer
The stable organoid line EMC-PCa-41 enabled us to perform treatment screening, 
phenotypic and genotypic characterization. Cell viability assays revealed that EMC-
PCa-41 displayed enzalutamide resistance, which reflected the patients response to the 
same treatment. The genetic composition of EMC-PCa-41 showed alterations frequently 
observed in CRPC, such as whole genome duplication, AR amplification and TMPRSS2-ERG 
fusion. In vitro models should reflect recurrent driver alterations in the different stages 
of cancer. However, the currently available PCa cell lines and organoid models that were 
propagated directly from patient samples, have been obtained from metastatic tissue. 
We therefore examined whether the somatic alterations frequently identified in mCRPC 
are reflected in EMC-PCa-41, the MSK organoid panel and the four classical PCa cell lines 
(Table 1).27,31,32 The most common alterations identified in mCRPC patients, inactivation 
of TP53 and PTEN, amplification of AR, MYC and the fusion of TMPRSS2-ERG are relatively 
well represented in the PCa models. Although some alterations are underrepresented, 
such as AR amplifications and TMPRSS2-ERG fusions, while alterations in TP53 and PTEN are 
seemingly overrepresented. Inactivation of TP53 interferes with apoptosis, senescence 
and cell cycle stalling in response to different stress signals such as cell DNA damage, 
which likely benefit cancerous cells exposed to a foreign environment.33 Amplifications 
and mutations in the AR are less frequently observed in vitro compared to the mCRPC 
patient population. Moreover, lack of AR/KLK3 RNA expression was observed in five of the 
seven organoid cell lines acquired by Gao et al.27 EMC-PCa-41 contains a focal amplification 
of the AR enhancer as the gene itself, a combination of alterations that was identified in 
almost 60% of the mCRPC patients.31 The amplification of the AR enhancer and gene body 
has previously been identified in LNCaP.31,34 Overall, in vitro PCa models that express the 
AR and model androgen-driven castrate disease are limited. This gap has been expanded 
by PDX-derived cell lines and CRPC models obtained through in vitro exposure to castrate 
conditions, although this does frequently result in AR negative clones. Therefore, our 


































































































































































































































































































































































































































































































199Summary and General Discussion 
In-depth analysis of the genomic alterations identified in EMC-PCa-41 suggested a lack 
of clonal heterogeneity, as the lower allele frequency was relatively stable. The presence 
of multiple clones with unique somatic variant would result in a more even distribution 
of the lower allele frequency. We therefore investigated genetic heterogeneity using 
matched single cell sequencing of CTCs and organoids obtained from two CRPC patients. 
Unfortunately, organoid cells obtained from early stage cultures were misidentified, most 
likely contaminated white blood cells and thus excluded. Within the CTC pool of both 
patients, several distinct clones with unique copy-number alterations were identified. 
These results suggest that the CTCs obtained by DLA capture inter and intra-patient 
heterogeneity. Whether the intra-patient heterogeneity was maintained upon organoid 
culture, or lost during extensive propagation should be further explored. 
We generated patient derived organoid cultures from 35% of the CTC samples which 
limited our capacity to perform comprehensive treatment screening PCa organoids. 
The primary obstacle was the limited proliferative capacity of PCa cells cultured ex vivo, 
which hampers initial organoid expansion, the number of organoids obtained and long-
term viability. Recent studies in pancreatic, colorectal and gastro-intestinal cancer have 
reported ~60-75% success-rate in patient derived organoid expansion.26,35,36 In contrast, 
the limited number of studies that reported on patient derived organoids obtained from 
mPCa showed a success-rate between 7 and 18%.27,29,37 We obtained sufficient number 
of organoids to perform treatment sensitivity assays at ~4 months of culture, while a 
recent colorectal cancer study reported a turn-over for treatment sensitivity screening of 
2 weeks.36 Taken together, for mPCa patients CTC derived organoids do not yet provide an 
platform for treatment evaluation in the context of personalized medicine. 
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Single tumor cell based disease modelling
Alternatively, viable CTCs may be directly used to assess response to treatment without ex 
vivo expansion. A direct readout of treatment activity could be based on general markers 
of cell viability or tailored to the individual drug. For example, treatment activity could be 
assessed using functional assays for microtubule stabilization, AR nuclear localization or 
DNA damage repair proficiency.38,39  If functional assays determine treatment response 
on a single cell level, this could provide insight into intra-tumor heterogeneity and detect 
underlying resistance mechanisms. Self-seeding microwells have been used to capture 
single breast and prostate CTCs, which remain viable for several days and can be used 
to quantify protein secretion.40 The seeding procedure ensures single cell capture using 
punctured microwells and a flow-through, where each cell that enters a well blocks the 
flow through. In a follow-up project of CIRCLE, DLA will be used to enrich CTCs from HSPC 
patients and investigate the impact of AR directed treatments on PSA secretion by CTCs, 
using self-seeding microwells. Potentially single cell PSA secretion can be combined with 
transcriptomic analysis to examine how CRPC cells cope with blocked AR signaling and 
how this translates to enzalutamide treatment efficacy. In conclusion, using short-term 
assays to investigate treatment response in viable CTCs might provide a solution for the 
limited success rate of ex vivo PCa organoid expansion.  
One of the main challenges in oncology is the emergence of (pre-existing) treatment 
resistant sub-clones through Darwinian selection. Applying single cell sequencing on 
CTCs obtained through serial sampling could help to identify emerging treatment resistant 
clones. In addition single cell based techniques will provide a more comprehensive 
insight into intra-tumor heterogeneity than deconvolution of bulk tumor tissue 
samples.41 We performed single cell low-coverage DNA sequencing on two enriched 
CTC pools obtained from CRPC patients. Copy number status was used to define clusters 
within the 18-21 CTCs obtained in each sample and to assess heterogeneity. Single cell 
sequencing and whole genome amplification of CTCs had a ~70% success-rate with 
85% of the sequenced cells passing quality control and validation. This shows that a 
substantial CTCs pool has to be isolated to generate significant insight into intra-tumor 
heterogeneity, which can be more easily obtained from enriched samples obtained by 
DLA. Previous studies using multiregional biopsy sampling at autopsy, have shown that 
mPCa harbors substantial intra-patient heterogeneity and revealed complex seeding 
routes.42,43 Such genetic heterogeneity will likely contribute to disease progression. 
Indeed, phylogenetic reconstruction of localized PCa revealed multi-clonality correlated 
with disease recurrence.44 In addition, single cell RNA-sequencing identified upregulation 
of Wnt signaling in mPCa patients receiving enzalutamide treatment which impaired 
enzalutamide activity in vitro.45 Our study showed that DLA resulted in a 240-fold 
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enrichment of CTCs in mPCa patients thus providing sufficient number of tumor cells 
to accurately determine intra-patient heterogeneity. Previous studies have also shown 
that CTCs can be identified in DLA samples obtained from patients with no tumor cells 
in peripheral blood samples. This provides the opportunity to trace back emerging 
treatment resistant subclones. Taken together, Part II of this thesis offers optimized CTC 
enrichment techniques which facilitate their use in single cell based characterization and 
describes the establishment of one stable CTC-based organoid line. 
The research presented in this thesis provides a step forward in bench-to-bedside and 
bedside-to-bench solutions for mPCa. 
202 Chapter VII
References
1. H. F, M. A, L B, et al. uitgezaaide kanker in beeld. Integraal Kankercentrum Nederland;2020.
2. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-
Sensitive Prostate Cancer. N Engl J Med. 2015;373(8):737-746.
3. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line 
long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, 
multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-
1177.
4. de Morree E, van Soest R, Aghai A, et al. Understanding taxanes in prostate cancer; importance 
of intratumoral drug accumulation. Prostate. 2016;76(10):927-936.
5. de Morree ES, Bottcher R, van Soest RJ, et al. Loss of SLCO1B3 drives taxane resistance in 
prostate cancer. Br J Cancer. 2016;115(6):674-681.
6. Snaterse G, Visser JA, Arlt W, Hofland J. Circulating steroid hormone variations throughout 
different stages of prostate cancer. Endocr Relat Cancer. 2017;24(11):R403-R420.
7. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in 
metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 
2008;68(11):4447-4454.
8. Mostaghel EA, Cho E, Zhang A, et al. Association of Tissue Abiraterone Levels and SLCO 
Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk 
Localized Prostate Cancer. Clinical Cancer Research. 2017.
9. Prabhu N, Dai L, Nordlund P. CETSA in integrated proteomics studies of cellular processes. 
Current Opinion in Chemical Biology. 2020;54:54-62.
10. Nieuweboer AJ, de Morree ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Inter-
patient variability in docetaxel pharmacokinetics: A review. Cancer Treat Rev. 2015;41(7):605-
613.
11. Lavaud P, Gravis G, Foulon S, et al. Anticancer Activity and Tolerance of Treatments Received 
Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or 
Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 
Phase 3 Trial. European Urology. 2018;73(5):696-703.
12. Azarenko O, Smiyun G, Mah J, Wilson L, Jordan MA. Antiproliferative mechanism of action 
of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 
breast cancer cells. Mol Cancer Ther. 2014;13(8):2092-2103.
13. Armstrong AJ, Garrett-Mayer E, Ou Yang Y-C, et al. Prostate-Specific Antigen and Pain 
Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. Journal of Clinical 
Oncology. 2007;25(25):3965-3970.
14. Armstrong AJ, Lin P, Higano CS, et al. Prognostic Association of Prostate-specific Antigen 
Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer 
Treated with Enzalutamide in a Randomized Clinical Trial. European Urology Oncology. 
2019;2(6):677-684.
15. Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with nonrising PSA in 
metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer 
and Prostatic Diseases. 2017;20(2):221-227.
16. Corn PG, Agarwal N, Araujo JC, Sonpavde G. Taxane-based Combination Therapies for 
Metastatic Prostate Cancer. Eur Urol Focus. 2019;5(3):369-380.
17. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic 
VII
203Summary and General Discussion 
castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The 
Lancet Oncology. 2013;14(13):1307-1316.
18. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel 
and prednisone for treatment of men with metastatic castration-resistant prostate cancer 
(VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760-768.
19. Chi KN, Higano CS, Blumenstein B, et al. Custirsen in combination with docetaxel and 
prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a 
phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017;18(4):473-485.
20. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of 
prostate cancer in bone and provides additional protection from osteolysis. Brit J Cancer. 
2009;101(2):263-268.
21. Lara PN, Evans CP. Dasatinib and docetaxel in advanced prostate cancer. The Lancet Oncology. 
2013;14(13):1248-1249.
22. Zasadil LM, Andersen KA, Yeum D, et al. Cytotoxicity of Paclitaxel in Breast Cancer Is due 
to Chromosome Missegregation on Multipolar Spindles. Science Translational Medicine. 
2014;6(229):229ra243-229ra243.
23. van Dessel LF, Martens JWM, Lolkema MP. Fundamentals of liquid biopsies in metastatic 
prostate cancer: from characterization to stratification. Current Opinion in Oncology. 
2020;32(5):527-534.
24. Armstrong AJ, Halabi S, Luo J, et al. Prospective Multicenter Validation of Androgen Receptor 
Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate 
Cancer: The PROPHECY Study. Journal of Clinical Oncology. 2019;37(13):1120-1129.
25. Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in 
cancer research. EMBO J. 2019;38(15):e101654.
26. Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment 
response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926.
27. Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate 
cancer. Cell. 2014;159(1):176-187.
28. Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from 
human circulating colon cancer cells. Cancer Res. 2015;75(5):892-901.
29. Lambros MB, Seed G, Sumanasuriya S, et al. Single-Cell Analyses of Prostate Cancer Liquid 
Biopsies Acquired by Apheresis. Clin Cancer Res. 2018;24(22):5635-5644.
30. Andree KC, Mentink A, Zeune LL, et al. Toward a real liquid biopsy in metastatic breast and 
prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective 
multicenter study (CTCTrap). Int J Cancer. 2018;143(10):2584-2591.
31. van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castration-
resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. 
Nature Communications. 2019;10(1):5251.
32. Ghandi M, Huang FW, Jané-Valbuena J, et al. Next-generation characterization of the Cancer 
Cell Line Encyclopedia. Nature. 2019;569(7757):503-508.
33. Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A. How does p53 induce apoptosis and how 
does this relate to p53-mediated tumour suppression? Cell Death Differ. 2018;25(1):104-113.
34. Takeda DY, Spisák S, Seo JH, et al. A Somatically Acquired Enhancer of the Androgen Receptor 
Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018;174(2):422-432 e413.
35. Tiriac H, Belleau P, Engle DD, et al. Organoid Profiling Identifies Common Responders to 
Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8(9):1112-1129.
204 Chapter VII
36. Ooft SN, Weeber F, Dijkstra KK, et al. Patient-derived organoids can predict response to 
chemotherapy in metastatic colorectal cancer patients. Sci Transl Med. 2019;11(513).
37. Puca L, Bareja R, Prandi D, et al. Patient derived organoids to model rare prostate cancer 
phenotypes. Nat Commun. 2018;9(1):2404.
38. Mukhtar E, Worroll D, Galletti G, Schuster S, Piha-Paul SA, Giannakakou P. Quantitative 
analysis of taxane drug target engagement of microtubules in circulating tumor cells from 
metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle 
of docetaxel. Cancer Drug Resist. 2020;3:636-646.
39. Meijer TG, Verkaik NS, Sieuwerts AM, et al. Functional Ex Vivo Assay Reveals Homologous 
Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clin Cancer Res. 
2018;24(24):6277-6287.
40. Andree KC, Abali F, Oomens L, et al. Self-Seeding Microwells to Isolate and Assess the Viability 
of Single Circulating Tumor Cells. Int J Mol Sci. 2019;20(3).
41. Baslan T, Hicks J. Unravelling biology and shifting paradigms in cancer with single-cell 
sequencing. Nat Rev Cancer. 2017;17(9):557-569.
42. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate 
cancer. Nature. 2015;520(7547):353-357.
43. Woodcock DJ, Riabchenko E, Taavitsainen S, et al. Prostate cancer evolution from multilineage 
primary to single lineage metastases with implications for liquid biopsy. Nat Commun. 
2020;11(1):5070.
44. Espiritu SMG, Liu LY, Rubanova Y, et al. The Evolutionary Landscape of Localized Prostate 
Cancers Drives Clinical Aggression. Cell. 2018;173(4):1003-1013 e1015.
45. Miyamoto DT, Zheng Y, Wittner BS, et al. RNA-Seq of single prostate CTCs implicates 
noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351-1356.
VII







Het vooruitzicht voor patiënten met uitgezaaide prostaatkanker is in de laatste twee decennia 
sterk verbeterd, dit komt voornamelijk door de introductie van nieuwe behandelingen. 
Een van de recente ontwikkelingen is de combinatie van hormonale therapie, ook wel 
androgeen deprivatie therapie genoemd, met het chemotherapeuticum docetaxel. Bij 
androgeen-deprivatie therapie wordt testosteronproductie met medicatie onderdrukt, 
wat de androgeenreceptor inactiveert en proliferatie van de prostaatkankercellen een 
halt toeroept. De combinatie van androgeen deprivatie therapie met docetaxel is in staat 
om ziekte progressie naar het castratie-resistente stadium, waarbij androgeen deprivatie 
therapie niet meer effectief is, sterk uit te stellen. Deze klinische resultaten suggereren 
dat de behandeling met docetaxel effectiever is door het wegnemen van testosteron 
en blokkeren van de androgeenreceptor activiteit. Deze interactie hebben wij in het 
laboratorium onderzocht om zo inzicht te genereren in de factoren die de effectiviteit van 
taxaan behandeling beïnvloeden.  
In hoofdstuk II en III van dit proefschrift hebben wij de interactie tussen testosteron en 
de effectiviteit van taxaan chemotherapeutica behandeling onderzocht in preklinische 
modellen van castratie-resistente prostaatkanker. Door tumordragende muizen te 
behandelen met testosteron, als zowel taxanen, toonden wij aan dat dit androgeen een 
sterk negatieve impact had op de behandeling. Terwijl in de afwezigheid van testosteron, 
taxaan behandeling de tumorgroei effectief onderdrukte, was er geen substantiële impact 
bij gelijktijdige toediening. Verder onderzoek onthulde een verlaagde concentratie van 
taxanen in de prostaattumoren van muizen met hoge testosteronspiegels, wat correleert 
met verminderde effectiviteit van de chemotherapie. Vervolgens hebben we in hoofdstuk 
III aangetoond dat testosteron kan interfereren met de opname van docetaxel via een 
transport eiwit, dit mechanisme kan de verlaagde taxaan concentraties in tumorcellen 
verklaren. Taxanen zoals docetaxel functioneren door tubuline eiwitten te binden en 
stabiliseren, wat de celdeling verstoord. In hoofdstuk IV hebben we tubuline-binding 
als marker voor taxaan-effectiviteit onderzocht. Gebruik makend van een nieuwe 
methode, genaamd CETSA, konden wij taxaan-resistente tumormodellen onderscheiden 
van de taxaan-gevoelige. Daarnaast kon CETSA ook worden toegepast op biopten van 
borstkankerpatiënten, wat het mogelijk maakt om het effect van chemotherapie en de 
uitkomst van behandeling in patiënten te onderzoeken.
In hoofdstuk V hebben we interactie tussen androgeenreceptor activiteit en taxaan 
behandeling bestudeerd door de taxaan cabazitaxel te combineren met de androgeen 
gerichte remmer enzalutamide. Opvallend genoeg was de toevoeging van enzalutamide 
op de antitumor effectiviteit van cabazitaxel groter dan de impact van enzalutamide 
alleen. Om de interactie tussen enzalutamide en cabazitaxel beter te begrijpen, hebben 
wij m.b.v. microscopie levende tumorcellen bestudeerd tijdens behandeling. Blootstelling 
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aan cabazitaxel resulteerde in tubuline stabilisatie en verstoorde celdelingen, maar leidde 
opvallend genoeg zelden tot celdood van de prostaatkankercellen. De toevoeging 
van enzalutamide zorgde ervoor dat deze resistente prostaatkankercellen wel vaker 
doodgingen aan de cabazitaxel behandeling, wat de effectiviteit van de combinatie 
behandeling onderstreept. Samengevat impliceren onze resultaten dat deze combinatie 
strategie, van een taxaan chemotherapeuticum met een androgeen gerichte remmer,  een 
veelbelovende optie is voor castratie-resistente prostaatkankerpatiënten. Deze strategie 
wordt momenteel onderzocht in verschillende klinische studies.
Selectie van de optimale behandeling voor de individuele prostaatkankerpatiënt wordt 
steeds complexer door de toevoegingen van nieuwe (combinatie)behandelingen. In 
hoofdstuk VI bespreken we de resultaten van een klinische studie die een nieuwe 
methode voor geïndividualiseerde therapieselectie onderzocht. Hierbij werden levende 
tumorcellen uit het bloed, ook wel circulerende tumorcellen genoemd, van uitgezaaide 
prostaatkanker patiënten geïsoleerd. Het doel was om deze tumorcellen te kweken in 
het laboratorium, als 3D celstructuren genaamd organoїden, om vervolgens therapie 
gevoeligheid te bepalen. Daarmee zouden deze organoїden fungeren als representatieve 
modellen voor de individuele patiënt en therapieselectie kunnen ondersteunen. 
Om zoveel mogelijk circulerende tumorcellen te isoleren, hebben we 
prostaatkankerpatiënten een leukaferese procedure laten ondergaan. Deze methode 
bleek zeer effectief de tumorcellen te verrijken en is over het algemeen weinig 
invasief. Het product wordt vervolgens verwerkt om de concentratie van ongewenste 
bloedcomponenten te verlagen, voornamelijk witte bloedcellen, terwijl de tumorcellen 
worden behouden. 
Na het kweken van deze samples groeiden bij 14 van de 40 (35%) de tumorcellen uit als 
organoїden, die meestal 6-8 weken in leven konden worden gehouden. Helaas leverde dit 
niet genoeg organoїden op om de therapiegevoeligheid voor verschillende medicijnen te 
kunnen testen. Bij twee samples waren we in staat de organoїden langdurig in kweek te 
houden wat uiteindelijk leidde tot één nieuwe stabiele organoїde lijn. Deze organoїde lijn 
bleek enzalutamide-resistent te zijn, wat een reflectie was van de kortdurende therapie 
response bij de patiënt waarvan we de circulerende tumorcellen hadden verkregen. Uit 
deze studie moeten we concluderen dat het kweken van prostaatkanker organoїden 
uit circulerende tumorcellen zeer beperkt mogelijk is en momenteel onvoldoende 
garantie biedt voor het testen van therapieresponse. Deze resultaten laten wel zien 
dat het mogelijk is om grote hoeveelheden tumorcellen te verzamelen met behulp 
van leukaferese. Dit biedt bijvoorbeeld de mogelijkheid om circulerende tumorcellen 
genetisch en fenotypisch te karakteriseren. Wanneer verschillende samples gedurende de 
ziekteverloop worden verzameld kan dit mogelijk inzicht bieden in de progressie van de 
ziekte en de response op behandeling. Samengevat bieden deze resultaten interessante 
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mogelijkheden voor vervolgstudies. 
De resultaten besproken in dit proefschrift bieden nieuwe aangrijpingspunten in 
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series op je favoriete streamingsdienst waren en eindigden bij politieke discussies. Maar 
het was altijd gezellig. Daarnaast wil ook zeker Ashraf, Mirella, Natasja en Diana bedanken 
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voor jullie betrokkenheid en enthousiasme.
Ook wil ik mijn collega’s van de Medisch Oncologie bedanken, want vooral bij het CIRCLE 
project was een goede samenwerking cruciaal. Beste Lisanne en Anouk, jullie hebben 
beide enorm veel energie in de klinische kant van dit project gestopt, iets wat voor mij 
vaak onzichtbaar bleef. Het was vaak een enorme puzzel om de enorme hoeveelheid data 
die uit dit project kwam op een duidelijke manier weer te geven en te beschrijven, maar ik 
denk dat we samen tot de beste versie zijn gekomen. Beste Jaco, jouw expertise was een 
belangrijke sleutel in dit geheel en heeft er voor gezorgd dat we grote stappen hebben 
gezet in het verwerken van de leukaferese samples. Ook John wil ik bedanken voor zijn 
input en ideeën die dit project hebben gevormd. En Khrystany, je hebt het gehoord, 
PICTURES gaat het grote succes worden en ik heb er alle vertrouwen in dat dit gaat lukken. 
Daarnaast wil ook het translationele farmacologie lab bedanken, beste Ron in de afgelopen 
jaren ben je nauw betrokken geweest bij het taxaan onderzoek wat ik heb verricht en had 
je vaak een scherp oog op de uitvoering en interpretatie. Peter, Mei en Inge, jullie wil ik 
bedanken voor de technische expertise, hulp en gezelligheid. Beste Bodine, samen met 
Ron heb jij de preklinische studies weten te vertalen naar een succesvolle fase I studie, 
het gebeurt niet vaak dat de kliniek op het lab vooruit loopt. Zo zie je dat een hechte 
samenwerking van biomedische onderzoekers en artsen het beste resultaat oplevert. 
Beste Stefan, ik weet zeker dat het vervolg dat deze studies in goede handen ligt bij jou 
en ik kijk uit naar het resultaat.  
Naast mijn (co)promotoren, heb ik de afgelopen jaren ook regelmatig advies gevraagd 
aan de wetenschappers die de promotie traject al hadden overwonnen. Dear Elena, 
you were often the person who provided me with a sufficient doses of tough love. You 
often advised me to stop doubting myself and confront my problems head-first, which 
changed the way I viewed and handled challenges. Beste Martin, ik ben heel erg blij dat 
de hoeveelheid tijd en energie die we in het live-cell imaging hebben gestoken zich heeft 
vertaald naar de prachtige resultaten in dit proefschrift. Je wist mijn ingewikkelde ideeën 
voor experimenten te vertalen naar daadwerkelijke resultaten en stopte niet tot de beste 
uitkomst was behaald. Daarnaast was je altijd bereid om te luisteren en advies te geven 
over de verschillende uitdagingen van promotieonderzoek. Beste Harmen, je kritische 
blik op de bioinformatica ging gelukkig gepaard met een uitgebreide uitleg over de opzet 
en interpretatie van de experimenten. Dit heeft samen met mijn korte deelname aan de 
CCBC journal club zeker mijn interesse in bioinformatica aangewakkerd. Daarnaast gaf je 
vaak een optimistisch perspectief aan alles wat gaande was. Rute, ook jou wil ik enorm 
bedanken voor alle goede adviezen in de afgelopen jaren. Ten slotte, beste Guido, ik heb 
met enige regelmaat jouw zondagse rust op het lab verstoordt, maar vol enthousiasme 
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gaf je antwoord op mijn overpeinzingen. Ik hoop dat ik ooit ook zo enthousiast en helder 
over mijn onderzoek kan praten.
One of the great aspects of being a PhD student is that you have the chance to meet 
a lot of people who deal with the same challenges. While having a cup of coffee, or a 
beer, you often find yourself sharing struggles but also victories. I fondly look back at the 
conversations I had with Ellen, Annelies, Merle, Job, Wesley, Youri, Eline, Daniela, Ardelan 
and all the student that passed through our lab in the last six years. The funny thing is that 
sometimes you find yourself discussing the same issues you had in the beginning.
As a PhD student you sometimes find yourself in the lucky position to spend some time 
in a lab abroad. Alex, I want to thank you and your lab members for the opportunity you 
provided, that short period of time had a tremendous positive impact on my personal and 
scientific development.
Ten slotte wil ik mijn vrienden en familie bedanken voor hun support. Elaisha, onze 
hechte vriendschap is van onschatbare waarde geweest in de afgelopen zes jaar. Of het 
nou een typische vrijdagavond met comfortfood, een blockbuster movie-night, een semi-
emergency phone call, je was altijd een luisterend oor met de emotionele support of 
afleiding die ik nodig had. Steef, weet dat ik enorm trots op je ben, ondanks alle tegenslagen 
heb je altijd de ene voet voor de andere weten te zetten. Jij bent zo’n zorgheld die tijdens 
deze crisis er altijd stond. Ik ben enorm blij dat jullie m’n paranimfen zijn. Lieve Mam en 
Pap, het advies was altijd, doe wat je leuk vindt en probeer het gewoon. Het was de steun 
die ik nodig had om dit pad te kiezen. Ik kan me voorstellen dat promotie onderzoek altijd 
een beetje vaag is geweest, maar ik hoop dat jullie trots zijn op het resultaat. Ik ben ook 
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